invas
mechan
ventil
due
dryness
medic
gase
necessari
provid
adequ
level
condit
hot
water
humidifi
hwh
heat
water
thu
allow
water
vapor
heat
humidifi
medic
gase
common
hwh
contact
medic
gase
steril
water
thu
increas
risk
patient
colon
infect
recent
avoid
condens
inspiratori
limb
ventil
circuit
new
heat
ventil
circuit
develop
vitro
studi
evalu
effici
absoluterel
humid
three
hwh
common
hwh
without
heat
ventil
circuit
mr
fisher
paykel
new
zeland
hwh
heat
ventil
circuit
mallinckrodt
dar
itali
new
hwh
dar
hc
mallinkckrodt
dar
itali
heat
ventil
circuit
water
vapor
reach
medic
gase
gorotex
membran
avoid
direct
contact
water
gase
temperatur
hwh
heat
tube
evalu
absolut
humid
ah
rel
humid
rh
measur
psychometr
method
minut
ventil
tidal
volum
respiratori
rate
oxygen
fraction
lmin
ml
bpm
respect
ventil
set
maintain
constant
studi
period
measur
taken
min
continu
use
output
mr
heat
tube
insuffici
provid
adequ
level
condit
three
devic
satisfactori
bougi
use
techniqu
use
bronchoscop
control
bougi
pass
tracheal
tube
tt
trachea
tt
withdrawn
cuff
vocal
cord
cuff
fulli
inflat
tt
advanc
use
bougi
guid
cuff
impact
vocal
cord
ga
tabl
complic
type
number
visibl
cut
bougi
tt
pull
back
far
enough
b
bougi
murphi
eye
tt
c
failur
advanc
blue
rhino
bleed
e
late
complic
f
one
case
selding
needl
also
block
bougi
materi
one
patient
hard
collar
b
one
case
selding
needl
perfor
tt
cuff
tt
prevent
tracheostomi
cuff
seal
one
case
selding
wire
pass
murphi
eye
tt
dilat
process
caus
tt
advanc
trachea
second
passag
dilat
done
bronchoscop
control
c
caus
problem
patient
previou
tracheostomi
serial
dilat
techniqu
use
e
thrombocytopaen
patient
damag
seen
bronchoscopi
f
infect
stoma
day
pneumopericardium
day
introduct
noninvas
mechan
ventil
nimv
support
ventil
patient
use
kind
mechan
mean
without
intub
advantag
nimv
well
known
autonom
interrupt
adapt
interv
use
selfperform
humidif
need
sedat
possibl
expector
cough
talk
feed
disadvantag
imv
intub
spasm
heart
attack
dilat
stomach
imv
obstruct
ventilatorassoci
pneumonia
vap
takeoff
intub
tracheostomia
among
differ
type
nimv
neg
pressur
iron
lung
posit
pressur
intermitt
posit
pressur
ventil
spontan
intermitt
mechan
ventil
psv
bipap
pav
cpap
recent
year
face
cpap
mask
boussignacvygon
develop
use
mode
cpap
ventil
suppli
use
creat
special
valv
mechan
continu
posit
pressur
airway
although
mask
effect
correct
hypoxemia
two
seriou
disadvantag
use
high
flow
creat
effect
cpap
result
uncontrol
fio
major
introduct
intrapulmonari
percuss
ventil
ipv
complementari
chest
physiotherapi
techniqu
restrict
obstruct
diseas
treatment
test
toler
efficaci
cardiac
surgeri
prospect
randomis
control
studi
patient
method
forti
patient
receiv
chest
physiotherapi
first
day
cardiac
surgeri
randomis
two
group
control
group
benefit
one
convent
chest
physiotherapi
per
day
ipv
group
receiv
treatment
altern
applic
day
treatment
durat
blood
ga
flowvolum
curv
subject
sensat
dyspnoea
use
visual
scale
thorax
radiograph
postop
complic
hospit
length
stay
analys
result
tabl
group
compar
regardless
type
intervent
comorbid
demographi
blood
ga
analysi
day
frequenc
postop
clinic
complic
statist
differ
howev
fewer
atelectasi
seen
ipv
group
thorax
radiograph
subject
dyspnoea
sensat
less
patient
ipv
group
hospit
length
stay
lo
longer
control
group
ipv
treatment
stop
intoler
conclus
toler
ipv
treatment
good
earli
cardiac
surgeri
studi
use
ipv
first
three
postop
day
reduc
hospit
lo
cardiac
surgeri
howev
larger
studi
necessari
confirm
result
measur
use
direct
method
certain
technic
innov
subject
breath
oronas
mask
oneway
valv
expir
air
collect
balloon
order
provid
adequ
mixtur
dead
space
alveolar
air
concentr
co
end
balloon
peco
measur
rgm
ohmeda
capnograph
infrar
techniqu
togeth
minut
ventil
arteri
oxygen
partial
pressur
pao
measur
simultan
arteri
blood
use
convent
method
proteom
approach
ventilatorinduc
lung
injuri
might
identifi
protein
pattern
contribut
epitheli
injuri
identifi
chang
alveolar
type
ii
cell
atii
rat
mechan
ventil
hour
high
tidal
volum
htv
mlkg
posit
end
expiratori
pressur
low
tidal
volum
ltv
mlkg
posit
end
expiratori
pressur
cmh
compar
pool
control
without
mechan
ventil
sv
atii
isol
lyse
protein
express
compar
use
recent
introduc
cleavabl
isotop
code
affin
tag
icat
methodolog
tryptic
digest
cystein
contain
peptid
tag
biotin
extract
use
avidinco
column
identifi
hplc
mass
spectrometri
collisioninduc
dissoci
spectra
interrog
swissprot
databas
quantifi
use
proteinprospector
softwar
htv
ventil
result
morpholog
chang
pulmonari
edema
neutrophil
influx
lung
quantiz
show
differenti
express
sever
hundr
protein
follow
htv
ltv
ventil
protein
upregul
ltv
ventil
compar
sv
protein
upregul
markedli
attenu
htv
compar
ltv
true
correl
increas
number
neutrophil
sampl
htv
surfact
protein
b
follow
differ
pattern
sinc
differenti
express
protein
play
import
role
innat
immun
pulmonari
edema
fluid
clearanc
attenu
respons
atii
htv
ventil
might
indic
clinic
relev
impedi
inspiratori
vs
expiratori
limb
pressurevolum
curv
posit
endexpiratori
pressur
set
acut
lung
injuri
result
pressurecontrol
pressur
support
mv
mode
often
use
differ
seen
four
mv
mode
asv
ippv
asb
pc
respect
appli
vt
peep
higher
level
peep
use
ard
patient
p
importantli
major
patient
vt
mlkg
moreov
vt
significantli
higher
ard
patient
nonard
patient
p
larg
discrep
ideal
vt
actual
appli
vt
possibl
explan
use
absolut
bodyweight
instead
ideal
bodyweight
calcul
vt
implement
small
vtmv
need
educ
program
evalu
current
progress
three
icu
initi
appli
peep
determin
optim
peep
differ
significantli
compar
baselin
pao
significantli
higher
follow
alveolar
recruit
ep
also
min
evlw
chang
significantli
studi
period
tabl
regress
analysi
could
reveal
signific
relationship
pao
evlw
differ
peep
recent
found
signific
correl
evlw
pao
fio
peep
level
date
clinic
trial
report
relationship
oxygen
evlw
alveolar
recruit
peep
optimis
base
current
result
pilot
studi
seem
evlw
directli
affect
oxygen
recruit
complet
studi
requir
evalu
effect
evlw
optim
peep
ard
szakmani
heigl
p
molnar
zs
anaesth
int
care
press
introduct
pneumothorax
present
case
acut
respiratori
distress
syndrom
ard
develop
becom
like
durat
process
increas
presenc
affect
patient
chanc
surviv
bronchopleur
fistula
prolong
pneumothorax
case
ard
increas
rate
mortal
prospect
control
studi
carri
manag
persist
air
leak
pal
ard
therapeut
option
treatment
prove
superior
anoth
pleurodesi
autolog
blood
pab
effect
simpl
inexpens
method
select
number
case
oncolog
pulmonari
surgeri
also
anecdot
descript
use
nonsurg
patient
object
goal
studi
compar
efficaci
pab
convent
continu
aspir
manag
pal
ard
patient
pneumothorax
design
nonrandom
studi
compar
two
group
undergo
artifici
pair
patient
two
group
patient
ard
pneumothorax
pal
intervent
one
group
undergon
convent
treatment
receiv
pab
averag
differ
group
day
less
seal
time
p
day
less
wean
time
p
day
less
averag
time
spent
icu
p
conclus
use
pab
comparison
exclus
use
thorac
drain
water
seal
treatment
pal
ard
effect
inexpens
simpl
method
decreas
ventil
wean
time
make
shorter
stay
icu
tabl
increas
day
day
respiratori
valu
studi
introduct
open
lung
biopsi
olb
regard
gold
standard
diagnosi
pulmonari
infiltr
procedur
associ
signific
risk
morbid
mortal
intens
care
unit
icu
set
wish
studi
efficaci
open
lung
biopsi
icu
patient
requir
advanc
respiratori
support
associ
bilater
pulmonari
infiltr
method
review
medic
case
record
patient
underw
open
lung
biopsi
icu
august
june
includ
patient
requir
advanc
ventilatori
support
persist
bilater
infiltr
chest
xray
fail
respond
firstlin
treatment
biopsi
perform
icu
univers
hospit
wale
gener
anaesthesia
access
lung
via
anterior
mini
thoracotomi
oper
lung
sampl
sent
bacteriolog
gram
stain
cultur
virolog
histolog
assess
perform
olb
studi
period
patient
demograph
survivor
versu
nonsurvivor
present
tabl
open
lung
biopsi
provid
diagnosi
patient
patient
specif
treatment
chang
implement
overal
mortal
conclus
olb
critic
ill
patient
accur
diagnost
tool
background
acut
respiratori
distress
syndrom
ard
characteris
develop
noncardiogen
pulmonari
oedema
lead
refractori
hypoxaemia
earli
clearanc
alveolar
oedema
import
determin
outcom
ard
shown
upregul
alveolar
fluid
clearanc
afc
primari
aim
studi
determin
concentr
salbutamol
achiev
plasma
treatment
intraven
iv
salbutamol
second
aim
determin
concentr
airspac
salbutamol
requir
stimul
afc
normal
rat
lung
method
patient
acut
lung
injuryard
randomis
infus
iv
salbutamol
placebo
plasma
salbutamol
level
measur
commerci
avail
elisa
hour
start
infus
second
seri
experi
afc
measur
rat
respons
salbutamol
previous
describ
result
twelv
patient
recruit
six
receiv
placebo
median
plasma
salbutamol
level
ngml
salbutamoltr
group
equival
compar
undetect
placebo
group
p
basal
afc
rat
hour
salbutamol
increas
afc
respect
baselin
p
plasma
concentr
follow
iv
administr
patient
ard
may
suffici
stimul
afc
similar
concentr
reach
airspac
aerosolis
deliveri
agonist
achiev
higher
concentr
distal
airspac
maxim
afc
although
iv
aerosolis
deliveri
achiev
effect
concentr
optim
rout
deliveri
treat
ard
patient
remain
uncertain
introduct
prone
posit
shown
attenu
ventilatorinduc
lung
injuri
experiment
model
recent
suggest
mechan
may
due
homogen
distribut
strain
within
lung
parenchyma
studi
perform
explor
hypothesi
method
total
anim
ventil
supin
n
prone
n
posit
similar
ventilatorinduc
lung
injuri
vili
reach
experi
interrupt
respiratori
system
elast
er
baselin
thereaft
vili
assess
lung
wettodri
wd
ratio
histolog
h
h
stain
five
anim
ct
scan
ge
medic
system
light
speed
qxi
mm
thick
kv
taken
endexpir
endinspir
inspiratori
capac
supin
prone
posit
quantit
analysi
maluna
mannheim
germani
perform
entir
lung
divid
lung
four
zone
along
vertic
axi
ventral
dorsal
also
consid
area
lung
seen
later
view
consid
height
scan
divid
upper
lower
region
accord
maxim
height
lung
endexpir
osiri
medic
imag
softwar
geneva
switzerland
tidal
volum
distribut
calcul
ratio
area
endinspir
endexpir
calcul
upper
lower
region
supin
prone
posit
data
shown
mean
sd
result
rat
ventil
compar
ventil
set
tidal
volum
inspiratori
capac
vs
supin
vs
prone
p
signific
ns
similar
vili
reach
assess
er
wd
histolog
time
taken
achiev
target
vili
longer
prone
posit
min
vs
supin
vs
prone
p
consid
ct
scan
analysi
lung
volum
similar
group
endexpir
ml
vs
supin
vs
prone
p
ns
endinspir
ml
vs
supin
vs
prone
p
ns
howev
endexpir
lung
densiti
along
vertebr
axi
similar
prone
posit
significantli
decreas
supin
posit
anova
p
ratio
endinspiratori
endexpiratori
area
greater
upper
region
oppos
lower
region
supin
posit
vs
upper
vs
lower
region
p
prone
posit
similar
vs
upper
vs
lower
p
ns
prone
posit
attenu
vili
allow
one
buy
time
progress
lung
volum
endexpir
tidal
volum
homogen
distribut
prone
posit
suggest
homogen
distribut
strain
within
lung
parenchima
may
explain
protect
role
prone
posit
progress
vili
introduct
continu
rotat
therapi
crt
use
special
design
bed
known
prevent
respiratori
complic
ventil
patient
exert
benefici
effect
patient
suffer
respiratori
failur
due
acut
lung
injuri
ali
andor
ard
littl
known
physiolog
effect
potenti
benefici
mechan
crt
moreov
data
optim
set
turn
angl
durat
paus
maxim
later
steep
posit
rare
method
twelv
patient
suffer
ali
ard
investig
patient
includ
pulmonari
arteri
cathet
place
decis
perform
crt
taken
patient
place
crt
posit
system
rotorest
kci
san
antonio
tx
usa
studi
perform
day
turn
first
phase
oxygen
hemodynam
assess
continu
turn
supin
maxim
steep
posit
angl
second
phase
patient
posit
maxim
steep
posit
half
hour
oxygen
hemodynam
assess
supin
posit
everi
min
steep
posit
patient
sedat
mechan
ventil
use
pressurecontrol
mode
ventil
paramet
chang
throughout
studi
period
result
ten
male
two
femal
patient
fulfil
diagnost
criteria
ard
evalu
median
age
year
rang
year
ten
patient
toler
prolong
later
steep
posit
well
two
patient
studi
broken
prematur
left
later
posit
due
decreas
blood
pressur
one
decreas
arteri
oxygen
satur
case
result
compar
phase
studi
overal
oxygen
chang
significantli
posit
tend
deterior
later
steep
compar
supin
posit
interindividu
chang
oxygen
differ
posit
show
high
variabl
tidal
volum
lung
complianc
declin
significantli
later
steep
posit
compar
supin
posit
cardiac
index
arteri
blood
pressur
chang
significantli
benefici
effect
crt
due
recruit
nonventil
lung
area
steep
posit
improv
oxygen
continu
turn
seem
exert
benefici
effect
due
mechan
crt
perform
without
prolong
paus
maxim
steep
posit
introduct
acut
respiratori
failur
arf
particular
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
chang
supin
posit
sp
prone
posit
pp
improv
oxygen
recruit
alveoli
situat
dorsaldepend
region
alter
ventilationperfus
ratio
efficaci
intervent
shown
cours
oxygen
index
aim
studi
demonstr
differ
effect
prone
posit
ventil
ppv
arf
patient
differ
concomit
diseas
studi
consecut
patient
ali
n
ard
n
mean
se
age
year
clinic
followup
design
surgic
icu
univers
hospit
use
american
european
consensu
definit
respiratori
failur
accompani
sole
combin
sepsi
n
pneumonia
n
malign
diseas
n
vascular
diseas
n
multipl
trauma
n
concomit
diseas
patient
ventil
intermitt
sp
pp
leftsiderightsid
posit
least
hoursday
support
treatment
respiratori
failur
data
collect
includ
apart
baselin
characterist
individu
oxygen
index
concomit
diseas
patient
discuss
especi
patient
arf
sepsi
show
earli
last
increas
oxygen
start
ppv
pneumonia
vascular
diseas
malign
diseas
show
visibl
increas
oxygen
first
day
start
ppv
less
clear
improv
follow
day
multipl
trauma
patient
show
trend
better
oxygen
signific
increas
introduct
sar
caus
newli
describ
coronaviru
sar
patient
requir
oxygen
supplement
mechan
ventil
icu
respiratori
failur
ard
aim
describ
ct
find
patient
late
stage
ard
caus
sar
report
chang
longterm
followup
method
retrospect
review
ct
find
eight
patient
met
cdc
criteria
sar
patient
met
criteria
ard
ct
perform
latestag
ard
week
onset
ard
discharg
hospit
survivor
relev
respiratori
ventilatori
paramet
total
steroid
dose
outcom
record
mechan
ventil
patient
receiv
low
pressur
peak
pressur
mmhg
low
volum
tidal
volum
mlkg
estim
lean
bodi
mass
ventil
five
patient
receiv
prolong
mechan
ventil
day
one
ventil
hour
two
patient
ventil
patient
receiv
highdos
puls
methylprednisolon
g
total
dose
three
patient
die
five
surviv
hospit
discharg
ard
chronic
stage
ct
find
consolid
present
five
patient
ground
glass
opacif
interstiti
thicken
present
patient
three
evid
fibrosi
small
pulmonari
cyst
present
five
patient
extrapulmonari
ga
pneumothorax
two
find
patient
longterm
mechan
ventil
day
shortterm
ventil
similar
followup
ct
mean
month
n
consolid
extrapulmonari
ga
resolv
ground
glass
opacif
improv
sign
fibrosi
gener
progress
ct
featur
latestag
ard
caus
sar
similar
seen
latestag
ard
caus
appar
differ
patient
receiv
prolong
mechan
ventil
fibrot
chang
seen
chronic
phase
ard
seem
resolv
significantli
discharg
method
retrospect
review
case
record
probabl
sar
patient
admit
design
nation
sar
icu
march
juli
last
sar
patient
discharg
result
one
hundr
ninetynin
probabl
sar
patient
admit
nation
sar
hospit
fortysix
requir
icu
admiss
mean
age
icu
patient
year
equal
sex
distribut
similar
racial
distribut
nation
popul
mean
apach
ii
score
median
interquartil
rang
iqr
pao
fio
ratio
icu
admiss
eightyf
per
cent
requir
mechan
ventil
complic
observ
includ
septicaemia
secondari
pneumonia
deep
vein
thrombosi
acut
renal
failur
acut
myocardi
infract
stress
hyperglycaemia
pneumothorax
pulmonari
embol
cerebrovascular
accid
pneumomediastinum
inicu
mortal
median
iqr
length
mechan
ventil
day
median
iqr
length
stay
hospit
icu
day
day
respect
cox
regress
analysi
show
male
sex
p
apach
ii
score
p
histori
congest
cardiac
failur
independ
predictor
mortal
among
sar
icu
patient
conclus
one
five
probabl
sar
patient
requir
icu
care
group
critic
ill
sar
patient
high
mortal
morbid
predictor
icu
mortal
male
sex
apach
ii
score
histori
congest
cardiac
failur
object
studi
aim
describ
patient
sar
develop
respiratori
failur
requir
icu
admiss
method
retrospect
analysi
prospect
collect
demograph
clinic
biochem
microbiolog
radiolog
data
sar
case
admit
icu
result
total
patient
includ
health
care
worker
admit
icu
clinic
diagnosi
sar
case
sar
cov
posit
mean
time
interv
symptom
onset
hospit
admiss
day
mean
time
symptom
onset
icu
admiss
day
patient
mean
sd
age
rang
year
sixtyeight
percent
known
contact
exposur
anoth
sar
person
signific
comorbid
present
treatment
consist
broadspectrum
antibiot
ribavarin
corticosteroid
mainten
puls
select
case
kaletra
immunoglobulin
convalesc
serum
chines
herbal
medicin
median
acut
physiolog
chronic
health
evalu
ii
score
rang
admiss
mean
ratio
partial
pressur
oxygen
fraction
inspir
oxygen
rang
seventysix
patient
requir
mechan
ventil
mortal
group
spontan
breath
patient
die
icu
ventil
patient
develop
barotauma
nonventil
patient
develop
barotrauma
spontan
renal
failur
occur
nonsurvivor
survivor
posit
blood
cultur
occur
nonsurvivor
survivor
median
durat
stay
icu
day
rang
day
overal
mortal
conclus
sar
carri
high
mortal
especi
mechan
ventil
patient
barotrauma
renal
failur
sepsi
preval
introduct
acut
lung
injuri
ali
found
frequent
complic
acut
liver
failur
alf
previou
studi
associ
mortal
high
sever
hypoxia
contraind
liver
transplant
lt
mani
transplant
center
tri
studi
incid
outcom
ali
heterogen
group
patient
alf
addit
aim
investig
role
extravascular
lung
water
index
evlwi
measur
diagnosi
manag
ali
liver
failur
method
retrospect
chart
review
patient
alf
fulfil
poor
prognost
criteria
admit
liver
itu
period
ali
find
chest
xray
cxr
around
period
list
periop
correl
oxygen
ventil
paramet
well
measur
evlwi
permeabl
index
evlwiintrathorac
blood
volum
index
measur
via
transpulmonari
thermodilut
picco
pulsion
munich
germani
caus
alf
paracetamol
overdos
patient
nanb
hepat
eight
patient
acut
buddchiari
syndrom
five
patient
remain
eight
patient
suffer
acut
hepat
b
viru
infect
wilson
diseas
druginduc
liver
failur
autoimmun
hepat
twentyeight
patient
transplant
surviv
hospit
discharg
nontranspl
patient
one
surviv
diagnosi
compat
ali
found
differ
transplant
nontranspl
patient
median
pao
fio
ratio
pf
ali
patient
nonlung
injuri
patient
mannwhitney
u
test
signific
two
patient
taken
transplant
list
due
combin
refractori
hypoxia
multipl
organ
failur
transplant
nontranspl
patient
differ
term
pf
posit
end
expiratori
pressur
peep
evlwi
permeabl
index
poor
outcom
associ
low
pf
cxr
sign
ali
high
evlwi
permeabl
index
bilater
infiltr
cxr
correl
peep
p
evlwi
p
permeabl
index
p
pf
focal
lung
infiltr
correl
paramet
twelv
patient
without
cxr
find
ali
signific
impair
ga
exchang
pf
suggest
extrapulmonari
reason
hypoxia
conclus
onequart
patient
alf
seri
show
sign
ali
sever
lung
injuri
peritranspl
period
associ
high
mortal
hypoxia
nonspecif
diagnosi
ali
use
sole
determin
remov
patient
transplant
list
evlwi
permeabl
index
readili
avail
bedsid
paramet
diagnosi
ali
howev
correl
patient
outcom
object
determin
incid
pulmonari
dysfunct
comatos
patient
sever
traumat
brain
injuri
evalu
effect
respiratori
failur
neurolog
outcom
method
retrospect
studi
trauma
patient
femal
male
admit
icu
juli
juli
isol
brain
injuri
glasgow
coma
score
gc
less
sedat
mechan
ventil
admiss
patient
enrol
studi
age
year
mean
age
year
pulmonari
function
evalu
latest
fourth
day
hospit
use
lung
injuri
score
li
follow
compon
chest
radiograph
find
pao
fio
posit
end
expiratori
pressur
li
zero
defin
normal
pulmonari
function
li
mild
moder
dysfunct
li
sever
pulmonari
dysfunct
maximum
li
taken
consider
statist
analysi
patient
brain
computeris
tomographi
ct
scan
admiss
grade
use
marshal
ct
score
system
glasgow
outcom
scale
go
use
followup
popul
good
recoveri
moder
disabl
sever
disabl
veget
state
death
consid
good
outcom
bad
outcom
mean
valu
sd
calcul
data
correl
variabl
assess
outcom
evalu
gc
admiss
maximum
li
record
fourth
day
hospit
mean
valu
six
patient
normal
pulmonari
function
mild
moder
dysfunct
one
patient
sever
pulmonari
dysfunct
base
go
good
outcom
mortal
reach
moder
statist
correl
found
li
gc
correl
coeffici
r
also
li
go
r
gc
go
invers
relat
r
sixtyon
patient
present
relat
li
ct
score
r
remain
nine
patient
show
relat
li
ct
score
aspir
prior
intub
atelectasi
mechan
ventil
overdistens
lung
aggrav
pulmonari
function
directli
independ
neurolog
statu
conclus
although
clinic
practic
experi
strong
relat
li
ct
scan
find
patient
sever
traumat
brain
injuri
evid
popul
studi
pulmonari
dysfunct
isol
complic
patient
brain
injuri
show
poor
prognosi
rather
repres
first
manifest
system
diseas
broader
studi
perform
order
assert
find
background
smoke
inhal
injuri
frequent
health
threat
contribut
signific
pulmonari
derang
object
studi
determin
potenti
interdepend
pulmonari
shunt
fraction
qsqt
tissu
oxygen
cardiac
perform
acut
phase
combin
burn
smoke
inhal
injuri
method
follow
thirddegre
burn
sheep
n
subject
cotton
smoke
accord
establish
protocol
breath
bl
set
cotton
smoke
inhal
qsqt
mean
pulmonari
arteri
pressur
cardiac
index
ci
left
ventricular
stroke
work
index
lvswi
deliveri
index
consumpt
index
vo
extract
rate
er
assess
time
point
arterioven
differ
venoarteri
pco
gradient
determin
statist
oneway
anova
studentnewmankeul
posthoc
test
linear
regress
appropri
data
express
mean
sem
pearson
correl
coeffici
respect
burn
injuri
led
immedi
sustain
decreas
ci
vs
lminm
accompani
depress
lvswi
vs
gmm
p
smoke
inhal
impair
hemodynam
chang
led
progress
increas
qsqt
maximum
p
vs
bl
interestingli
degre
qsqt
invers
correl
arterioven
differ
r
venoarteri
pco
gradient
r
er
remain
unchang
reduct
vs
mlmin
vo
vs
mlmin
occur
p
vs
bl
conclus
studi
demonstr
acut
phase
combin
burn
smoke
inhal
injuri
deterior
tissu
oxygen
link
depress
myocardi
contractil
global
oxygen
transport
well
increas
qsqt
arterioven
differ
appropri
mirror
ventilationperfus
mismatch
compar
venoarteri
pco
gradient
examin
expir
air
condens
eac
patient
variou
stage
ard
use
spectrophotometri
studi
metabolit
fluoresc
studi
h
identif
fa
blood
cell
detect
use
monoclon
antibodi
investig
show
increas
metabolit
level
eac
patient
first
second
stage
ard
signific
decreas
eac
patient
third
fourth
stage
level
h
eac
elev
progress
ard
patient
increas
fasl
product
note
reduct
level
patient
final
ard
stage
data
show
alveolar
epitheli
injuri
ali
ard
part
associ
upregul
fasfasl
system
activ
oxid
stress
marker
find
suggest
oxygenindepend
pathway
may
mainli
oper
process
fasinduc
apoptosi
introduct
addit
high
level
peep
patient
mechan
ventil
part
recruit
maneuv
alveolar
protect
howev
also
caus
deleteri
effect
right
ventricular
function
studi
patient
admit
trauma
icu
period
januaryaugust
patient
mechan
ventil
without
signific
pulmonari
diseas
submit
systemat
increas
peep
zeep
cmh
everi
min
time
measur
haemodynam
effect
alter
oxygen
transport
result
traumat
patient
without
signific
pulmonari
diseas
mean
age
year
male
mean
apach
ii
score
mean
sap
ii
score
initi
mean
sofa
score
addit
peep
caus
progress
increas
pulmonari
arteri
pressur
central
venou
pressur
cvp
oxygen
extract
rate
time
caus
progress
decreas
cardiac
index
ci
right
ventricular
systol
work
index
rvswi
cvp
increas
ci
decreas
rvswi
decreas
alter
statist
signific
p
conclus
addit
peep
patient
mechan
ventil
without
signific
pulmonari
diseas
caus
progress
right
ventricular
dysfunct
haemodynam
care
support
taken
peep
increas
recruit
maneuv
alveolar
protect
even
done
short
period
time
introduct
tidal
volum
limit
increment
posit
end
expiratori
pressur
peep
correl
improv
surviv
acut
respiratori
distress
syndrom
ard
impact
haemodynam
respons
well
establish
aim
studi
evalu
haemodynam
volumetr
respons
increment
chang
tidal
volum
haemodynam
volumetr
respons
increment
chang
peep
twenti
acut
lung
injuri
ali
ard
patient
mechan
ventil
connect
integr
monitor
system
picco
system
agil
fiberopt
arteri
cathet
pv
central
venou
cathet
patient
randomis
receiv
mechan
ventil
increment
tidal
volum
tv
mlkg
zeep
group
tv
mlkg
increment
peep
cmh
group
b
everi
chang
respiratori
paramet
main
haemodynam
volumetr
data
evalu
cardiac
output
co
evalu
continu
onlin
data
express
mean
sd
anova
test
use
compar
chang
differ
tv
increment
level
peep
p
consid
statist
signific
avail
onlin
http
tabl
group
p
valu
co
lminm
tv
vs
tv
mlkg
map
mmhg
tv
vs
tv
mlkg
detriment
hemodynam
effect
posit
pressur
ventil
hypovolem
state
well
describ
year
nevertheless
typic
paramed
train
program
applic
prehospit
resuscit
trauma
protocol
unit
state
elsewher
often
call
hyperventil
therapi
eg
rate
particularli
moribund
trauma
patient
typic
paramed
train
anecdot
rational
pump
oxygen
better
compens
metabol
acidosi
therefor
consid
mani
patient
receiv
assist
ventil
sever
hemorrhag
exist
concern
practic
may
underrecogn
contributor
wors
outcom
may
even
overrid
mask
potenti
posit
effect
resuscit
studi
intervent
begin
address
issu
studi
perform
demonstr
slow
respiratori
rate
rr
preserv
adequ
oxygen
acidbas
statu
hemorrhag
state
also
normal
higher
rr
worsen
hemodynam
even
case
mild
moder
hemorrhag
method
eight
pig
ventil
mlkg
tidal
volum
intub
posit
end
expiratori
pressur
lung
diseas
fio
rr
pig
hemorrhag
mmhg
systol
arteri
blood
pressur
sabp
reach
steadi
state
rr
sequenti
chang
everi
min
respect
result
rr
anim
maintain
ph
increas
mean
sabp
mmhg
p
timeaverag
coronari
perfus
pressur
cpp
mmhg
p
cardiac
output
qt
lmin
p
rr
sabp
mmhg
cpp
mmhg
qt
lmin
decreas
pao
paco
mmhg
p
comparison
respect
rr
return
sbp
mmhg
cpp
mmhg
qt
lmin
improv
significantli
p
conclus
follow
moder
hemorrhag
anim
maintain
adequ
oxygen
ventil
slow
rr
increasingli
higher
rr
progress
impair
hemodynam
directli
result
diminish
coronari
perfus
qt
probabl
effect
pronounc
sever
hemorrhag
state
may
even
contribut
wors
outcom
underappreci
compromis
studi
result
current
resuscit
protocol
trauma
involv
provis
posit
pressur
ventil
reexamin
introduct
volumetr
monitor
right
ventricular
enddiastol
volum
index
rvedvi
global
enddiastol
volum
index
gedvi
increasingli
suggest
better
preload
indic
tradit
intracardiac
fill
pressur
central
venou
pressur
cvp
pulmonari
arteri
occlus
pressur
paop
static
volumetr
monitor
howev
consist
shown
correl
cardiac
index
ci
studi
aim
evalu
influenc
eject
fraction
ef
rvedvi
gedvi
studi
effect
rvedvi
gedvi
chang
correct
right
ventricl
eject
fraction
rvef
global
eject
fraction
gef
respect
identifi
optim
resuscit
target
volum
complet
hemodynam
profil
volef
picco
cathet
pulsion
germani
obtain
five
mechan
ventil
medic
icu
patient
age
year
sapsii
apach
ii
sofa
total
pair
measur
cvp
paop
rvedvi
rvef
gedvi
gef
ci
perform
figur
show
correl
correct
rvef
r
p
figur
show
similar
correl
correct
gef
r
p
adjust
volum
achiev
exponenti
correct
ef
deviat
normal
fig
rvedvic
gedvic
volumetr
target
correct
ef
present
tabl
found
correl
fill
pressur
static
volum
ci
conclus
fill
pressur
static
volum
unreli
preload
indic
ef
correct
target
volum
better
predict
fluid
respons
suggest
use
rvedvic
gedvic
target
resuscit
restor
organ
perfus
endpoint
unneccessari
overresuscit
past
valu
benefit
patient
tabl
eject
fraction
rvedvi
background
pressur
record
analyt
method
pram
recent
develop
method
beattobeat
quantif
cardiac
output
co
base
analysi
arteri
waveform
sinc
pram
implement
variou
condit
flow
assess
accuraci
cardiac
surgeri
extracorpor
circul
ecc
use
roller
pump
devic
rp
refer
gold
standard
patient
undergo
cardiac
surgeri
co
valu
obtain
pram
radial
arteri
compar
bolu
thermodilut
td
ecc
rp
read
ecc
aortic
clamp
pram
flow
measur
ecc
base
analysi
sinusoid
arteri
waveform
continu
compon
flow
produc
rp
estim
blood
flow
measur
pram
close
agre
td
r
p
bia
coeffici
variat
simultan
rp
read
r
p
bia
coeffici
variat
wean
ecc
two
pattern
hemodynam
adapt
document
pram
follow
resumpt
cardiac
contract
background
ntermin
prohormon
natriuret
peptid
anp
bnp
ntproanp
ntprobnp
accept
marker
myocardi
dysfunct
increasingli
use
critic
ill
patient
well
recogn
plasma
level
anp
alter
variat
thorac
blood
volum
intraven
sodium
load
incomplet
data
avail
cours
bnp
intervent
two
group
eight
healthi
subject
randomli
tilt
fd
hd
posit
ten
volunt
crossov
subject
infus
mlkg
nacl
min
control
observ
period
hour
blood
sampl
time
interv
ntproanp
ntprobnp
determin
radiochemiluminesc
electrochemoluminisc
immunoassay
respect
result
ntproanp
level
baselin
level
higher
p
hd
fd
ntprobnp
level
affect
tilt
follow
sodium
load
fig
plasma
ntproanp
level
increas
immedi
return
back
baselin
hour
contrast
ntprobnp
level
increas
hour
infus
doubl
end
observ
period
conclus
besid
relev
physiolog
implic
sequenti
increas
ntproanp
ntprobnp
sodium
load
shown
previous
human
data
show
ntprobnp
level
influenc
sodium
infus
may
relev
interpret
ntprobnp
level
critic
ill
patient
cours
plasma
level
ntproanp
ntprobnp
healthi
volunt
control
protocol
sodium
load
protocol
data
mean
sem
p
betweengroup
differ
p
versu
baselin
valu
friedman
test
wilcoxon
match
pair
test
appropri
studi
surgic
patient
suggest
use
noninvas
measur
cardiac
output
guid
intraop
fluid
resuscit
result
improv
patient
outcom
test
hypothesi
patient
major
elect
surgeri
method
fifti
patient
schedul
major
urolog
surgeri
sequenti
random
control
c
group
flow
guid
fg
group
c
group
intraop
fluid
given
accord
blood
pressur
heart
rate
blood
loss
fg
group
addit
volum
given
maxim
cardiac
output
cardiac
index
lminm
achiev
use
nico
novametrix
noninvas
cardiac
output
record
continu
measur
cardiac
index
patient
follow
postop
investig
team
record
return
bowel
function
time
hospit
discharg
decis
discharg
patient
made
surgic
team
per
protocol
result
patient
demograph
present
tabl
patient
fg
group
older
c
group
patient
fg
group
given
significantli
volumehour
surgeri
c
group
time
passag
flatu
abil
toler
soft
diet
hospit
discharg
decreas
fg
group
tabl
differ
morbid
mortal
two
group
conclus
studi
sugest
use
continu
noninvas
measur
cardiac
output
guid
intraop
volum
replac
result
volum
given
faster
postop
recoveri
bowel
function
faster
hospit
discharg
introduct
central
venou
oxygen
satur
scvo
reflect
tissu
oxygen
deliveri
consumpt
shown
experiment
close
reflect
rang
circulatori
disturb
relat
paramet
use
success
improv
outcom
variou
patient
group
despit
fact
littl
observ
data
link
derang
paramet
outcom
highrisk
surgic
patient
method
data
collect
highrisk
surgic
patient
first
eight
postop
hour
routin
monitor
includ
cardiac
output
central
venou
satur
patient
divid
high
low
scvo
group
accord
whether
scvo
fell
two
consecut
hourli
read
follow
day
result
seventynin
patient
enrol
eight
death
morbid
episod
episod
per
patient
median
age
year
year
median
apach
ii
score
trend
scvo
cardiac
index
indic
circulatori
failur
mani
routin
paramet
normal
eg
blood
pressur
heart
rate
serum
lactat
higher
incid
complic
particular
septic
cardiac
complic
longer
hospit
stay
trend
toward
increas
mortal
found
patient
low
scvo
see
tabl
low
scvo
appear
indic
patient
high
risk
complic
surgeri
scvo
may
indic
hypovolaemia
earlier
stage
tradit
paramet
scvo
may
suitabl
haemodynam
goal
surgic
patient
shown
sever
sepsi
object
pilot
investig
describ
two
egdt
implement
model
medic
intens
care
unit
micu
initi
model
emerg
depart
ed
initi
model
prospect
descript
studi
report
qualit
assess
advantag
rel
barrier
two
model
egdt
implement
model
develop
two
tertiari
care
hospit
patient
elig
egdt
protocol
suspect
infect
criteria
either
septic
shock
systol
blood
pressur
despit
cm
kg
fluid
resuscit
lactat
mmoll
implement
center
includ
initi
phase
compris
micu
ed
physician
nurs
staff
educ
micudriven
protocol
conduct
baselin
data
collect
period
result
model
collabor
vari
term
initi
protocol
micudriven
model
develop
introduc
protocol
ensu
support
ed
eddriven
model
develop
introduc
protocol
ensu
support
deriv
micu
time
patient
identif
protocol
complianc
ed
transfer
time
micu
continu
evalu
model
insert
scvo
central
venou
oximetri
cathet
presep
share
micu
ed
team
base
ed
acuiti
oper
skill
physiolog
urgenc
micudriven
protocol
strongli
support
intens
care
staff
earli
transfer
ed
micu
prioriti
cours
studi
time
patient
identif
micu
collabor
continu
improv
eddriven
protocol
team
found
earli
identif
initi
protocol
combin
strong
support
icu
result
collabor
streamlin
base
ed
micu
workload
institut
found
challeng
patient
identif
line
insert
present
timeconsum
obstacl
protocol
initi
conclus
implement
egdt
protocol
possibl
collabor
process
whether
driven
intens
care
unit
emerg
depart
team
frequent
educ
collabor
commun
appear
key
element
success
peripher
perfus
index
pfi
deriv
puls
oximetri
signal
permit
quantit
analysi
peripher
perfus
patient
howev
relationship
variat
index
variat
peripher
blood
flow
critic
ill
patient
studi
therefor
studi
abil
pfi
detect
vascular
respons
produc
induc
reactiv
hyperemia
critic
ill
patient
materi
method
pfi
obtain
use
convent
puls
oximetri
peripher
temperatur
measur
use
proxim
temperatur
probe
phillip
place
forearm
distal
probe
place
middl
fingertip
arm
use
pfi
measur
skinsurfac
temperatur
gradient
proxim
distal
probe
dt
calcul
measur
chang
forearm
bloodflow
reactiv
hyperemia
produc
arrest
forearm
blood
flow
sphygmomanomet
pneumat
cuff
place
around
upper
arm
use
arteri
cannul
cuff
inflat
pressur
approxim
mmhg
greater
systol
pressur
min
cuff
rapidli
deflat
mmhg
hyperem
respons
analys
measur
maximum
increas
pfi
rel
baselin
pfi
student
test
use
assess
differ
baselin
maximum
pfi
p
consid
statist
signific
result
fiftysix
measur
carri
patient
patient
pfi
increas
releas
pneumat
cuff
chang
hemodynam
pfi
dt
present
tabl
conclus
pfi
use
assess
vascular
reactiv
critic
ill
patient
primari
goal
treatment
patient
shock
restor
tissu
perfus
oxygen
clinic
endpoint
resuscit
ie
bloodpressur
heart
rate
urin
output
oxygen
satur
give
incomplet
even
mislead
pictur
tissu
oxygen
tension
pto
reflect
tissu
oxygen
may
use
endpoint
howev
clinic
set
pto
measur
subcutan
pto
sc
muscl
pto
im
use
although
compar
studi
never
perform
critic
ill
patient
simultan
continu
measur
use
polarograph
clarktyp
electrod
licox
cathet
measur
system
gm
place
subcutan
bicep
brachii
upper
arm
eighteen
men
two
women
septic
shock
n
sever
sepsi
n
sepsi
n
polytrauma
n
nonsept
acut
respiratori
distress
syndrom
ard
n
includ
median
age
year
rang
year
median
apach
score
admiss
rang
median
durat
tissu
oxygen
measur
day
rang
day
median
pto
valu
differ
group
present
tabl
wilcoxon
sign
rank
test
use
compar
chang
within
group
oneway
analysi
varianc
anova
use
comparison
variat
pto
valu
within
group
although
differ
pto
sc
pto
im
found
individu
patient
goup
clear
pattern
could
establish
measur
tissu
oxygen
perform
subcutan
tissu
well
muscl
tissu
compar
efficaci
transcutan
monitor
co
tcco
tradit
paco
arteri
bloodga
sampl
method
studi
consecut
icu
admiss
period
includ
new
patient
age
expect
surviv
hour
tosca
transcutan
monitor
tcco
attach
earlob
probe
move
everi
hour
routin
arteri
bloodga
sampl
taken
paco
valu
record
studi
eight
patient
four
male
four
femal
mean
age
year
mean
admiss
apach
ii
sap
score
respect
mean
hospit
stay
day
icu
surviv
two
patient
ventil
use
highfrequ
oscil
total
comparison
made
detect
signific
differ
bloodga
paco
tosca
tcco
kpa
pair
test
p
figur
show
bia
limit
agreement
regress
line
fit
slope
intercept
highli
signific
possibl
predict
paco
tcco
use
follow
regress
equat
paco
tcco
conclus
although
differ
paco
tcco
possibl
accur
predict
paco
level
use
tcco
moder
precis
tcco
may
adequ
altern
arteri
blood
ga
sampl
bland
altman
plot
tosca
data
object
demonstr
relat
plasma
ntermin
probrain
natriuret
peptid
ntprobnp
concentr
sever
heart
failur
underl
heart
diseas
new
york
heart
associ
nyha
function
classif
patient
cardiovascular
diseas
method
plasma
ntprobnp
concentr
patient
cardiovascular
diseas
n
normal
control
n
measur
nonextract
enzymelink
sandwich
immunoassay
elecsi
admiss
construct
function
paramet
heart
measur
echocardiographi
patient
time
plasma
ntprobnp
concentr
patient
significantli
higher
normal
control
also
increas
accord
sever
heart
failur
classifi
nyha
function
classif
p
plasma
ntprobnp
concentr
left
ventricular
end
diastol
introduct
recent
less
invas
cardiovascular
monitor
transpulmonari
thermodilut
picco
system
use
central
venou
line
arteri
thermodilut
cathet
got
increasingli
popular
last
issu
yearbook
intens
care
emerg
medicin
opinion
state
singl
cold
salin
inject
suffici
adequ
measur
cardiac
output
deriv
thermodilut
paramet
sinc
report
investig
literatur
subject
want
examin
hypothesi
retrospect
examin
data
picco
system
pulsion
munich
germani
patient
treat
neurosurg
intens
care
unit
neurosurg
diagnosi
mainli
sever
subarachnoid
hemorrhag
patient
addit
diagnos
system
inflammatori
respons
syndrom
acut
respiratori
distress
syndrom
cardiac
failur
thermodilut
measur
consist
five
singl
inject
bolu
cm
ice
salin
data
automat
store
laptop
connect
picco
system
raw
data
volum
mb
thermodilut
measur
extract
analys
repeat
analysi
varianc
anova
perform
quantifi
disagr
singl
measur
result
total
thermodilut
procedur
consist
singl
bolu
inject
analyz
index
cardiac
output
ci
intrathorac
blood
volum
itbi
extrapulmonari
lung
water
elwi
median
differ
lowest
highest
valu
singl
seri
lminm
ci
mlm
itbi
mlkg
elwi
respect
calcul
withinsubject
varianc
anova
repeat
coeffici
two
measur
thermodilut
sequenc
lminm
ci
mlm
itbi
mlkg
elwi
translat
ci
itbi
elwi
measur
paramet
normal
rang
accord
data
disadvis
use
singl
inject
measur
transpulmonari
thermodilut
especi
preload
paramet
mean
least
three
repeat
measur
reflect
patient
statu
appropri
remain
clinic
judgement
much
imprecis
measur
data
clinician
will
accept
may
vari
differ
situat
matter
principl
solvabl
statist
introduct
cardiac
output
measur
continu
invas
pulmonari
arteri
cathet
pac
noninvas
imped
cardiographi
purpos
studi
determin
well
two
method
correl
ventil
patient
patient
cardiac
output
less
lmin
correl
coeffici
r
r
cardiac
output
measur
imped
cardiographi
good
correl
pac
patient
cardiac
output
less
lmin
time
correl
two
method
decreas
studi
indic
determin
method
best
suit
ventil
patient
intestin
perfus
oxygen
peep
level
cmh
therefor
explor
effect
peep
anim
model
itbvguid
volum
load
method
twenti
anesthet
ventil
pig
studi
ultrason
flow
probe
place
around
superior
mesenter
arteri
cathet
insert
femor
arteri
mesenter
vein
anim
randomli
assign
group
control
n
receiv
crystalloid
group
itbv
n
receiv
crystalloid
continu
colloid
substitut
maintain
itbv
baselin
level
analyz
intrathorac
blood
volum
index
itbvi
pulmonari
arteri
occlus
pressur
paop
respect
stroke
volum
index
svi
preload
index
extravascular
lung
water
index
respect
pao
fio
ratio
also
analyz
prospect
studi
patient
septic
shock
monitor
pulmonari
arteri
cathet
cold
system
pulsion
medic
system
munich
germani
measur
perform
everi
hour
studi
admiss
hour
relationship
variabl
analyz
linear
regress
linear
regress
itbvisvi
r
p
paop
fail
correl
r
fig
evlwi
show
signific
correl
pao
fio
r
p
fig
result
show
itbvi
reliabl
indic
paop
preload
assess
septic
shock
patient
evlwi
confirm
interest
bedsid
lung
edema
index
select
popul
method
retrospect
studi
surgic
intens
care
unit
fortysix
patient
analys
patient
mechan
ventil
patient
picco
puls
contour
cardiac
output
cathet
insert
variabl
suxh
length
icu
admiss
length
pressur
control
ventil
ventil
set
apach
ii
score
acut
physiolog
chronic
health
evalu
evlw
collect
correl
variabl
evalu
linear
regress
model
median
apach
ii
score
includ
patient
rang
patient
mechan
ventil
pressur
control
mode
posit
end
expiratori
pressur
rang
inspir
pressur
rang
cmh
divid
patient
two
group
one
includ
patient
evlw
one
includ
patient
evlw
group
evlw
saw
higher
mortal
rate
compar
group
evlw
vs
group
found
correl
length
icu
admiss
length
mechan
ventil
apach
ii
score
evlw
although
found
associ
evlw
mortal
surgic
critic
ill
patient
could
confirm
relat
evlw
length
icu
admiss
length
mechan
ventil
patient
popul
studi
introduct
use
hemodynam
monitor
allow
one
evalu
followup
patient
acut
myocardi
infarct
ami
monitor
effect
treatment
compar
differ
treatment
option
hand
creat
addit
problem
choos
method
monitor
cheap
reliabl
easi
use
staff
aim
evalu
possibl
continu
hemodynam
monitor
applic
patient
ami
compar
result
two
noninvas
method
imped
cardiographi
icg
transthorac
echocardiographi
tte
patient
ami
design
prospect
studi
set
kauna
univers
medicin
clinic
cardiolog
patient
patient
ami
admit
within
hour
onset
diseas
method
standard
eightelectrod
icg
record
averag
valu
stroke
volum
sv
deriv
last
min
icg
record
sv
instantan
valu
use
comparison
icg
tte
result
svtte
calcul
differ
left
ventricular
enddiastol
endsystol
volum
fourchamb
twochamb
view
use
svtte
analysi
svtte
altern
evalu
measur
flow
velocitytim
integr
left
ventricular
outflow
tract
result
eightyseven
patient
investig
accord
studi
protocol
result
patient
use
compar
analysi
men
women
averag
age
year
bodi
mass
index
bmi
eject
fraction
compar
valu
sv
deriv
icg
tte
calcul
correl
coeffici
r
correl
method
icg
tte
reach
r
men
r
women
week
correl
method
observ
sv
valu
compar
patient
bmi
r
well
sv
measur
evalu
flow
velocitytim
integr
left
ventricl
outflow
tract
r
conclus
signific
correl
sv
observ
icg
tte
noninvas
monitor
ami
consid
reliabl
method
applic
benefit
routin
measur
cardiac
output
cardiac
surgeri
still
discuss
studi
found
benefit
routin
right
heart
catheteris
other
found
reduc
length
stay
clinic
predict
cardiac
output
poor
cardiac
surgeri
clinician
also
realli
know
valu
cardiac
output
necessari
cardiac
surgeri
aim
present
studi
verifi
whether
commonli
accept
lower
valu
cardiac
index
lminm
arriv
icu
good
predictor
complic
cardiac
surgeri
method
seventythre
consecut
patient
valu
cardiac
index
lower
equal
includ
prospect
observ
studi
right
heart
catheteris
decid
oper
room
patient
complex
surgeri
left
ventricular
dysfunct
routin
hemodynam
measur
perform
arriv
icu
hour
later
includ
arteri
mix
venou
blood
gase
postop
complic
defin
death
renal
insuffici
need
prolong
mechan
ventil
result
fiftyon
patient
complic
group
patient
group
present
postop
complic
includ
four
death
differ
found
two
group
preoper
intraop
data
age
eject
fraction
euroscor
length
bypass
aortic
clamp
blood
lactat
level
ph
base
excess
arriv
icu
hour
later
hemodynam
paramet
similar
two
group
complic
patient
lower
cardiac
output
svo
valu
hour
arriv
icu
logist
regress
analysi
reduc
cardiac
index
hour
admiss
icu
strongest
independ
predict
valu
postop
complic
discuss
low
cardiac
output
hour
arriv
icu
associ
high
level
postop
complic
use
right
heart
catheteris
allow
earli
predict
treatment
low
cardiac
output
order
prevent
postop
complic
microcirculatori
failur
septic
shock
relationship
modif
macrocircul
microcircul
may
depend
resuscit
microcircul
modifi
cardiac
output
co
increas
fluid
four
septic
shock
patient
year
old
investig
orthogon
polar
spectral
imag
op
swanganz
cathet
sap
score
norepinephrin
three
sublingu
area
per
patient
number
vessel
small
medium
larg
quot
flow
sludg
moder
normal
allow
one
comput
microcirculatori
ratio
vessel
categori
system
hemodynam
op
data
taken
within
min
fluid
bolu
mlkg
op
data
present
median
interquartil
rang
demograph
hemodynam
data
present
median
se
number
small
vesselsfield
tend
increas
fluid
p
fig
vessel
categori
increas
ratio
p
blood
pressur
increas
fluid
challeng
wherea
co
increas
p
fig
size
microvessel
chang
fluid
load
differ
pattern
small
larger
vessel
go
recruit
increas
blood
veloc
studi
undertaken
test
whether
endotoxin
administr
human
volunt
use
model
studi
sepsisinduc
increas
microvascular
permeabl
healthi
nonsmok
volunt
microvascular
permeabl
assess
hour
administr
endotoxin
ngkg
bodi
weight
n
placebo
n
transcapillari
escap
rate
albumin
teralb
venou
occlus
straingaug
plethymographi
determin
filtrat
capac
kf
bioelectr
imped
analysi
bia
determin
extracellular
water
ecw
total
bodi
water
tbw
administr
endotoxin
result
expect
increas
proinflammatori
cytokin
pgml
p
accompani
fever
maximum
temperatur
p
flulik
symptom
cardiovascular
chang
heart
rate
bpm
baselin
bpm
hour
p
mean
arteri
pressur
mmhg
mmhg
p
forearm
blood
flow
mlmindl
mlmindl
forearm
volum
chang
significantli
differ
control
group
endotoxintr
subject
microvascular
permeabl
paramet
remain
unchang
teralb
p
ns
kf
p
ns
ecwtbw
measur
bia
p
ns
also
signific
chang
appear
microvascular
permeabl
paramet
control
group
although
endotoxin
frequent
use
model
studi
sepsisassoci
effect
endotoxininduc
increas
microvascular
permeabl
vivo
could
detect
three
differ
method
endotoxin
administr
human
volunt
suitabl
model
studi
chang
microvascular
permeabl
experiment
studi
use
periton
model
sepsi
rat
report
abnorm
microvascular
perfus
includ
increas
stop
flow
capillari
increas
fast
flow
capillari
impair
regul
blood
flow
use
spectrophotometr
function
microvascular
imag
system
quantifi
capillari
geometri
red
blood
cell
flow
red
blood
cell
hemoglobin
oxygen
satur
sepsi
found
oxygen
satur
entranc
capillari
bed
unaffect
sepsi
signific
drop
satur
venou
end
capillari
normal
veloc
although
fall
oxygen
satur
correl
number
stop
flow
capillari
could
determin
data
whether
tissu
oxygen
consumpt
chang
sepsi
whether
fast
flow
capillari
act
function
oxygen
shunt
whether
region
tissu
anox
address
question
construct
comput
model
simul
transport
threedimension
volum
tissu
suppli
heterogen
space
capillari
fast
normal
stop
flow
model
base
experiment
oxygen
transport
data
capillari
densiti
number
stop
flow
capillari
capillari
red
blood
cell
veloc
suppli
rate
entranc
oxygen
satur
level
model
predict
oxygen
consumpt
tissu
oxygen
level
oxygen
transport
fast
flow
capillari
data
could
measur
experiment
current
technolog
tissu
oxygen
consumpt
model
adjust
yield
venou
end
oxygen
satur
valu
measur
experiment
two
case
model
averag
sepsi
stop
normal
fast
flow
extrem
sepsi
es
stop
normal
fast
flow
simul
found
approxim
twofold
fourfold
increas
tissu
oxygen
consumpt
es
respect
averag
minimum
tissu
po
decreas
mmhg
control
mmhg
es
respect
cluster
fast
flow
capillari
increas
flow
heterogen
result
slight
decreas
minimum
tissu
po
mmhg
although
fast
flow
capillari
appear
oxygen
shunt
higher
venou
oxygen
satur
signific
factor
prevent
tissu
anoxia
sepsi
despit
contribut
fast
flow
capillari
simul
tissu
po
valu
continu
fall
degre
microvascular
injuri
increas
model
predict
microvascular
oxygen
transport
abnorm
associ
sepsi
expos
tissu
local
region
hypox
environ
may
lead
ultim
signific
chang
cellular
function
introduct
accord
modifi
fick
equat
venoarteri
pco
gradient
invers
correl
cardiac
output
increas
valu
alert
presenc
lowflow
state
least
mismatch
tissu
blood
flow
metabol
septic
shock
patient
howev
relat
cardiac
output
quit
complex
due
possibl
distribut
abnorm
macrocirculatori
microcirculatori
blood
flow
object
studi
determin
whether
good
correl
cardiac
output
group
septic
shock
patient
base
excess
arteri
lactat
concentr
lac
two
latter
alreadi
demonstr
good
predictor
mortal
critic
ill
patient
retriev
patient
prospect
collect
data
base
januari
decemb
apach
ii
score
calcul
admiss
cardiac
output
lac
record
moment
pulmonari
arteri
cathet
insert
hour
four
variabl
normal
distribut
sampl
correl
three
variabl
perform
use
pearson
coeffici
patient
age
year
apach
ii
score
correl
three
variabl
pearson
correl
coeffici
p
p
p
cardiac
output
lac
respect
background
goal
studi
monitor
organ
function
often
crucial
guid
therapi
critic
ill
patient
recent
indocyanin
green
plasma
disappear
rate
icgpdr
suggest
assess
liver
function
transcutan
system
clinic
introduc
valid
studi
analyz
agreement
icgpdr
measur
recommend
dosag
mgkg
reduc
dosag
mgkg
studi
critic
ill
patient
five
femal
male
underw
monitor
icgpdr
clinic
indic
limon
pulsion
medic
system
germani
compar
measur
random
fashion
either
mgkg
mgkg
icg
inject
follow
correspond
dosag
min
later
analyz
pair
icgpdr
measur
appli
recommend
dosag
mgkg
icgpdr
reduc
dosag
mgkg
icgpdr
respir
set
dosag
vasoact
drug
remain
unchang
studi
drug
may
influenc
hepat
blood
flow
administ
studi
period
chang
fluid
statu
central
venou
pressur
unchang
two
time
point
result
discuss
min
min
respect
linear
regress
analysi
reveal
icgpdr
icgpdr
min
r
p
mean
bia
min
standard
deviat
min
residu
rate
also
highli
correl
r
p
mean
bia
conclus
reduc
dosag
icg
mgkg
suffici
accur
transcutan
measur
icgpdr
critic
ill
patient
introduct
indocyaninegreen
icg
clearanc
measur
limon
devic
pulsion
germani
express
plasma
disappear
rate
pdr
icg
normal
valu
residu
icg
min
normal
valu
studi
investig
correl
iap
sofa
score
classic
liver
function
test
mix
icu
patient
method
total
pair
measur
perform
patient
iap
obtain
use
balloontip
stomach
cathet
connect
iap
monitor
spiegelberg
germani
malefemal
ratio
age
year
apach
ii
score
sap
ii
score
mod
sofa
score
number
measur
patient
calcul
correl
perform
prism
softwar
version
octob
valu
present
mean
sd
valu
iap
mmhg
normal
valu
mmhg
pdr
correl
iap
poor
although
signific
r
correl
classic
liver
test
r
aspart
aminotransferas
alanin
aminotransferas
lactat
dehydrogenas
gammaglutamyl
transferas
alkalin
phosphatas
venou
nh
socal
liver
synthesi
function
test
albumin
bilirubin
plasma
cholinesteras
level
prothrombin
time
latter
good
correl
neither
platelet
gener
hemodynam
paramet
lactat
well
correl
signific
reason
correl
observ
sofa
score
number
organ
failur
final
correl
pdr
good
r
mortal
pdr
significantli
lower
vs
patient
die
iap
vs
sofa
score
vs
number
organ
failur
vs
significantli
higher
number
measur
failur
softwar
upgrad
conclus
limon
measur
feasibl
bedsid
correl
limon
deriv
paramet
classic
liver
function
test
except
coagul
correl
iap
signific
poor
limon
deriv
paramet
correl
sofa
score
number
organ
failur
give
addit
inform
pdr
lower
patient
die
iap
sofa
organ
failur
higher
introduct
ultrasoundguid
catheter
intern
jugular
vein
prove
benefit
especi
patient
specif
problem
hospit
icu
purpos
evalu
use
method
compar
landmark
method
former
perform
senior
intensivist
train
ultrasound
year
recent
taught
doppler
guidanc
method
latter
experienc
staff
patient
method
prospect
random
studi
perform
period
multidisciplinari
icu
g
gennimata
gener
hospit
novemb
novemb
one
group
assign
intern
jugular
vein
cannul
landmark
method
control
group
ultrasound
guidanc
ultrasound
group
sixtysix
patient
women
men
examin
thirtyf
patient
submit
catheter
landmark
method
patient
ultrasound
guidanc
intern
jugular
vein
cannul
success
case
control
group
case
ultrasound
group
p
carotid
arteri
punctur
occur
two
case
first
group
one
case
second
p
jugular
cannul
success
first
attempt
case
first
second
group
correspondingli
p
averag
access
time
longer
control
group
vs
ultrasound
group
conclus
ultrasound
guidanc
improv
success
rate
jugular
vein
cannul
reduc
number
failur
complic
well
number
attempt
differ
two
method
signific
familiar
oper
method
probabl
contribut
factor
must
taken
account
unit
kingdom
use
realtim
ultrasound
us
recommend
insert
central
venou
cathet
cvc
intern
jugular
vein
adult
associ
decreas
complic
decreas
failur
rate
possibl
faster
insert
standard
landmark
techniqu
concern
howev
exist
regard
train
implic
cost
use
recommend
evalu
effect
usguid
central
line
insert
method
februari
august
prospect
collect
data
regard
use
us
cvc
insert
use
ultrasound
machin
gener
intens
care
unit
junior
doctor
underw
bedsid
theoret
teach
one
junior
doctor
underw
formal
train
result
eightytwo
usguid
cvc
insert
major
senior
hous
offic
inexperienc
use
us
less
previou
usguid
cvc
insert
experienc
nonu
placement
greater
previou
nonusguid
cvc
insert
eightyf
per
cent
cvc
insert
intern
jugular
vein
insert
femor
vein
failur
rate
sixtythre
per
cent
cvc
insert
first
attempt
insert
second
attempt
averag
durat
insert
min
take
less
min
complic
rate
exclud
thread
guid
wirerel
problem
minor
conclus
usguid
cvc
insert
inexperienc
junior
doctor
minim
train
feasibl
also
appear
decreas
complic
failur
rate
well
increas
rate
first
pass
insert
object
sepsi
lead
caus
mortal
intens
care
unit
icu
septic
patient
better
prognos
multipl
organ
dysfunct
syndrom
present
regard
heart
variabl
rr
interv
hrv
also
depend
coupl
heart
organ
sepsi
may
readili
avail
tool
evalu
nonlinear
dynam
relationship
among
organ
multipl
organ
dysfunct
syndrom
develop
conduct
prospect
studi
analyz
hrv
hemodynam
ecocardigraph
serum
cardiac
marker
troponin
creatin
phosphat
kinas
evalu
possibl
relat
outcom
design
prospect
observ
analysi
serum
patient
meet
criteria
septic
shock
set
medicalsurg
icu
univers
hospit
patient
twentyf
patient
analyz
studi
select
consecut
patient
met
criteria
septic
shock
icu
collect
blood
sampl
analysi
day
death
analyz
creatin
phosphat
kinas
total
cpk
mb
ckmb
also
analyz
troponin
analyz
hemodynam
paramet
pulmonari
cathet
cardiac
ultrasonographi
holter
record
hour
time
point
day
statist
analysi
result
present
mean
standard
deviat
analysi
divid
patient
survivor
nonsurvivor
hospit
releas
perform
anova
repeat
measur
continu
variabl
correl
coeffici
determin
accord
multiplelevel
regess
analysi
p
consid
signific
mortal
patient
nonsurvivor
group
patient
survivor
two
group
similar
apach
ii
score
nonsurvivor
survivor
ns
cpk
ckmb
ecocardiographi
analysi
cardiac
output
vascular
resist
show
signific
differ
moment
studi
period
howev
troponin
show
signific
differ
first
day
studi
follow
stroke
work
analysi
signific
differ
survivor
nonsurvivor
differ
stroke
work
data
becom
higher
day
onward
hrv
show
signific
differ
maxim
minim
low
frequenc
lf
maxim
high
frequenc
correl
independ
variabl
maxim
lf
predictor
patient
outcom
conclus
studi
hrv
show
capabl
prognos
patient
outcom
heart
dysfunct
detect
serum
troponin
level
hemodynam
data
stroke
work
introduct
whether
day
time
icu
admiss
discharg
impact
patient
care
outcom
focu
recent
inquiri
may
also
relationship
time
outcom
event
occur
within
icu
first
step
explor
issu
aim
describ
time
new
acut
hemodynam
event
larg
icu
popul
hypothesi
acut
hemodynam
event
equal
distribut
throughout
day
throughout
week
although
trend
less
event
earli
morn
even
event
frequenc
gener
vari
littl
hour
day
fig
distribut
event
throughout
day
data
hospit
stay
analyz
major
patient
n
prove
ischem
heart
pain
group
develop
mi
angina
treat
accordingli
rest
patient
could
divid
two
group
patient
heart
condit
group
b
n
discharg
musculoskelet
pain
n
cholecyst
n
gastriti
n
depress
n
sepsi
n
mening
n
patient
cardiovascular
diseas
actual
ischemia
group
c
n
discharg
heart
failur
n
hypertens
n
tachycardia
n
bradycardia
n
dissect
aorta
n
pulmonari
embol
n
statist
signific
differ
gender
group
patient
group
b
c
older
group
p
signific
even
greater
compar
group
b
p
durat
examin
er
influenc
accuraci
diagnosi
patient
group
b
c
even
longer
examin
p
found
proport
patient
histori
angina
mi
greater
group
group
b
c
respect
statist
signific
p
smoke
high
cholesterol
hypertens
diabet
significantli
differ
group
interestingli
found
proport
patient
admit
afternoon
night
weekend
higher
group
b
c
group
p
although
characterist
patient
differ
admit
icu
staff
shift
follow
clinic
evalu
includ
ecg
patient
subject
routin
laboratori
test
includ
liver
kidney
function
lipid
profil
cbc
random
blood
sugar
specif
laboratori
test
includ
serum
fibrinogen
plasma
express
metabolit
nitrit
nitrat
nox
measur
griess
reaction
patient
control
subject
diagnost
coronari
arteriographi
assess
extent
coronari
diseas
number
affect
vessel
well
sever
stenosi
use
gensini
score
system
myocardi
dysfunct
common
critic
ill
patient
diagnosi
acut
coronari
syndrom
revolutionis
protein
isom
cardiac
troponin
ctnt
nonintens
care
set
earli
recognit
patient
elev
ctnt
instig
appropri
treatment
shown
reduc
risk
death
myocardi
infarct
concern
rais
prognost
valu
ctnt
patient
renal
dysfunct
troponin
renal
excret
method
retrospect
audit
carri
consecut
admiss
gener
noncardiothorac
intens
care
unit
icu
establish
incid
rais
ctnt
ctnt
ngml
patient
without
renal
dysfunct
renal
dysfunct
defin
creatinin
result
express
median
minimummaximum
outcom
ctnt
patient
without
renal
dysfunct
present
tabl
correl
renal
function
ctnt
level
r
signific
differ
outcom
rais
ctnt
patient
without
renal
dysfunct
conclus
elev
marker
cardiac
myocyt
damag
common
critic
ill
patient
associ
increas
mortal
rate
effect
seen
irrespect
renal
function
method
thirtysix
hour
intraven
endotoxin
lp
administr
rabbit
anaesthetis
ventil
systol
arteri
pressur
sap
diastol
arteri
pressur
dap
mean
arteri
pressur
map
mmhg
systol
aortic
blood
flow
veloc
saov
mean
aortic
blood
flow
veloc
maov
mhz
puls
doppler
cm
systol
renal
arteri
blood
flow
sren
diastol
renal
arteri
blood
flow
dren
transon
doppler
mlmin
measur
anaesthetis
ventil
rabbit
heart
inotrop
qualiti
estim
maxim
acceler
gmax
cm
saov
min
stabilis
rabbit
receiv
levosimendan
ls
salin
ls
min
separ
four
group
ls
ne
min
ls
avp
ngkgmin
min
ne
alon
avp
alon
paramet
gaussian
statist
analysi
perform
use
oneway
twoway
anova
result
ls
consist
improv
saov
gmax
within
min
p
sap
dap
map
decreas
p
addit
avp
ne
similarli
restor
mean
arteri
pressur
howev
effect
myocardi
function
diverg
ne
alter
saov
gmax
avp
dramat
deterior
contractil
paramet
respect
min
p
effect
avp
observ
use
combin
ls
alon
signific
effect
treatment
observ
sren
dren
studi
demonstr
ls
good
altern
restor
cardiac
contractil
function
combin
ne
use
avp
may
lead
deterior
sepsisrel
myocardi
dysfunct
even
combin
posit
inotrop
agent
levosimendan
use
intraven
manag
heart
failur
therapeut
dose
levosimendan
act
predominantli
calcium
sensit
atpsensit
k
channel
katpchannel
open
bind
directli
calciumdepend
site
troponin
c
stabil
calciuminduc
conform
chang
enhanc
calcium
sensit
cardiac
myofila
advantag
calcium
sensit
dobutamin
lack
intracellular
calcium
overload
act
without
increas
energi
demand
handl
intracellular
calcium
method
fifteen
patient
cardiogen
septic
mix
cardiogenicsept
shock
administ
load
dose
levosimendan
follow
continu
infus
hour
five
patient
diagnos
septic
shock
six
cardiogen
shock
four
mix
septic
cardiogen
shockth
mean
apach
ii
score
arteri
blood
pressur
patient
monitor
close
via
arteri
cathet
intraven
noradrenalin
administ
necessari
maintain
mean
arteri
pressur
mmhg
echocardiograph
left
ventricular
eject
fraction
lvef
simpson
method
plasma
btype
natriuret
peptid
biosit
triag
method
measur
within
hour
levosimendan
infus
lvef
show
significantli
rel
small
improv
respons
levosimendan
infus
pre
vs
post
repres
absolut
chang
p
plasma
btype
natriuret
peptid
concentr
demonstr
signific
decreas
pgml
levosimendan
infus
p
use
levosimendan
shock
patient
prove
feasibl
hold
promis
potenti
altern
catecholamin
inotrop
introduct
levosimendan
ls
new
inodil
improv
surviv
patient
congest
heart
failur
data
critic
care
patient
cardiorespiratori
failur
scanti
aim
studi
evalu
homodynam
volumetr
respons
ls
critic
care
patient
cardiogen
shock
ten
critic
care
patient
cardiogen
shock
studi
patient
mechan
ventil
connect
integr
monitor
system
picco
systemagil
fiberopt
arteri
cathet
pv
swanganz
cathet
basal
time
hour
hour
hour
hour
ls
infus
hour
post
ls
suspens
main
haemodynam
volumetr
data
studi
data
express
mean
sd
anova
test
rm
use
compar
chang
time
studi
tabl
present
main
hemodynam
chang
cardiac
output
co
pulmonari
capillari
wedg
pressur
pcwp
intrathorac
blood
volum
itbvi
extravascular
lung
water
evlwi
background
levosimendan
new
calcium
sensit
inodilatori
properti
aim
case
seri
report
evalu
effect
periop
postop
use
levosimendan
cardiosurg
patient
high
periop
risk
compromis
left
ventricular
lv
function
difficulti
wean
cardiopulmonari
bypass
cpb
sixteen
cardiosurg
patient
receiv
levosimendan
infus
maximum
durat
hour
eight
infus
initi
preoper
eight
postop
patient
receiv
levosimendan
bolu
min
main
oper
indic
coronari
arteri
diseas
seventyf
per
cent
subject
highrisk
patient
cardiac
pace
postop
heart
rate
analys
continu
infus
levosimendan
increas
cardiac
index
group
significantli
pulmonari
capillari
wedg
pressur
systol
blood
pressur
chang
crystalloid
vasopressor
commonli
noradrenalin
adrenalin
administ
need
wean
cpb
success
patient
two
infus
discontinu
due
hypotens
one
highrisk
patient
preoper
group
die
oper
postop
group
two
patient
multiorgan
failur
die
postop
introduct
aim
studi
determin
hemodynam
clinic
effect
levosimendan
ls
cardiosurg
patient
ls
enhanc
contractil
function
stun
myocardium
without
increas
concetr
intracellular
calcium
myocardi
oxygen
consumpt
method
ten
patient
age
year
mechan
ventil
sedat
includ
studi
n
diagnosi
coronari
arteri
bypass
oper
n
valv
replac
n
pulmonari
edema
n
patient
prospect
select
receiv
ls
hemodynam
data
measur
pulmonari
arteri
cathet
estim
cardiac
function
echocardiographi
indic
need
posit
inotrop
support
infus
rate
ls
preexist
infus
epinephrin
norepinephrin
titrat
maintain
mean
arteri
pressur
mmhg
crystalloid
colloid
administ
maintain
pulmonari
capillari
wedg
pressur
pcwp
mmhg
measur
obtain
baselin
hour
hour
start
ls
infus
statist
analysi
perform
pair
test
p
consid
statist
signific
result
ls
caus
signific
increas
cardiac
index
ci
lminm
baselin
lminm
hour
infus
increas
ci
due
mainli
increas
stroke
volum
heart
rate
remain
nearli
unchang
studi
period
stroke
volum
index
increas
mlm
mlm
p
left
ventricular
eject
fraction
estim
echocardiographi
increas
p
system
vascular
resist
index
significantli
decreas
dynscm
dynscm
p
ls
caus
signific
chang
pulmonari
vascular
resist
pvri
baselin
dynscm
hour
dynscm
fall
pcwp
although
signific
studi
effect
new
calcium
sensitis
evalu
cardiac
surgeri
studi
demonstr
ls
exert
favour
hemodynam
respons
patient
without
increas
myocardi
oxygen
consumpt
ls
potenti
treat
low
cardiac
output
state
cardiopulmonari
bypass
surgeri
use
situat
might
special
valu
acut
decompens
heart
failur
adhf
repres
sever
form
heart
failur
shortterm
mortal
approach
surviv
studi
first
prospect
randomis
trial
utilis
mortal
primari
variabl
evalu
efficaci
intraven
drug
therapi
adhf
levosimendan
ls
new
calcium
sensitis
treatment
adhf
previou
studi
ls
shown
decreas
mortal
comparison
placebo
dobutamin
db
studi
howev
power
mortal
suspicion
detriment
mortal
effect
db
also
rais
proven
suffici
power
singl
studi
metaanalysi
therefor
db
still
wide
use
intraven
iv
inotrop
agent
treatment
adhf
surviv
studi
multicentr
parallelgroup
randomis
doubleblind
doubledummi
studi
patient
adhf
compar
efficaci
ls
db
surviv
studi
includ
hospitalis
patient
adhf
left
ventricular
eject
fraction
clinic
need
iv
inotrop
support
primari
endpoint
studi
allcaus
mortal
day
follow
randomis
patient
receiv
two
simultan
intraven
infus
lsplacebo
maximum
durat
hour
dbplacebo
accord
clinic
judgement
minim
hour
start
dose
period
origin
randomis
studi
drug
readminist
clinic
justifi
altogeth
patient
recruit
sampl
size
base
assum
mortal
db
group
rel
risk
reduct
ls
group
power
alphalevel
studi
ongo
eight
countri
finland
franc
germani
israel
latvia
poland
russia
uk
patient
follow
month
death
occur
data
safeti
monitor
board
make
recommend
continuationdiscontinu
studi
follow
prespecifi
stop
rule
separ
steer
committe
follow
mortal
rate
without
open
treatment
code
may
recommend
increas
sampl
size
surviv
thu
repres
first
studi
two
ambiti
goal
adhf
studi
new
drug
accept
refer
treatment
db
assess
mortal
futur
trial
probabl
follow
new
standard
design
set
background
hospitalis
especi
length
stay
intens
care
main
cost
driver
heart
failur
hf
levosimendan
novel
calcium
sensitis
improv
shortterm
longterm
outcom
patient
acut
hf
object
evalu
length
intens
care
hospit
stay
acut
decompens
hf
patient
treat
levosimendan
compar
placebo
reviv
trial
pilot
trial
compris
patient
acut
hf
hospitalis
worsen
hf
dyspnea
rest
despit
intraven
iv
diuret
patient
randomis
doubleblind
receiv
placebo
pbo
n
iv
levosimendan
ls
n
given
load
dose
min
follow
continu
infus
min
hour
among
measur
durat
hospitalis
intens
care
icuccu
prospect
record
baselin
patient
ls
group
patient
pbo
group
treat
icuccu
one
levosimendan
three
placebotr
patient
subsequ
admit
icuccu
randomis
mean
treatment
time
icuccu
day
ls
group
day
pbo
group
median
day
vs
day
mean
durat
index
hospit
random
day
ls
group
day
pbo
group
median
day
group
initi
discharg
one
patient
ls
group
seven
patient
pbo
group
admit
icuccu
subsequ
rehospit
day
mean
treatment
time
icuccu
patient
day
ls
group
pbo
group
median
day
vs
day
acut
hf
patient
admit
intens
care
treat
levosimendan
spent
averag
day
less
icuccu
patient
treat
usual
care
shorten
icu
treatment
time
day
without
increas
total
length
initi
hospitalis
could
reduc
total
hospitalis
cost
us
per
patient
promis
initi
result
await
confirm
ongo
reviv
ii
trial
total
patient
hospit
worsen
hf
dyspnea
rest
despit
iv
diuret
random
doubleblind
receiv
placebo
pbo
n
iv
levosimendan
ls
n
given
load
dose
min
follow
continu
infus
min
hour
patient
follow
close
addit
day
patient
classifi
improv
report
hf
moder
markedli
improv
specif
timepoint
patient
classifi
wors
die
receiv
iv
medic
worsen
hf
studi
period
patient
consid
unchang
neither
improv
wors
differ
model
use
differ
definit
improv
worsen
prospect
retrospect
examin
initi
model
defin
improv
base
respons
hour
day
restrict
definit
worsen
use
iv
vasodil
inotrop
agent
use
model
improv
observ
frequent
ls
pbo
vs
betweengroup
differ
proport
patient
wors
overal
p
definit
worsen
expand
includ
use
iv
diuret
worsen
hf
confin
occurr
clinic
event
lstreat
patient
like
show
improv
vs
less
like
exhibit
worsen
vs
overal
p
definit
improv
expand
includ
respons
hour
addit
hour
day
separ
treatment
group
increas
even
improv
vs
worsen
vs
overal
p
ls
vs
pbo
greater
level
improv
clinic
composit
levosimendan
support
signific
reduct
median
plasma
btype
natriuret
peptid
concentr
compar
placebo
hour
pgml
vs
pgml
p
day
pgml
vs
pgml
p
find
indic
clinic
composit
approach
use
develop
endpoint
distinguish
effect
iv
ls
set
acut
decompens
hf
new
endpoint
use
prospect
evalu
effect
ls
definit
second
studi
calcium
sensit
levosimendan
novel
inotrop
use
treatment
cardiac
failur
anim
data
suggest
pulmonari
vasodil
properti
levosimendan
suggest
treatment
right
ventricular
rv
failur
despit
scarc
data
patient
set
icu
echolaboratori
tertiari
teach
hospit
review
prospect
record
transthorac
echocardiogram
seven
cardiac
failur
patient
six
critic
ill
patient
hour
levosimendan
infus
bolu
continu
wave
doppler
signal
cw
peak
tricuspid
regurgit
tr
flow
veloc
record
levosimendan
infus
avail
left
ventricular
eject
fraction
lvef
measur
simpson
method
rv
contractil
assess
maxim
tricuspid
annulu
displac
cardiac
cycl
mmode
six
patient
andor
blind
observ
maxim
rvright
atrium
gradient
trmax
calcul
cw
record
modifi
bernoulli
equat
peak
tr
flow
veloc
parastern
short
axi
apic
fourchamb
view
regard
preload
independ
estim
pulmonari
arteri
vascular
resist
pvr
valu
express
mean
sd
wilcoxon
signedrank
test
use
calcul
differ
levosimendan
infus
patient
male
three
femal
mean
age
year
mean
trmax
mmhg
prior
levosimendan
infus
hour
levosimendan
infus
trmax
decreas
mmhg
p
patient
markedli
elev
baselin
trmax
mmhg
median
drop
trmax
pronounc
patient
mild
elev
baselin
trmax
mmhg
vs
mmhg
although
lvef
increas
patient
rv
contractil
assess
mmode
better
cm
cm
blind
observ
abl
confirm
improv
rv
contractil
conclus
levosimendan
reduc
te
trmax
peak
tr
flow
veloc
cardiac
failur
critic
ill
patient
impli
reduct
pvr
degre
pvr
reduct
greater
patient
baselin
pulmonari
hypertens
vasodil
might
caus
deterior
ga
exchang
isol
case
report
oral
sildenafil
select
phosphodiestras
inhibitor
pdei
use
altern
prostacyclin
primari
ph
earli
success
aim
assess
acut
shortterm
effect
sildenafil
patient
ph
differ
etiolog
seven
patient
studi
four
femal
three
male
mean
age
year
includ
two
patient
primari
ph
two
patient
eisinmeng
syndrom
two
patient
thromboembol
ph
one
patient
bilharzi
ph
follow
clinic
evalu
patient
subject
swanganz
catheter
mean
pulmonari
arteri
pressur
mpap
pulmonari
vascular
resist
pvr
mix
venou
oxygen
satur
mvo
invas
measur
patient
also
subject
echocardiograph
evalu
right
ventricular
diamet
rvd
short
axi
left
ventricular
stroke
volum
sv
cardiac
output
cop
read
record
day
month
start
sildenafil
use
oral
sildenafil
mg
everi
hour
patient
seven
patient
five
show
signific
clinic
new
york
heart
associ
nyha
class
iv
nyha
class
iii
hemodynam
echocardiograph
improv
day
therapi
five
patient
includ
two
patient
primari
ph
one
patient
eisenmeng
syndrom
one
bilharzi
ph
one
thromboembol
patirnt
latter
patient
show
signific
reduct
mpap
mmhg
p
mpvr
dynesscm
p
insignific
rise
mvo
torr
hemodynam
chang
occur
without
signific
reduct
arteri
blood
pressur
svr
echocardiographi
show
insignific
mild
reduct
rvd
cm
signific
rise
sv
ml
cop
lmin
followup
month
later
show
improv
four
latter
five
patient
fifth
patient
bilharzi
ph
one
die
suddenli
day
discharg
four
patient
show
subject
improv
nyha
class
iii
ii
reduct
mpap
mmhg
p
mean
pvr
dynesscm
p
rise
mvo
torr
echocardiographi
also
show
signific
reduct
rvd
cm
rise
sv
ml
cop
lmin
p
conclus
sildenafil
prove
effect
acut
shortterm
condit
subject
object
especi
patient
primari
ph
yet
longterm
effect
mortal
evalu
effect
sildenafil
bilharzi
ph
guard
larger
group
bilharzi
ph
patient
studi
especi
milder
form
intervent
none
total
patient
includ
af
occur
patient
univari
analysi
advanc
age
preexist
cardiovascular
diseas
previou
treatment
calciumchannel
blocker
simplifi
acut
physiolog
score
sap
ii
signific
predictor
af
patient
af
receiv
significantli
fluid
catecholamin
experienc
sepsi
shock
especi
septic
shock
acut
renal
failur
sever
sap
ii
icu
workload
omega
icu
hospit
length
stay
mortal
significantli
increas
patient
develop
af
multivari
analysi
identifi
five
independ
predictor
af
advanc
age
blunt
thorac
trauma
shock
pulmonari
arteri
cathet
previou
treatment
calciumchannel
blocker
incid
af
sicu
appear
frequent
gener
popul
less
cardiac
surgeri
unit
onset
af
reflect
sever
diseas
associ
increas
mortal
morbid
five
independ
risk
factor
af
identifi
af
seem
frequent
blunt
thorac
trauma
cardiac
surgeri
present
time
studi
devot
evolut
natriuret
peptid
perioper
period
object
aim
studi
examin
releas
pattern
bnp
nt
probnp
periop
period
coronari
surgeri
two
group
patient
ventricular
eject
fraction
vef
vef
secondari
aim
compar
plasmat
level
bnp
nt
probnp
homodynam
paramet
method
twentyon
patient
undergo
coronari
arteri
bypass
graft
cabg
sternotomi
cardiopulmonari
bypass
cpb
moder
system
hypothermia
divid
two
group
group
patient
normal
left
ventricular
eject
fraction
lvef
group
ii
patient
deterior
lvef
lvef
intraop
anesthet
manag
uniform
patient
blood
sampl
taken
surgic
incis
remov
aortic
cross
clamp
min
follow
crossclamp
remov
surgeri
arriv
intens
care
hour
day
cpb
bnp
nt
probnp
concentr
measur
electrochemiluminesc
immunoassay
hemodynam
paramet
measur
time
blood
sampl
taken
statist
statist
comparison
perform
mannwhitney
u
test
wilcoxon
nonparametr
test
p
consid
indic
statist
signific
result
bnp
nt
probnp
decreas
aortic
clamp
appli
remov
aortic
cross
clamp
bnp
nt
probnp
increas
gradual
two
group
peak
bnp
rang
hour
peak
nt
probnp
rang
hour
bnp
nt
probnp
increas
manner
similar
exponenti
fashion
hour
surgeri
logarithm
model
show
constant
time
group
good
correl
bnp
nt
probnp
hemodynam
paramet
left
ventricl
cohort
uncompl
cabg
patient
bnp
nt
probnp
increas
similar
exponenti
fashion
hour
surgeri
strong
correl
bnp
nt
probnp
time
point
baselin
valu
impli
similar
process
occur
patient
undergo
cardiac
surgeri
nt
probnp
sensit
bnp
chang
hemodynam
paramet
result
cp
myocardi
necrosi
detect
releas
tni
ck
mb
cs
appear
first
minut
reperfus
increas
time
fig
earli
postop
perform
heart
inferior
precpb
valu
tabl
conclus
cp
associ
irrevers
myocardi
injuri
contractil
function
heart
evalu
pulmonari
arteri
cathet
provid
littl
inform
exent
myocardi
damag
method
one
hundr
twentythre
elderli
patient
ami
admit
chines
pla
gener
hospit
januari
august
patient
divid
two
group
patient
group
die
patient
group
b
aliv
hospit
within
day
clinic
characterist
risk
factor
clinic
present
treatment
complic
analyz
result
twentysix
patient
die
ami
within
day
univari
analysi
indic
histori
diabet
prior
myocardi
infarct
cerebr
infarct
high
white
blood
cell
count
l
low
left
ventricular
eject
fraction
inhospit
complic
includ
arrhythmia
pump
failur
pneumonia
well
therapi
without
aspirin
significantli
associ
inhospit
mortal
within
day
multivari
logist
regress
analysi
use
mortal
depend
variabl
use
histori
inhospit
complic
independ
variabl
show
major
determin
inhospit
mortal
histori
diabet
odd
ratio
confid
interv
ci
cerebr
infarct
odd
ratio
ci
inhospit
complic
pump
failur
odd
ratio
ci
conclus
find
demonstr
histori
diabet
cerebr
infarct
well
inhospit
complic
pump
failur
independ
impact
factor
shortterm
prognosi
elderli
patient
ami
myocardi
infarct
occur
within
less
day
less
hour
one
vessel
treat
case
ratio
stent
segment
successseg
full
procedur
success
obtain
incomplet
success
sixteen
per
cent
attempt
fail
inhospit
mortal
inhospit
major
advers
event
death
cabg
myocardi
infarct
occur
surviv
year
year
ns
respect
surviv
year
success
procedur
versu
incomplet
successfailur
p
multivari
analysi
show
four
independ
variabl
longterm
outcom
age
left
ventricular
dysfunct
extent
coronari
arteri
diseas
procedur
result
aim
assess
safeti
feasibl
efficaci
impella
devic
patient
cardiogen
shock
patient
undergo
highrisk
surgeri
pci
studi
triplecentr
prospect
nonrandomis
twoarm
studi
patient
popul
arm
cardiogen
shock
patient
low
cardiac
output
defin
cardiac
index
lminm
pulmonari
capillari
wedg
pressur
pcw
mmhg
patient
pcw
mmhg
systol
blood
pressur
bp
mmhg
need
inotrop
keep
systol
bp
mmhg
arm
highrisk
cabg
highrisk
pci
follow
euroscor
criteria
sampl
size
patient
includ
hemodynam
includ
assess
cardiac
output
co
pcw
arteria
pulmonali
ap
arteri
bp
intracardiac
pump
paramet
biochemistri
includ
free
hemoglobin
baselin
hour
pump
run
hour
remov
pump
result
first
patient
present
tabl
conclus
preliminari
data
indic
feasibl
impella
pump
patient
cardiogen
shock
highrisk
cabg
pci
data
avail
march
result
discuss
sixti
patient
succes
treat
fiftysix
total
recoveri
four
partial
respons
treatment
fail
five
patient
embol
migrat
occur
five
patient
two
patient
die
three
patient
hemorrhag
disord
conclus
thrombolyt
therapi
feasibl
safe
surgic
treatment
contraind
even
thrombolit
therapi
partial
fail
allow
better
hemodynam
statu
introduct
deep
vein
thrombosi
dvt
seriou
complic
may
develop
critic
ill
icu
patient
consequ
immobil
femor
central
venou
cathet
cvc
placement
activ
thrombot
cascad
investig
epidemiolog
dvt
critic
ill
icu
patient
expect
hospit
least
week
use
triplex
examin
lower
extrem
admiss
day
clinic
suspicion
dvt
invas
natur
technic
complex
pulmonari
angiographi
pa
golden
diagnost
standard
routin
procedur
herebi
report
experi
emerg
pa
clinic
suspect
case
pe
highlight
merit
limit
clinic
examin
studi
patient
clinic
suspect
pe
six
male
femal
mean
age
year
predispos
factor
includ
heart
diseas
two
patient
diabet
mellitu
five
patient
polytrauma
three
patient
autoimmun
diseas
ie
behcet
diseas
one
patient
four
patient
dehydr
bedridden
follow
clinic
evalu
elctrocardiogram
chest
xray
patient
subject
routin
laboratori
evalu
arteri
blood
ga
measur
specif
coagul
profil
fibrin
fibrin
degrad
product
ddimer
patient
subject
firstpass
radionuclid
angiographi
pa
done
patient
within
mean
period
day
day
follow
acut
imag
pa
reveal
presenc
pe
eight
patient
form
distal
cutoff
andor
fill
defect
patient
neg
pa
pe
compar
patient
neg
pa
posit
find
frequent
hypotens
vs
hypox
vs
congest
vs
posit
echocardiograph
data
vs
also
exhibit
signific
scintigraph
evid
impair
rv
eject
fraction
patient
negativev
pa
vs
conclus
emerg
pa
feasibl
safe
highli
sensit
diagnost
tool
acut
pe
start
intrapulmonari
system
thrombolyt
therapi
potenti
hazard
view
readi
avail
cathet
laboratori
well
safeti
eas
perform
emerg
diagnost
pa
recommend
suspect
clinic
set
pe
object
primari
object
studi
estim
preval
incid
diagnost
confirm
dvt
pe
medicalsurg
icu
patient
secondari
object
examin
vte
prophylaxi
longitudin
estim
proport
vte
event
associ
prophylaxi
failur
versu
failur
implement
prophylaxi
tertiari
object
estim
morbid
mortal
outcom
patient
vte
design
retrospect
observ
multicent
cohort
studi
patient
admit
icu
set
twelv
universityaffili
close
medicalsurg
icu
eight
citi
three
provinc
identifi
medicalsurg
adult
icu
patient
either
upper
lower
limb
dvt
pe
hour
preced
icu
admiss
hour
posticu
admiss
preval
case
time
icu
admiss
week
follow
icu
discharg
incid
case
dvt
diagnos
compress
ultrasound
upper
lower
extrem
venographi
pe
diagnos
ventil
perfus
lung
scan
chest
computer
tomographi
pulmonari
angiogram
echocardiogram
ekg
autopsi
base
priori
criteria
patient
categor
definit
indetermin
vte
burden
ill
associ
diagnost
confirm
dvt
pe
medicalsurg
critic
ill
patient
low
comparison
higher
event
rate
detect
screen
ultrasonographi
autopsi
studi
vte
event
although
underdiagnos
associ
prophylaxi
failur
rather
failur
prophylax
activ
implement
vte
prevent
strategi
need
icu
well
rigor
evalu
vte
prevent
strategi
acknowledg
studi
fund
unrestrict
grant
pharmacia
inc
physician
servic
incorpor
ontario
ontario
thorac
societi
event
definit
indeterminit
definit
term
hypercoagul
randomli
use
describ
increas
risk
patholog
thrombu
format
traumat
brain
injuri
tbi
often
complic
lifethreaten
thromboembol
event
trauma
patient
incid
deep
venou
thrombosi
dvt
estim
pulmonari
embol
pe
use
thrombelastograph
teg
proven
use
determin
adult
patient
coagul
statu
measur
enzymaticprotein
element
coagul
platelet
function
fibrinolysi
whole
blood
sampl
purpos
studi
compar
teg
screen
tool
hypercoagul
known
paramet
univers
mississippi
medic
center
jackson
ms
use
tbi
patient
male
eight
femal
rang
age
year
teg
panel
drawn
use
either
venou
arteri
blood
hour
post
tbi
admiss
thirti
replic
measur
made
twochannel
teg
machin
total
subject
consid
hypercoagul
eight
emerg
hypercoagul
nine
normal
fibrinogen
level
well
factor
level
measur
time
intrasampl
variat
expect
fibrinogen
result
estim
coeffici
variat
subject
random
effect
analysi
variat
anova
perform
coeffici
variat
r
estim
measur
ratio
hypercoagul
fibrinogen
factor
level
confid
consid
statist
signific
coeffici
variat
fibrinogen
level
factor
although
sampl
size
small
suggest
teh
teg
use
screen
tool
hybercoagul
tbi
henc
care
monitor
dvt
pe
introduct
heparininduc
thrombocytopenia
hitii
signific
complic
heparin
therapi
depend
type
durat
therapi
patient
popul
although
incid
known
high
cardiac
orthopaed
surgeri
remain
unknown
patient
gener
intens
care
unit
icu
patient
purpos
investig
frequenc
clinic
signific
posit
heparinplatelet
antibodi
icu
patient
prospect
investig
incid
icu
patient
treat
unfraction
heparin
ufh
low
molecular
weight
heparin
lmwh
prophylaxi
treatment
venou
thromboembol
intermitt
flush
solut
ufh
iuml
mainten
central
venou
arteri
cathet
patenc
fufh
perform
enzymelink
immunosorb
assay
elisa
asserachrom
hpia
stago
day
admiss
treatment
result
defin
neg
absorb
nm
posit
hitii
defin
clinic
evalu
investig
patient
femal
median
age
year
rang
year
ill
sever
score
apach
ii
eleven
patient
treat
fufh
fufh
lmwh
three
lmwh
one
ufh
posit
detect
patient
day
patient
day
tabl
none
patient
develop
hitii
despit
high
preval
posit
icu
patient
treat
fufh
lmwh
clinic
signific
remain
investig
larger
number
patient
especi
case
reexposur
heparin
introduct
abnorm
endotheli
physiolog
implic
earli
atherogenesi
later
control
dynam
plaqu
behavior
biolog
link
endotheli
damag
atherosclerosi
may
relat
decreas
arteri
bioavail
nitric
oxid
may
predispos
leucocyt
platelet
adhes
vasoconstrict
smooth
muscl
cell
prolifer
substanc
releas
endothelium
includ
prostacyclin
endothelin
von
willebrand
factor
thrombomodulin
tm
tm
integr
membran
glycoprotein
chang
function
thrombin
anticoagul
activ
protein
c
presenc
protein
inactiv
factor
viiia
factor
va
therebi
inhibit
format
thrombin
solubl
tm
thought
indic
endothelialcel
damag
posit
relat
concentr
solubl
thrombomodulin
risk
atherosclerot
diseas
wide
assum
aim
studi
assess
diagnost
role
circul
tm
marker
extent
sever
coronari
arteri
atherosclerosi
studi
patient
ischem
heart
diseas
male
femal
mean
age
year
rang
year
togeth
nonischem
patient
catheter
prior
valv
replac
male
seven
femal
mean
age
year
serv
control
ischem
patient
angin
pain
ap
acut
myocardi
infarct
ami
follow
clinic
evalu
patient
subject
ecg
routin
laboratori
work
coronari
arteriographi
assess
extent
sever
stenot
lesion
use
gensini
score
system
patient
tm
level
measur
arteri
sampl
withdrawn
coronari
arteri
cathet
procedur
use
enzym
immunoassay
elisa
compar
control
subject
ischem
patient
exhibit
significantli
higher
level
serum
tm
vs
p
progress
higher
level
serum
tm
angin
group
ami
group
vs
p
serum
tm
correl
significantli
sever
coronari
arteri
patholog
express
gensini
score
p
angina
group
p
ami
group
group
exhibit
signific
correl
serum
tm
number
diseas
vessel
p
group
conclus
tm
endotheli
glycoprotein
result
damag
vascular
endothelium
atheromat
process
show
signific
correl
extent
sever
coronari
arteri
diseas
express
gensini
score
system
higher
tm
level
ami
group
compar
ap
group
point
signific
endotheli
damag
former
compar
latter
stress
import
serum
tm
molecular
marker
endotheli
dysfunct
acut
ischem
syndrom
background
plasmat
activ
antithrombin
physiolog
coagul
inhibitor
antiinflammatori
properti
marker
sever
valid
sepsi
nonthyroid
ill
syndrom
whose
first
stage
decreas
free
triiodothyronin
plasmat
concentr
frequent
observ
intens
care
unit
icu
patient
plasmat
level
free
thyroxin
respect
correl
sever
prognosi
aim
studi
determin
whether
signific
correl
exist
sepsi
method
eightytwo
patient
suffer
sepsi
admit
icu
gener
hospit
period
includ
random
exclus
criteria
histori
dysthyroid
treatment
intak
affect
thyroid
function
level
thyroid
stimul
hormon
tsh
c
reactiv
protein
crp
leukocyt
count
measur
admiss
investig
concern
blood
sampl
part
routin
biolog
balanc
apach
ii
sap
ii
score
calcul
use
data
first
hour
icu
stay
patient
follow
icu
discharg
death
determin
surviv
rate
p
r
consid
signific
result
nonlinear
signific
correl
shown
nonsept
p
r
septic
p
r
popul
wherea
neither
nonsept
group
p
septic
group
p
tsh
nonsept
group
p
septic
group
p
septic
group
significantli
correl
graviti
evalu
apach
iisap
ii
score
signific
correl
admiss
surviv
p
exist
patient
septic
shock
ngl
vs
ngl
p
vs
p
significantli
lower
septic
group
among
measur
paramet
crp
mgl
vs
mgl
p
vs
ngml
p
discrimin
two
group
contrari
leukocyt
count
p
propos
explan
interrel
sepsi
base
upon
nuclear
properti
gene
upon
effect
path
regul
peripher
deiodin
conclus
signific
correl
underlin
septic
group
icu
admiss
wherea
neither
tsh
apach
iisap
ii
graviti
score
signific
correl
admiss
surviv
found
septic
shock
subgroup
decreas
involv
decreas
reliabl
graviti
prognosi
physiopatholog
explan
sepsi
could
impli
measur
realiz
septic
patient
could
use
complet
measur
heparinis
venou
blood
sampl
obtain
healthi
adult
volunt
pmnl
isol
densiti
gradient
centrifug
suspend
minimum
essenti
medium
supplement
autolog
plasma
cell
incub
hour
either
lipopolysaccharid
lp
stimul
phosphatebuff
salin
unstimul
presenc
rspc
ei
cell
wash
treat
annexin
vpropidium
iodid
stain
analys
duallas
flow
cytometri
percentag
earli
apoptot
cell
determin
use
fourquadr
analysi
data
analys
use
friedman
analysi
varianc
post
hoc
test
wilcoxon
sign
rank
test
pair
data
tabl
result
pilot
studi
show
rspc
significantli
increas
activ
pmnl
apoptosi
maintain
presenc
ei
suggest
possibl
use
rspc
elastas
inhibitor
induc
neutrophil
apoptosi
henc
clearanc
neutrophil
aliard
studi
need
avail
onlin
http
background
induc
cox
isoform
catalyz
format
prostaglandin
respons
proinflammatori
cytokin
prostacyclin
major
prostanoid
gener
endotheli
cell
potent
inhibitor
platelet
aggreg
power
vasodil
although
role
drotrecogin
alfa
activ
recombin
human
activ
protein
c
rhapc
modul
microvascular
coagul
inhibit
thrombin
gener
well
studi
experiment
clinic
set
sever
sepsi
littl
known
effect
prostanoid
releas
endotheli
cell
effect
rhapc
express
human
umbil
vein
endotheli
cell
huvec
measur
colorimetr
assay
quantikin
protein
content
endotheli
cell
determin
western
blot
cell
supernant
assay
stabl
hydrolysi
product
prostacyclin
elisa
statist
analysi
perform
unpair
student
test
anova
result
rhapc
dosedepend
upregul
mrna
endotheli
cell
incub
time
hour
control
amolml
huvec
treat
rhapc
amolml
mean
sem
p
western
blot
analysi
reveal
increas
protein
content
treatment
rhapc
rhapc
dosedepend
increas
huvec
supernat
control
pgml
huvec
treat
rhapc
pgml
p
shown
antagonist
thrombin
receptor
wede
monoclon
antibodi
endotheli
protein
c
receptor
epcr
effect
rhapc
mrna
upregul
mediat
epcr
receptor
abil
rhapc
upregul
human
endotheli
cell
well
releas
prostanoid
probabl
mediat
epcr
receptor
may
repres
new
molecular
mechan
oxygen
deliveri
site
injuri
may
improv
intravascular
aggreg
platelet
may
reduc
therebi
contribut
efficaci
rhapc
system
inflamm
sepsi
sever
thrombocytopenia
might
risk
factor
seriou
bleed
therapi
median
plasma
concentr
apc
steadi
state
previou
studi
reveal
apcdepend
reduct
platelet
surfac
exclus
activ
recombin
tissu
factor
howev
amount
apc
use
high
steadyst
concentr
effect
apc
therapeut
concentr
express
platelet
receptor
yet
studi
systemat
object
evalu
influenc
drotrecogin
alfa
activ
vitro
express
platelet
receptor
therapeut
concentr
method
citrat
blood
drawn
healthi
blood
donor
n
male
age
year
mean
sd
exclus
criteria
smoke
diabet
use
drug
interf
platelet
function
blood
sampl
adjust
apc
final
concentr
apc
group
therapeut
dose
apc
group
fivefold
therapeut
dose
respect
control
group
receiv
addit
apc
evalu
platelet
reactiv
sampl
activ
bachem
heidelberg
germani
adenosinediphosph
adp
sigma
taufkirchen
germani
sampl
incub
min
fluorescencelabel
monoclon
antibodi
mab
fluorescein
isothiocyan
fitc
phycoerythrin
pe
pe
fitc
beckmancoult
krefeld
germani
fitc
becton
dickinson
san
jose
ca
usa
analys
perform
flowcytomet
epic
xl
beckmancoult
mean
fluoresc
intens
calcul
mab
except
gate
granulocyt
percentag
complex
count
calcul
run
use
winmdi
softwar
statist
intergroup
differ
perform
oneway
anova
result
apc
group
signific
influenc
platelet
activ
without
stimul
group
show
slight
nonsignific
decreas
conclus
studi
demonstr
therapeut
plasma
concentr
drotrecogin
alfa
activ
neither
influenc
express
platelet
activ
marker
plateletgranulocyt
complex
vitro
thu
disturb
primari
hemostasi
seem
unlik
statist
wilcoxon
signedrank
test
use
pair
sampl
patient
mannwhitney
u
test
use
comparison
control
higher
level
tatc
lower
level
paa
found
infect
lung
compar
noninfect
lung
lung
control
p
protein
c
apc
concentr
significantli
decreas
infect
site
p
see
fig
pneumonia
character
strong
procoagul
shift
site
infect
caus
local
activ
coagul
inhibit
fibrinolysi
low
level
apc
horizont
line
median
interquartil
rang
healthi
upper
panel
mechan
ventil
lower
panel
control
subject
method
retrospect
clinic
studi
perform
consecut
patient
admit
intens
critic
care
unit
june
octob
patient
whose
platelet
count
decreas
less
cours
diseas
regard
state
predic
relat
subsequ
decreas
rate
platelet
occurr
dic
investig
obtain
follow
platelet
count
platelet
start
decreas
minimum
platelet
count
subsequ
observ
number
day
requir
observ
minimum
platelet
count
platelet
start
decreas
platelet
count
decreas
less
patient
hospit
stay
among
patient
develop
dic
signific
differ
age
sex
apach
ii
score
sofa
score
frequenc
system
inflammatori
respons
syndrom
dic
nondic
patient
platelet
count
intern
normalis
ratio
fibrinogen
level
fibrinfibrinogen
degrad
product
fdp
valu
abnorm
white
blood
cell
count
nondic
patient
compar
observ
time
dic
onset
dic
patient
fdp
valu
significantli
higher
dic
patient
nondic
dic
p
significantli
higher
dic
patient
nondic
patient
patient
less
platelet
whose
platelet
decreas
averag
strong
possibl
develop
dic
background
famili
natriuret
peptid
compris
sever
structur
relat
amino
acid
peptid
atrial
natriuret
peptid
anp
brain
natriuret
peptid
bnp
vasoact
peptid
vasodil
diuret
properti
play
import
role
cardiovascular
homeostasi
salutari
cardiovascular
effect
natriuret
peptid
suggest
anp
bnp
pathophysiolog
signific
cardiac
depress
septic
patient
aim
present
studi
determin
plasma
level
stabl
ntermin
prohormon
form
anp
ntproanp
bnp
ntprobnp
septic
patient
treat
without
drotrecogin
alfa
activ
troponin
tni
paramet
cardiac
dysfunct
also
evalu
patient
method
ntproanp
ntprobnp
tni
level
measur
plasma
sampl
septic
patient
day
sever
sepsi
septic
patient
treat
drotrecogin
alfa
activ
elisa
method
statist
analysi
perform
unpair
student
test
mean
sap
ii
score
septic
patient
day
treat
without
drotrecogin
alfa
activ
compar
sap
ii
score
mean
significantli
lower
concentr
ntprobnp
p
ntproanp
p
measur
patient
treat
drotrecogin
alfa
activ
compar
patient
receiv
drotrecogin
alfa
activ
tni
valu
significantli
lower
p
septic
patient
treat
drotrecogin
alfa
activ
mean
sd
ngml
compar
untreat
patient
mean
sd
ngml
correl
ntprobnp
ntproanp
valu
r
p
septic
patient
ntprobnp
level
fmolml
higher
risk
death
patient
ntprobnp
level
fmolml
p
conclus
ntproanp
ntprobnp
level
significantli
lower
septic
patient
treat
drotrecogin
alfa
activ
ntprobnp
serv
predictor
surviv
septic
patient
drotrecogin
alfa
activ
may
influenc
cardiac
depress
septic
patient
control
pathway
ntproanp
ntprobnp
product
benefici
effect
drotrecogin
alfa
activ
cardiac
function
also
reflect
lower
tni
valu
patient
group
method
inclusionexclus
criteria
similar
prowess
patient
elig
particip
known
suspect
infect
met
three
four
criteria
defin
system
inflammatori
respons
syndrom
one
acut
sepsisinduc
hour
durat
organ
dysfunct
patient
classifi
time
interv
first
document
organ
dysfunct
administr
drotaa
timetotreat
patient
receiv
drotaa
within
hour
n
versu
hour
n
first
document
organ
dysfunct
result
figur
show
overal
kaplanmei
surviv
curv
prowess
enhanc
percent
mortal
shown
surviv
curv
patient
receiv
drotaa
essenti
ident
prowess
enhanc
day
result
maintain
patient
subgroup
baselin
apach
ii
score
n
vs
n
two
organ
dysfunct
n
vs
n
similar
result
observ
mod
subgroup
overal
popul
enhanc
mod
patient
tend
lower
apach
score
greater
organ
support
baselin
compar
prowess
patient
mortal
similar
drotaatr
patient
enhanc
prowess
lower
prowess
placebo
patient
seriou
bleed
numer
higher
enhanc
prowess
patient
treat
within
hour
first
organ
dysfunct
lower
mortal
n
treat
hour
n
conclus
result
global
enhanc
reinforc
benefitrisk
profil
drotaa
observ
prowess
mod
subgroup
addit
earlier
treatment
hour
appear
associ
lower
mortal
background
global
singlearm
openlabel
trial
drotrecogin
alfa
activ
drotaa
adult
patient
sever
sepsi
subsequ
conduct
site
countri
enhanc
n
report
allcaus
mortal
safeti
data
method
inclusionexclus
criteria
definit
seriou
advers
event
sae
similar
prowess
patient
high
risk
blede
exclud
particip
sae
bleed
rate
includ
intracrani
hemorrhag
ich
studi
drug
infus
period
infus
period
day
determin
allcaus
mortal
assess
day
seriou
bleed
rate
fatal
event
rate
prowess
enhanc
present
tabl
overal
mortal
prowess
placebo
prowess
drotaa
enhanc
drotaa
prowess
bleed
common
drugrel
complic
associ
drotaa
total
sae
bleed
event
adjud
procedurerel
enhanc
ich
rate
infus
n
five
fatal
ich
rate
placebo
vs
drotaa
prowess
n
fatal
respect
higher
postinfus
rate
seriou
bleed
observ
enhanc
suggest
higher
overal
background
bleed
rate
rel
prowess
conclus
twentyeightday
surviv
similar
prowess
enhanc
seriou
bleed
event
infus
drotaa
slightli
frequent
enhanc
prowess
proport
fatal
bleed
event
howev
background
bleed
rate
enhanc
may
higher
enhanc
safeti
efficaci
data
highli
consist
prowess
reinforc
favor
benefitrisk
profil
drotaa
patient
sever
sepsi
acknowledg
research
support
eli
lilli
compani
indianapoli
usa
avail
onlin
http
method
inclus
exclus
criteria
similar
prowess
patient
elig
particip
known
suspect
infect
met
three
four
criteria
defin
system
inflammatori
respons
syndrom
one
acut
sepsisinduc
hour
durat
organ
dysfunct
day
icu
day
hospit
day
ventil
use
monitor
start
time
drotaa
infus
patient
classifi
respect
time
interv
first
document
organ
dysfunct
administr
drotaa
intenttotreat
popul
two
organ
dysfunct
baselin
receiv
drotaa
within
hour
first
organ
dysfunct
time
hour
n
vs
hour
first
organ
dysfunct
time
hour
n
result
tabl
describ
patient
two
organ
dysfunct
baselin
administr
drotaa
within
hour
first
organ
dysfunct
associ
reduct
day
icu
hospit
length
stay
mechan
ventil
use
rel
patient
receiv
drotaa
hour
first
organ
dysfunct
conclus
earlier
treatment
drotaa
associ
reduc
hospit
resourc
use
decreas
length
stay
patient
two
organ
dysfunct
baselin
data
suggest
time
administr
drotaa
may
import
clinic
econom
valu
acknowledg
research
support
eli
lilli
compani
indianapoli
usa
method
inclus
exclus
criteria
similar
prowess
patient
elig
particip
known
suspect
infect
three
four
criteria
defin
system
inflammatori
respons
syndrom
one
acut
sepsisinduc
hour
durat
organ
dysfunct
day
icu
day
hospit
day
ventil
use
day
vasopressor
use
monitor
start
time
drotaa
infus
patient
subclassifi
respect
time
interv
first
document
organ
dysfunct
administr
drotaa
timetotreat
timetotreat
consid
intenttotreat
popul
apach
ii
score
baselin
receiv
drotaa
within
hour
first
organ
dysfunct
n
vs
receiv
drug
hour
first
organ
dysfunct
n
result
data
present
sever
sepsi
patient
apach
ii
score
baselin
administr
drotaa
within
hour
first
observ
organ
dysfunct
associ
signific
reduct
day
icu
median
icu
day
time
hour
time
hour
p
mechan
ventil
use
median
ventil
day
time
hour
time
hour
p
vasopressor
use
median
vasopressor
day
time
hour
time
hour
p
rel
patient
receiv
drotaa
hour
first
organ
dysfunct
median
day
hospit
lower
patient
receiv
drotaa
within
hour
first
organ
dysfunct
differ
statist
signific
median
hospit
day
time
hour
time
hour
p
conclus
earlier
treatment
drotaa
associ
reduc
hospit
resourc
use
patient
apach
ii
score
baselin
data
suggest
time
administr
drotaa
may
import
clinic
econom
valu
introduct
shown
age
number
organ
dysfunct
od
correl
outcom
patient
suffer
sever
sepsi
ss
recent
prowess
studi
phase
iii
doubleblind
placebocontrol
trial
demonstr
recombin
human
activ
protein
c
rhapc
reduc
absolut
risk
allcaus
mortal
patient
suffer
ss
result
mexico
august
octob
patient
treat
rhapc
present
studi
identifi
main
variabl
contribut
earli
mortal
first
day
patient
treat
rhapc
method
data
patient
treat
rhapc
public
privat
medic
institut
mexico
analyz
retrospect
age
origin
ss
number
od
time
rhapc
administr
andcompl
rhapc
use
independ
variabl
crosstabul
chisquar
analysi
perform
identifi
variabl
contribut
mortal
day
ss
result
intraabdomin
sepsi
common
origin
ss
follow
postop
sepsi
pneumonia
other
respect
differ
mortal
patient
treat
public
hospit
compar
patient
treat
privat
hospit
mean
age
patient
treat
year
year
mean
od
mean
time
administr
rhapc
hour
hour
global
mortal
week
age
associ
mortal
patient
younger
year
mortal
contrast
patient
older
year
mortal
p
number
od
associ
mortal
patient
one
od
mortal
contrast
mortal
patient
three
od
p
patient
younger
year
one
od
mortal
two
od
three
od
patient
year
one
od
mortal
two
od
three
od
patient
older
year
one
od
mortal
two
od
three
od
p
bleed
observ
patient
one
dead
cerebr
haemorrhag
associ
rhapc
report
conclus
age
number
od
highli
associ
mortal
week
ss
patient
treat
rhapc
patient
suffer
ss
treat
earli
stage
sepsi
introduct
neuroaxi
anaesthesia
reduc
risk
postop
complic
highrisk
patient
undergo
major
abdomin
surgeri
benefit
neuroaxi
anaesthesia
less
clear
signific
proport
patient
develop
sepsi
follow
laparotomi
recent
drotrecogin
alfa
activ
shown
reduc
risk
death
sepsi
due
increas
risk
bleed
presenc
neuroaxi
cathet
absolut
contraind
use
hypothes
presenc
neuroaxi
cathet
exclud
signific
number
septic
patient
receiv
potenti
benefici
therapi
method
patient
admit
unit
period
follow
major
intraabdomin
surgeri
review
among
neuroaxi
cathet
data
collect
system
inflammatori
respons
syndrom
sir
criteria
presenc
infect
organ
failur
hospit
surviv
sepsi
defin
accord
critic
care
medicin
consensu
committe
result
see
tabl
sixtyseven
patient
admit
follow
major
abdomin
surgeri
neuroaxi
cathet
develop
sepsi
mortal
group
unit
patient
receiv
drotrecogin
alfa
mortal
expect
mortal
patient
sepsi
group
undergo
major
abdomin
surgeri
compar
observ
prowess
studi
vs
given
drotrecogin
alfa
shown
reduc
risk
death
neuroaxi
anaesthesia
confer
littl
surviv
benefit
follow
major
abdomin
surgeri
avoid
use
earli
remov
cathet
sepsi
may
confer
signific
increas
surviv
avail
onlin
http
method
council
sic
agre
audit
use
xigri
conduct
licens
scottish
intens
care
societi
audit
group
sicsag
implement
studi
behalf
sic
inform
manual
contain
guidelin
data
collect
methodolog
introduc
throughout
scottish
icu
guidelin
also
made
avail
interact
format
icu
audit
system
ward
watcher
critic
care
audit
ltd
yorkshir
uk
provid
clinician
electron
tool
help
determin
fulfil
criteria
pharmacist
icu
staff
inform
sicsag
whenev
drug
administ
attempt
review
record
patient
receiv
drug
first
month
made
nurs
audit
group
conclus
earli
use
drug
stabl
monthonmonth
overal
use
less
anticip
shown
mark
variat
unit
consult
gener
follow
aspect
guidelin
relat
sir
criteria
organ
dysfunct
seem
reluct
base
prescrib
decis
apach
score
method
fifteen
patient
receiv
drotrecogin
alfa
match
icnarc
diagnost
categori
apach
ii
score
two
histor
control
select
patient
admit
prior
avail
drotrecogin
alfa
follow
success
match
mortal
unblind
two
group
control
drotrecogin
alfa
compar
apach
ii
score
vs
risk
death
admiss
vs
respect
mortal
histor
control
receiv
drotrecogin
alfa
standardis
mortal
ratio
respect
chisquar
p
conclus
protocoldriven
drotrecogin
alfa
treatment
septic
patient
appear
confer
surviv
benefit
uk
district
gener
intens
care
unit
absolut
mortal
reduct
consider
higher
prowess
object
assess
epidemiolog
prognosi
thrombocytopenia
tp
icu
patient
design
monocentr
retrospect
analysi
data
prospect
collect
databank
set
adult
medic
icu
univers
hospit
patient
three
hundr
twentyf
consecut
icu
patient
admit
hour
januari
decemb
includ
measur
main
result
tp
defin
two
consecut
platelet
count
gl
main
outcom
measur
icu
mortal
main
reason
icu
admiss
tp
patient
acut
respiratori
failur
n
shock
n
sepsi
n
coma
n
acut
renal
failur
n
metabol
disord
n
schedul
surgeri
n
acut
poison
n
trauma
n
miscellan
caus
n
overal
popul
mean
platelet
count
upon
admiss
gl
tp
observ
present
admiss
patient
mean
count
gl
icuacquir
tp
occur
median
delay
day
rang
day
icu
mortal
n
tp
popul
n
nontp
popul
bone
marrow
aspir
perform
tp
patient
tp
previou
red
blood
cell
rbc
transfus
record
seven
case
previou
plasma
infus
two
case
prior
exposur
heparin
case
diagnosi
heparininduc
tp
exclud
case
unlik
three
case
possibl
three
case
like
two
case
tp
relat
sepsi
case
dissemin
intravascular
coagul
case
among
associ
sepsi
central
megacaryocyt
deplet
five
case
hemophagocyt
histiocytosi
four
case
combin
two
mechan
observ
case
patient
etiolog
tp
undetermin
relat
anoth
caus
univari
analysi
tp
significantli
associ
p
higher
sap
ii
score
vs
higher
soa
score
vs
need
renal
replac
therapi
vs
need
invas
mechan
ventil
vs
higher
length
stay
day
vs
day
icu
mortal
vs
statist
differ
detect
patient
characterist
two
tp
popul
tp
present
admiss
icu
acquir
twentyeight
tp
patient
requir
platelet
transfus
rbc
concentr
plasma
concentr
administ
studi
infus
tp
patient
presenc
tp
indic
subgroup
patient
high
mortal
account
blood
productrel
cost
icu
object
studi
prospect
incid
complic
financi
impact
deriv
cvc
placement
patient
bd
without
previou
correct
method
total
cvc
patient
place
period
bd
defin
prothrombin
time
pt
less
andor
activ
partial
thromboplastin
time
aptt
rang
andor
platelet
count
pc
extern
intern
bleed
consid
cvc
placementrel
complic
intern
jugular
vein
subclavian
vein
femor
vein
chosen
insert
site
procedurerel
transfus
requir
surgic
correct
lengthen
hospit
stay
defin
major
complic
fresh
frozen
plasma
ffp
platelet
unit
ptl
requir
correct
bd
estim
standard
formula
mean
age
year
year
malefemal
ratio
intern
jugular
vein
insert
site
patient
apach
ii
score
three
oper
perform
procedur
mortal
major
complic
associ
cvc
placement
patient
show
local
hematoma
result
pt
aptt
pc
mm
mean
sd
averag
pc
patient
thrombocytopenia
ffp
ptl
unit
save
local
us
save
charg
accord
publish
payment
rate
depict
tabl
need
coagulopathi
correct
level
coagul
test
consid
safe
cvc
placement
still
matter
debat
studi
popul
previou
correct
shown
impos
increas
risk
avail
onlin
http
background
thrombocytopenia
may
marker
sever
ill
predictor
poor
outcom
critic
ill
medicalsurg
icu
patient
object
estim
preval
incid
risk
factor
consequ
thrombocytopenia
defin
platelet
l
heparininduc
thrombocytopenia
test
serotonin
releas
assay
none
posit
patient
ever
develop
thrombocytopenia
versu
long
stay
icu
stay
day
vs
day
similar
hospit
stay
day
vs
day
icu
mortal
vs
hospit
mortal
vs
platelet
count
l
independ
predict
mortal
adjust
age
ill
sever
hr
wherea
platelet
count
l
hr
conclus
medicalsurg
icu
patient
thrombocytopenia
common
associ
increas
durat
icu
stay
increas
risk
mortal
platelet
count
l
trauma
databas
sunnybrook
women
colleg
health
scienc
centr
univers
toronto
toronto
canada
region
level
one
trauma
centr
method
two
hundr
seventyf
consecut
patient
receiv
unit
pack
red
blood
cell
first
hour
admiss
hospit
januari
decemb
review
trauma
databas
criteria
use
determin
appropri
transfus
blood
product
first
hour
admiss
accord
american
societi
anesthesiologist
hemoglobin
gl
platelet
count
l
intern
normalis
ratio
inr
fibrinogen
gl
inappropri
transfus
unit
blood
product
count
blood
unit
administ
despit
last
laboratori
read
meet
aforement
criteria
assess
period
time
frame
clinic
action
extend
min
last
laboratori
data
min
next
laboratori
data
data
collect
laboratori
data
hemoglobin
valu
platelet
count
inr
fibrinogen
level
transfus
data
pack
rbc
plt
ffp
cri
first
hour
admiss
collect
result
see
tabl
conclus
may
exist
substanti
inappropri
blood
product
transfus
treatment
resuscit
trauma
patient
howev
also
possibl
routin
laboratori
measur
sensit
enough
indic
appropri
patient
popul
patient
frequent
may
activ
bleed
without
opportun
laboratori
sampl
obtain
potenti
caus
former
includ
lack
knowledg
exist
guidelin
decis
follow
guidelin
overcorrect
coagulopathi
possibl
solut
includ
redistribut
guidelin
variou
depart
hospit
oper
room
emerg
room
critic
care
cell
saver
techniqu
accept
lower
blood
pressur
select
patient
use
antifibrinolyt
use
factor
viia
regrett
trauma
patient
popul
heterogen
group
patient
similar
therapeut
trial
sepsi
trauma
patient
repres
group
extrem
high
morbid
mortal
incid
potenti
complic
interpret
data
bovin
hemoglobin
repres
interest
altern
avail
larg
quantiti
steer
approxim
l
blood
gdl
hemoglobin
totalbodi
hemoglobin
content
kg
bovin
blood
avail
unlimit
suppli
hemopur
bovin
product
approv
veterinarian
use
unit
state
human
south
africa
multicent
random
phase
iii
control
trial
demonstr
safeti
efficaci
hemopur
biopur
corpor
also
known
product
ultrapurifi
remov
plasma
protein
rbc
stroma
potenti
pathogen
materi
manufactur
process
crosslink
polymer
stabil
hemoglobin
molecul
increas
vascular
persist
well
effici
oxygen
transport
tissu
mean
cost
per
patient
use
rhepo
strategi
vs
rhepo
fewer
unit
prbc
administ
rhepo
arm
result
lower
infect
rate
rhepo
use
therefor
less
expens
effect
ie
domin
strategi
oneway
sensit
analys
reveal
administr
rhepo
remain
prefer
strategi
provid
prbc
cost
greater
rhepo
cost
less
u
result
gener
provid
cost
rhepo
cost
u
prbc
rhepo
strategi
prefer
advantag
treatment
rhepo
maintain
expect
transfus
rate
u
prbc
per
patient
per
admiss
decreas
probabl
infect
increas
longterm
cost
infect
significantli
affect
model
manag
chronic
anemia
among
icu
patient
admit
hour
use
rhepo
appear
costeffect
provid
rhepo
cost
less
time
cost
u
prbc
effect
retain
low
expect
transfus
rate
chang
cost
risk
infect
aris
blood
administr
result
function
capillari
densiti
significantli
higher
anim
receiv
he
vs
nacl
p
wherea
erythrocyt
veloc
alter
consider
either
group
histolog
grade
reveal
sever
mucos
atrophi
nacl
he
group
p
number
roll
leukocyt
notabl
higher
nacl
compar
he
anim
vs
p
result
show
benefici
effect
he
microvascular
perfus
mucos
cellular
integr
gut
possibl
mechan
may
inhibit
leukocyteendothelium
interact
mesenter
circul
object
aim
studi
investig
effect
fluid
resuscit
modifi
fluid
gelatin
gel
versu
hydroxyethyl
starch
he
extravascular
lung
water
evlw
oxygen
patient
septic
shock
acut
lung
injuri
ali
design
prospect
random
doubleblind
clinici
trial
set
intens
care
unit
univers
hospit
patient
thirti
hypovolem
patient
intrathorac
blood
volum
index
itbvi
mlm
septic
shock
ali
random
he
gel
group
patient
intervent
fluid
resuscit
min
bolus
maximum
ml
given
end
point
itbvi
mlm
reach
repeat
haemodynam
measur
perform
baselin
tb
end
point
tep
min
end
point
reach
xardiac
output
stroke
volum
evlw
oxygen
deliveri
determin
assess
point
statist
analysi
twoway
anova
use
itbvi
cardiac
index
stroke
volum
index
oxygen
deliveri
index
increas
significantli
tep
remain
elev
signific
differ
two
group
evlw
although
moder
elev
remain
unchang
signific
differ
group
introduct
acut
hemorrhag
necrot
pancreat
ap
still
essenti
problem
high
mortal
disturb
microcircul
consequ
decreas
tissu
oxygen
crucial
effect
cascad
selflimit
mild
edemat
often
fatal
form
ap
aim
studi
evalu
therapeut
approach
isovolem
hemodilut
ihd
hydroxyethyl
starch
he
alon
combin
ringer
solut
regard
pancreat
tissu
oxygen
tension
surviv
pig
suffer
acut
pancreat
method
approv
local
ethic
committe
pig
anesthet
endotrach
intub
normoventil
fio
laparotomi
splenectomi
pancreat
duct
cannul
pancreat
tissu
oxygen
tension
tpo
measur
use
silicon
cathet
licox
medic
system
gm
germani
min
equilibr
ap
induc
combin
intraven
cerulean
intraduct
glycodeoxychol
acid
fifteen
min
induct
ap
anim
random
isovolem
paop
constant
hemodilut
he
plu
gdl
plasmat
hemoglobin
oxyglobin
biopur
usa
heshboc
group
he
he
group
ringer
solut
ringer
group
hematocrit
hct
tpo
measur
everi
hour
min
reach
hct
hour
cathet
remov
abdomen
close
anim
extub
day
hour
anim
sacrifi
statist
analys
perform
use
kolmogorovsmirnov
test
normal
distribut
student
test
use
normal
distribut
data
chisquar
test
surviv
rate
signific
p
result
induct
ap
tpo
decreas
group
increas
significantli
ihd
heshboc
comparison
he
ringer
group
p
tpo
remain
low
he
ringer
group
decreas
hour
p
hour
p
ringer
group
comparison
he
group
surviv
rate
end
observ
period
higher
heshboc
group
p
comparison
ringer
group
p
he
vs
ringer
group
p
ihd
he
plu
abl
normal
pancreat
tissu
oxygen
tension
comparison
ihd
he
ringer
solut
induct
sever
ap
complementari
strategi
ihd
addit
applic
combin
rheolog
deliv
therapi
may
repres
novel
therapeut
option
treatment
acut
pancreat
futur
object
patient
cirrhosi
tens
ascit
treat
paracentesi
requir
repeat
intravascular
fluid
load
colloid
solut
patient
human
albumin
suggest
superior
synthet
colloid
fluid
load
albeit
higher
cost
thu
start
trial
aim
compar
outcom
patient
cirrhosi
treat
albumin
outcom
treat
bovinederiv
polygelin
also
aim
investig
hospit
cost
trial
prematur
interrupt
due
theoret
concern
regard
safeti
bovinederiv
product
method
multicent
random
doubleblind
trial
conduct
patient
tens
ascit
randomli
assign
receiv
intraven
either
human
albumin
polygelin
prespecifi
primari
end
point
time
first
liverrel
event
composit
death
episod
recurr
tens
ascit
renal
impair
hyponatremia
bacteri
infect
encephalopathi
portal
hypertens
bleed
occurr
hepatocellular
carcinoma
liver
transplant
intrial
period
ie
period
patient
receiv
assign
colloid
event
blindli
adjud
result
thirti
patient
assign
albumin
polygelin
baselin
patient
therapeut
paracentesi
durat
intrial
period
higher
albumin
group
polygelin
group
mean
sd
day
vs
day
p
due
lower
frequenc
unblind
colloid
infus
dropout
patient
assign
albumin
liverrel
first
event
albumin
group
per
personmonth
liverrel
first
event
polygelin
group
per
personmonth
hazard
ratio
first
liverrel
event
albumin
therapi
confid
interv
p
median
time
first
event
higher
albumin
group
polygelin
group
day
confid
interv
day
vs
day
confid
interv
day
p
median
total
hospit
cost
lower
albumin
group
polygelin
group
period
vs
period
respect
p
patient
cirrhosi
tens
ascit
treat
paracentesi
human
albumin
effect
polygelin
prevent
occurr
first
event
relat
liver
diseas
benefici
effect
seem
associ
decreas
hospitalizationrel
cost
background
albumin
furosemid
report
improv
cardiovascular
stabil
oxygen
adult
respiratori
distress
syndrom
ard
method
fourteen
patient
meet
ard
criteria
po
fio
ratio
kpa
mmhg
plu
bilater
xray
shadow
without
cardiac
caus
recruit
chelsea
westminst
hospit
london
oxygen
cardiovascular
paramet
measur
min
min
rapid
intraven
administr
ml
human
albumin
solut
bpl
mg
furosemid
result
analys
anova
bonferonnidunn
posthoc
signific
test
p
consid
signific
albumin
concentr
correct
chang
plasma
volum
express
mean
sd
colloid
osmot
pressur
cop
albumin
chang
significantli
signific
immedi
elev
declin
although
elev
baselin
remain
signific
plasma
albumin
gdl
gdl
gdl
cop
mmhg
mmhg
mmhg
signific
chang
also
occur
po
fio
central
venou
pressur
cvp
signific
increas
sustain
po
fio
kpa
kpa
kpa
cvp
mmhg
mmhg
mmhg
heart
rate
cardiac
output
significantli
affect
albumin
administr
although
increas
cardiac
output
correl
nonsignificantli
improv
po
fio
ratio
correl
correl
discuss
cardiovascular
stabil
unaffect
albumin
furosemid
administr
immedi
improv
oxygen
sustain
hour
introduct
recombin
factor
viia
rfviia
prohaemostat
agent
success
use
treatment
patient
haematolog
malign
coagulopathi
also
use
postsurg
patient
coagulopathi
combin
hypothermia
metabol
acidosi
caus
increas
mortal
earli
post
oper
recent
report
use
rfviia
patient
normal
coagul
system
undergo
major
surgeri
order
reduc
intraop
bleed
need
transfus
present
experi
rfviia
use
icu
patient
period
januari
decemb
icu
patient
receiv
recombin
factor
viia
men
six
women
averag
age
year
patient
admit
icu
post
oper
reason
rfviia
administr
sever
bleed
despit
surgic
intervent
massiv
blood
compon
transfus
rfviia
administ
six
patient
haematolog
malign
five
reduc
coagul
disord
one
patient
coagulopathi
undergo
invas
therapeut
procedur
order
prevent
bleed
patient
infus
bodi
weight
rfviia
evalu
treatment
prothrombin
time
activ
partial
thromboplastin
time
aptt
fibrinogen
level
measur
well
number
blood
compon
transfus
rfviia
administr
success
rfviia
treatment
confirm
clinic
stabil
outcom
result
see
tabl
mean
valu
rfviia
infus
advers
effect
observ
bleed
control
patient
patient
five
die
reason
multipl
organ
dysfunct
two
patient
despit
high
dose
rfviia
die
continu
bleed
result
show
treatment
rfviia
coagul
paramet
blood
requir
decreas
use
rfviia
icu
patient
safe
effect
method
control
lifethreaten
bleed
manag
surgic
method
two
hundr
fortyf
cirrhot
patient
childpugh
childpugh
b
c
ugib
varic
nonvaric
equal
random
receiv
eight
dose
rfviia
placebo
addit
pharmacolog
endoscop
treatment
primari
composit
endpoint
failur
control
ugib
within
hour
postdos
failur
prevent
rebleed
hour
day
death
within
day
result
baselin
characterist
similar
two
group
result
primari
exploratori
analys
present
tabl
subgroup
childpugh
b
c
varic
bleeder
significantli
fewer
patient
rfviiatreat
group
fail
primari
composit
endpoint
p
hourbleed
control
endpoint
p
compar
placebo
rfviia
improv
efficaci
standard
treatment
childpugh
cirrhot
patient
signific
effect
found
analys
applic
patient
incid
advers
event
includ
thromboembol
event
similar
signific
differ
mortal
conclus
exploratori
analys
childpugh
b
c
cirrhot
patient
indic
administr
rfviia
safe
significantli
reduc
proport
patient
fail
control
varic
bleed
studi
need
verifi
find
conclus
accord
studi
mortal
rate
sever
burn
patient
remain
high
despit
burn
care
chang
consider
report
sever
ill
admiss
icu
extent
burn
contributor
mortal
rate
moreov
earli
excis
burn
seem
associ
better
outcom
introduct
prospect
studi
examin
efficaci
predict
power
mortal
two
differ
prehospit
score
system
major
trauma
present
improv
mee
combin
capnometri
mee
combin
capnometri
meesc
new
score
system
prehospit
set
valu
mee
capnometri
initi
final
collect
patient
ad
final
valu
partial
pressur
endtid
co
petco
mee
score
system
rank
final
maximum
sum
score
system
would
without
chang
minimum
score
studi
undertaken
year
januari
includ
consecut
patient
hospit
major
trauma
defin
injuri
sever
score
requir
intub
roadsid
prehospit
petco
record
patient
younger
year
old
exclud
studi
male
femal
method
sixteen
patient
schb
middl
end
stage
underw
mar
therapi
mar
treatment
group
retrospect
review
patient
chosen
previou
therapi
data
also
schb
clinic
match
mar
group
regard
standard
medic
therapi
smt
group
treat
gener
method
except
mar
prognosi
two
group
studi
treatment
effect
level
serum
total
bilirubin
nonconjug
bilirubin
mean
arteri
pressur
map
observ
mar
group
singl
hour
mar
treatment
singl
mar
treatment
contribut
signific
decreas
level
serum
total
bilirubin
mmoll
mmoll
p
nonconjug
bilirubin
mmoll
mmoll
p
respect
map
increas
mmhg
mmhg
p
mar
therapi
statist
differ
prognosi
surviv
two
group
smt
group
six
patient
middl
stage
surviv
mar
group
surviv
compar
middlestag
patient
endstag
subgroup
comparison
four
patient
die
smt
group
mar
therapi
improv
surviv
four
patient
overal
surviv
two
group
middlestag
endstag
schb
patient
smt
mar
p
conclus
mar
therapi
effect
remov
serum
bilirubin
albuminbound
toxin
increas
map
inhibit
hepatocellular
necrosi
thu
contribut
organ
protect
result
mar
treatment
associ
signific
reduct
albuminbound
toxin
variou
cytokin
well
watersolubl
toxin
patient
show
posit
respons
therapi
proven
increas
prothrombin
time
activ
mean
arteri
pressur
decreas
hepatoencephalopathi
grade
childturcottepugh
index
significantli
eightyfour
patient
surviv
hospit
includ
aliv
liver
transplant
surviv
acut
liver
failur
subacut
liver
failur
acut
chronic
liver
failur
patient
acut
chronic
liver
failur
patient
form
major
patient
end
stage
present
largest
among
subgroup
acut
chronic
liver
failur
patient
earli
middl
stage
gain
favor
outcom
c
grade
vs
tabl
random
control
studi
china
ongo
verifi
optim
therapeut
result
mar
materi
nineteen
patient
nine
femal
year
age
sepsi
receiv
continu
hemodiafiltr
chdf
treatment
examin
apach
ii
score
fifteen
patient
underw
mechan
lung
ventil
inotrop
support
mortal
rate
hemoprocessor
prisma
kit
membran
solut
hospal
compani
franc
use
chdf
mean
durat
chdf
hour
filtrat
volum
lday
concentr
chdf
pgml
signific
amount
cytokin
measur
effluent
sampl
pgml
daili
elimin
clearanc
lday
onethird
blood
volum
perfus
hemodiafilt
found
correl
volum
effluent
elimin
r
n
p
differ
content
plasma
volum
hemodiafilt
mean
blood
speed
mlmin
hematocrit
plasma
flow
mlmin
pgmin
chdf
speed
mlmin
pgmin
elimin
differ
content
plasma
effluent
volum
pgmin
acknowledg
receipt
signific
absorpt
cytokin
hemodiafilt
membran
first
hour
chdf
procedur
conclus
signific
amount
elimin
use
chdf
filtrat
absorpt
import
absenc
natur
hepatoren
clearanc
multipl
organ
failur
hemodynam
pattern
sepsi
character
high
cardiac
index
associ
low
system
vascular
resist
alter
tissu
oxygen
caus
releas
mediat
hostinfect
microorgan
interact
thought
remov
endotoxin
inflammatori
mediat
plasmapheresi
would
improv
hemodynam
chang
tissu
oxygen
ethic
approv
trial
obtain
patient
prepar
plasmapheresi
criteria
entri
trial
sepsi
describ
bone
colleagu
sever
ill
mortal
rate
classifi
calcul
use
apach
ii
scale
mod
sofa
obtain
laboratori
data
calcul
score
hemodynam
assess
tissu
oxygen
calcul
perform
use
thermodilut
techniqu
first
plasmapheresi
plasmapheresi
perform
twice
substitut
fresh
frozen
plasma
ratio
calcul
plasma
volum
second
plasmapheresi
perform
hour
hemodynam
assess
tissu
oxygen
calcul
repeat
second
plasmapheresi
end
procedur
hour
outcom
day
record
statist
analysi
perform
spss
version
window
chicago
il
usa
valu
express
mean
sd
p
consid
statist
signific
studi
patient
treat
icu
plasmapheresi
differ
calcul
mortal
rate
base
initi
apach
ii
score
mortal
patient
signific
p
enhanc
apach
ii
mod
sofa
score
baselin
end
procedur
statist
signific
p
chang
hemodynam
paramet
signific
tabl
despit
improv
oxygen
deliveri
oxygen
consumpt
oxygen
extract
ratio
signific
first
plasmapheresi
decreas
plasma
lactat
level
statist
signific
end
procedur
p
correl
mortal
chang
plasma
creactiv
protein
also
signific
p
sepsi
describ
malign
intravascular
inflammatori
caus
mediat
hypothesi
remov
mediat
improv
therapeut
effort
thought
earli
stage
sepsi
plasmapheresi
may
consid
therapeut
method
even
progress
sepsi
complic
dissemin
intravascular
coagul
limit
endotoxin
hemoadsorpt
therapi
pmxdhp
optim
time
start
pmxdhp
examin
patient
septic
multipl
organ
failur
hypercytokinemia
pgml
studi
includ
patient
infecti
system
inflammatori
respons
syndrom
pgml
pmxdhp
therapi
subject
separ
two
group
surviv
day
start
pmxdhp
therapi
group
patient
surviv
ns
group
patient
sever
symptom
background
factor
hemodynam
paramet
pao
fio
endotoxin
cytokin
vascular
endotheli
cell
functionrel
marker
examin
pmxdhp
statist
analys
perform
chisquar
test
background
factor
wilcoxon
sign
rank
test
comparison
within
group
mannwhitney
u
test
comparison
group
studi
approv
irb
tokyo
medic
univers
apacheii
score
sofa
score
ns
group
respect
show
significantli
higher
score
ns
group
number
day
laps
onset
shock
pmxdhp
initi
day
group
longer
day
ns
group
pmxdhp
hour
endotoxin
level
decreas
pgml
statist
signific
p
group
ns
group
tend
decreas
pgml
result
suggest
pmxdhp
could
save
live
patient
septic
multipl
organ
failur
pgml
appli
earli
onset
shock
object
high
sustain
high
level
inflammatori
cytokin
tissu
necrosi
factor
tnf
interleukin
il
believ
respons
advers
clinic
effect
patient
undergo
cardiopulmonari
bypass
cpb
explor
use
mathemat
model
whether
modul
respons
might
benefici
develop
mathemat
model
acut
inflammatori
respons
calibr
rat
endotoxemia
hemorrhag
shock
data
model
accommod
varieti
initi
acut
inflamm
provid
dynam
profil
serum
marker
inflamm
time
express
outcom
global
tissu
dysfunct
irrevers
dysfunct
interpret
death
construct
popul
case
differ
level
initi
stress
propens
mount
inflammatori
respons
initi
stress
chosen
result
cohort
mortal
last
less
hour
cpb
intervent
consist
remov
circul
tnf
period
hour
stress
inflict
acut
inflamm
trigger
equat
degre
remov
cytokin
observ
applic
biocompat
adsorb
polym
hemoperfus
column
endotoxem
rat
result
death
correl
serum
lesser
degre
tnf
cumul
level
patient
highest
level
hour
insult
go
die
fig
examin
result
show
level
decreas
tnf
level
period
shortli
cpb
patient
would
surviv
compar
control
arm
conclus
global
nonspecif
reduct
inflamm
improv
outcom
simul
acut
inflammatori
challeng
cpb
avail
onlin
http
sepsi
complic
dissemin
intravascular
coagul
dic
frequent
caus
mortal
icu
despit
improv
patient
care
plasmapheresi
tool
remov
endotoxin
inflammatori
mediat
respons
pathophysiolog
design
studi
small
group
septic
patient
complic
dic
evalu
chang
coagul
paramet
sever
sepsi
outcom
plasmapheresi
ethic
approv
trial
written
inform
consent
obtain
patient
prepar
plasmapheresi
criteria
entri
trial
sepsi
describ
bone
dic
describ
bick
exclus
criteria
uncontrol
hemorrhagia
recent
hour
cardiac
surgeri
recent
hour
resuscit
platelet
posit
human
immunodefici
viru
serolog
morbid
obes
pregnanc
obtain
laboratori
data
score
first
plasmapheresi
perform
use
fresh
frozen
plasma
ratio
calcul
plasma
volum
patient
second
plasmapheresi
perform
hour
sever
ill
mortal
rate
calcul
use
apach
ii
scale
sever
dic
calcul
dic
score
outcom
day
record
statist
analysi
perform
spss
version
window
chicago
il
usa
valu
express
mean
sd
p
consid
statist
signific
thirteen
patient
treat
icu
plasmapheresi
differ
calcul
mortal
rate
base
initi
apach
ii
score
mortal
patient
signific
p
decreas
prothrombin
time
activ
partial
thromboplast
time
base
initi
result
signific
hour
p
enhanc
dic
score
baselin
end
procedur
statist
signific
p
level
ddimer
first
plasmapheresi
decreas
significantli
end
procedur
p
increas
biolog
marker
sepsi
antithrombin
protein
c
protein
activ
statist
signific
p
also
found
protein
c
activ
controversi
correl
surviv
p
thought
repeat
plasmapheresi
earli
stage
sepsi
may
consid
therapeut
method
even
progress
sepsi
complic
dic
introduct
high
cutoff
hemofilt
character
increas
effect
pore
size
design
facilit
elimin
inflammatori
mediat
sepsi
studi
compar
diffus
versu
convect
high
cutoff
renal
replac
therapi
rrt
term
cytokin
clearanc
rate
effect
plasma
protein
method
twentyfour
patient
sepsisinduc
acut
renal
failur
studi
polyflux
hemofilt
cutoff
point
approxim
kda
use
rrt
patient
randomli
alloc
either
continu
venoven
hemofiltr
cvvh
ultrafiltr
rate
lhour
group
lhour
group
continu
venoven
hemodialysi
cvvhd
dialys
flow
rate
lhour
group
lhour
group
tumor
necrosi
plasma
protein
measur
daili
result
cvvh
achiev
significantli
higher
clearanc
compar
cvvhd
p
differ
found
p
increas
ultrafiltr
volum
dialys
flow
led
highli
signific
increas
clearanc
rate
p
peak
clearanc
mlmin
mlmin
clearanc
poor
rrt
modal
signific
declin
plasma
observ
patient
high
baselin
level
protein
albumin
loss
highest
lh
hemofiltr
mode
conclus
high
cutoff
rrt
novel
strategi
clear
cytokin
effect
convect
advantag
diffus
clearanc
capac
associ
higher
plasma
protein
loss
method
one
hundr
ten
singl
mar
treatment
perform
length
hour
variou
pathogen
mod
patient
femal
see
tabl
mar
therapi
associ
signific
remov
certain
cytokin
lipopolysaccharid
bind
protein
lbp
see
tabl
togeth
mark
reduct
nonwatersolubl
albuminbound
toxin
watersolubl
toxin
associ
improv
patient
clinic
condit
includ
hepat
encephalopathi
derang
hemodynam
situat
renal
respiratori
function
thu
result
mark
decreas
teh
sequenti
organ
failur
assess
sofa
score
improv
outcom
patient
abl
discharg
hospit
bridg
success
liver
transplant
overal
surviv
patient
confirm
posit
therapeut
impact
safeti
use
mar
variou
pathogen
mod
patient
associ
elev
level
cytokin
sledd
figur
show
mortal
differ
sharf
categori
icu
hospit
length
stay
higher
patient
rrt
observ
mortal
lower
expect
nonrrt
parallel
expect
rrt
interim
result
ongo
studi
show
sharf
score
paramet
hour
good
predict
valu
estim
prognosi
arf
patient
overal
mortal
need
rrt
mortal
regardless
rrt
use
major
problem
lay
recruit
center
use
techniqu
equal
randomis
rate
lower
expect
avail
onlin
http
method
retrospect
studi
consecut
patient
diagnosi
rhabdomyolysi
seen
emerg
depart
month
normal
serum
creatinin
defin
less
mgdl
laboratori
data
includ
initi
peak
creatin
kinas
ck
anion
gap
calcium
phosphat
potassium
blood
urea
nitroben
bun
white
blood
cell
count
wbc
urin
toxicolog
screen
hematocrit
second
hematocrit
collect
follow
hydrat
compar
first
approxim
percentag
initi
volum
deplet
second
creatinin
also
taken
follow
hydrat
median
hour
admiss
patient
obviou
renal
insuffici
defin
creatinin
mgdl
patient
peak
ck
exclud
multivari
logist
regress
analysi
perform
use
small
stata
continu
variabl
data
dichotom
base
upper
limit
normal
valu
phosphat
potassium
bun
low
limit
calcium
median
valu
anion
gap
hematocrit
percentag
decreas
hematocrit
wbc
ck
signific
independ
predictor
normal
first
creatinin
present
tabl
power
independ
predictor
normal
posthydr
creatinin
normal
admiss
creatinin
odd
ratio
confid
interv
ci
p
elev
bun
ck
greater
neg
predictor
normal
second
creatinin
ci
p
ci
p
conclus
normal
admiss
creatinin
associ
wbc
absenc
cocain
amphetamin
less
volum
deplet
normal
bun
normal
calcium
normal
first
creatinin
strong
predictor
normal
second
creatinin
hydrat
suggest
otherwis
healthi
patient
uncompl
rhabdomyolysi
normal
first
creatinin
hydrat
oral
may
safe
discharg
acut
emerg
care
correct
volum
deficit
result
plasma
peak
averag
day
ck
patient
ck
increas
parallel
decreas
exponenti
hour
ck
hour
fig
patient
isol
increas
observ
major
patient
abdomin
complic
found
patient
isol
increas
ck
observ
typic
relat
mobilis
patient
arf
treat
continu
venoven
haemofiltr
major
patient
rhabdomyolysi
ck
increas
decreas
parallel
mediums
molecul
transport
directli
muscl
blood
larg
molecul
ck
transport
lymphat
system
therefor
isol
increas
plasma
ck
might
observ
follow
mobilis
isol
increas
plasma
ought
rais
suspicion
abdomin
complic
patient
rhabdomyolysi
measur
nephrotox
molecul
use
predict
risk
arf
routin
screen
patient
sever
muscular
exert
presenc
rhabdomyolysi
evalu
signific
low
initi
creatin
kinas
ck
factor
associ
rise
ck
group
method
consecut
patient
rhabdomyolysi
indentifi
month
subgroup
analysi
acut
exert
rhabdomyolysi
initi
ck
ul
identifi
two
group
patient
whose
ck
valu
remain
stabl
whose
ck
valu
rose
greater
ul
one
exclud
student
test
fisher
exact
test
use
analyz
continu
categor
variabl
respect
result
see
tabl
patient
ck
ul
rise
ck
significantli
associ
elev
anion
gap
increas
frequenc
moder
larg
urin
test
heme
stabl
ck
group
significantli
higher
blood
urea
nitrogen
bun
case
anion
gap
resolv
sedat
hydrat
clinic
consist
acut
lactic
acidosi
five
patient
rise
ck
aim
studi
assess
efficaci
renal
replac
therapi
adopt
icu
patient
affect
acut
renal
failur
admiss
icu
evalu
role
age
relat
renal
function
surviv
probabl
period
month
februari
treat
patient
acut
renal
failur
mean
continu
renal
replac
therapi
patient
male
femal
divid
two
group
one
group
patient
group
younger
year
second
group
group
b
older
year
group
made
patient
suffer
polytrauma
four
acut
pancreat
mean
age
year
second
group
made
patient
underw
major
surgic
intervent
four
open
heart
surgeri
four
gynaecolog
surgeri
eight
abdomin
surgeri
mean
age
year
patient
got
icu
acut
respiratori
failur
need
mechan
ventil
oliguria
diagnos
urin
output
less
mlday
acut
renal
failur
due
hypotens
sepsi
renal
replac
therapi
start
oliguria
andor
volem
overload
observ
patient
treat
slow
loweffici
daili
dialysi
sledd
singl
pass
adapt
patient
low
flow
therapi
hour
order
obtain
good
haemodynam
stabil
ensur
urea
clearanc
lday
ktv
weekli
statist
analysi
made
anova
logist
regress
patient
icu
length
stay
day
group
group
b
sledd
therapi
last
day
group
day
group
b
qb
mlmin
qd
mlmin
mean
ultrafiltr
mlhour
calor
intak
kcalkgday
proteic
intak
gkgday
six
patient
group
patient
group
b
die
survivor
recov
renal
function
sepsi
relev
reason
acut
renal
insuffici
mortal
critic
ill
patient
accord
experi
sledd
consid
safe
efficaci
treatment
patient
allow
aggress
volem
remov
adequ
nutrit
support
coupl
haemodynam
stabil
urem
control
logist
regress
show
age
sever
ill
amount
organ
affect
independ
risk
factor
poor
outcom
acut
renal
failur
arf
common
critic
care
patient
one
risk
factor
arf
age
howev
access
dialysi
often
limit
older
patient
due
wors
prognosi
report
experi
dialyz
old
patient
compar
younger
patient
arf
unit
sinc
septemb
record
dialyz
patient
treat
intermitt
dialysi
ihd
continu
dialysi
crrt
depend
clinic
decis
ihd
use
freseniu
e
machin
polysulfon
dialyz
crrt
first
use
dm
freseniu
machin
diapactcrrt
braun
machin
polysulfon
hemofilt
sinc
patient
male
mean
age
rang
year
mean
apach
ii
score
admiss
eightythre
percent
need
mechan
ventil
primarili
surgic
relev
infect
sepsi
total
patient
older
year
mean
age
year
group
male
need
mechan
ventil
receiv
nephrotox
agent
includ
radiocontrast
primarili
surgic
sepsi
compar
younger
patient
older
patient
often
male
higher
apach
score
versu
p
mortal
versu
p
older
group
main
differ
survivor
nonsurvivor
incid
sepsi
nonsurvivor
versu
survivor
type
patient
nonsurvivor
surgic
versu
survivor
surgic
age
use
mechan
ventil
apach
score
differ
survivor
nonsurvivor
regard
modal
dialysi
crrt
use
patient
death
contrast
mortal
younger
patient
treat
crrt
arf
outcom
nonsurvivor
maintain
arf
death
contrast
none
survivor
requir
dialysi
discharg
hospit
throughout
year
dialysi
often
consid
older
patient
dialyz
admit
often
also
crrt
use
two
crrt
older
group
conclus
arf
common
old
patient
even
though
arf
dialysi
associ
high
mortal
still
old
patient
submit
acut
dialysi
surviv
discharg
free
dialysi
time
old
patient
admit
icu
treat
dialysi
author
conclud
age
use
isol
factor
decid
treat
arf
dialysi
aim
studi
compar
outcom
critic
ill
patient
requir
rrt
without
hm
well
assess
whether
presenc
hm
independ
relat
higher
mortal
popul
conclus
incid
arf
import
picu
associ
signific
mortal
risk
factor
multipl
could
prevent
first
prospect
epidemiolog
studi
focus
pediatr
arf
picu
multicentr
studi
plan
confirm
result
yet
evalu
gener
icu
popul
rifl
defin
three
grade
sever
arf
basi
either
urin
output
u
acut
increas
serum
creatinin
c
risk
c
u
mlkghour
hour
injuri
c
u
mlkghour
hour
failur
c
c
mgdl
u
mlkghour
hour
anuria
hour
prospect
collect
data
patient
admit
icu
juli
june
univers
pittsburgh
medic
center
tertiari
hospit
icu
bed
serv
medic
surgic
trauma
neurolog
transplant
patient
test
two
hypothes
increas
rifl
class
correspond
decreas
icu
occurr
increas
hospit
mortal
patient
classifi
c
u
criteria
similar
occurr
mortal
classifi
patient
accord
worst
class
c
u
criteria
baselin
c
select
lower
admiss
c
predict
c
base
age
sex
race
use
modif
diet
renal
diseas
formula
result
total
admiss
patient
evalu
occurr
mortal
present
tabl
conclus
rifl
criteria
appear
clinic
sensibl
increas
mortal
unfortun
c
u
criteria
alon
yield
differ
result
occurr
decreas
c
criteria
use
alon
method
posthoc
analysi
random
prospect
trial
patient
present
urban
emerg
depart
ed
sever
sepsi
septic
shock
patient
enrol
studi
two
system
inflammatori
respons
syndrom
criteria
plu
hypotens
lactic
acidosi
mmoll
patient
random
either
convent
care
egdt
includ
resuscit
goal
central
venou
pressur
cvp
mean
arteri
pressur
map
central
venou
oximetri
scvo
greater
ten
patient
esrd
control
group
eight
treatment
group
baselin
hemodynam
heart
rate
hr
map
cvp
scvo
sever
ill
score
apach
mod
sap
differ
group
seven
patient
control
group
die
compar
egdt
group
p
hour
hr
cvp
remain
equal
group
statist
signific
rise
scvo
map
found
group
p
addit
treatment
group
display
signific
fall
lactat
apach
mod
sap
score
p
differ
lactat
sever
ill
remain
signific
hour
p
conclus
egdt
safe
efficaci
patient
esrd
result
reduct
morbid
mortal
improv
outcom
explain
erad
global
tissu
hypoxia
aggress
resuscit
guid
goaldirect
care
although
egdt
perform
hour
ed
physiolog
benefit
persist
group
hour
object
although
simpl
closureoment
patch
sc
standard
procedur
perfor
duoden
ulcer
pdu
institut
japan
procedur
origin
perform
poorrisk
patient
basic
evalu
concern
sc
insuffici
sc
perform
base
experi
gastrointestin
endoscop
examin
gf
make
possibl
evalu
fine
structur
howev
known
whether
earli
endoscop
examin
sc
safe
aim
studi
clarifi
macroscop
find
heal
process
sc
pdu
perform
sc
patient
pdu
without
stenosi
without
promin
ulcer
ridg
start
medic
ppi
oper
oral
feed
day
oper
independ
postop
gf
eleven
patient
pdu
treat
sc
underw
postop
gf
postop
day
heal
process
examin
perform
radiograph
examin
leakag
anastomosi
patient
inform
could
convinc
heal
process
unknown
risk
three
patient
gf
find
show
activ
stage
heal
stage
two
surgic
techniqu
thought
insuffici
distanc
stitch
edg
ulcer
insuffici
patient
postop
gf
perform
postop
day
transfer
anoth
minor
hospit
eight
patient
show
scar
phase
good
granul
without
exposur
stitch
iatrogen
perfor
bleed
sever
abdomin
pain
postop
gf
seen
case
conclus
postop
gf
earli
phase
sc
use
safe
evalu
heal
process
sc
pdu
start
oral
intak
week
surgic
procedur
kinet
pancreat
hormon
glucagon
patient
acut
pancreat
investig
care
insulin
spite
crucial
influenc
energi
metabol
present
studi
studi
kinet
glucagon
glucagonrel
peptid
assess
radioimmunoassay
furthermor
molecular
form
peptid
examin
use
gel
filtrat
chromatographi
glucagon
process
pancrea
intestin
earli
stage
patient
acut
pancreat
investig
methodolog
fourteen
patient
acut
pancreat
enrol
studi
eight
sever
pancreat
group
six
mild
pancreat
group
ten
healthi
volunt
also
enrol
normal
control
group
c
serum
level
glucagon
glucagonrel
peptid
assess
second
admiss
day
group
earli
morn
fast
state
group
c
use
glucagon
nonspecif
ntermin
glucagonlik
immunoreact
gli
specif
ctermin
immunoreact
glucagon
irg
radioimmunoassay
molecular
form
peptid
also
estim
use
gel
filtrat
chromatographi
discuss
glucagon
process
base
find
serum
gli
irg
group
significantli
higher
group
c
p
group
also
significantli
higher
group
p
patient
group
except
three
group
peculiar
glicentinlik
peptid
gllp
molecular
weight
pancreat
glucagon
observ
irg
gel
filtrat
chromatographi
clearli
absent
group
c
kinet
process
glucagon
patient
acut
pancreat
quit
differ
healthi
subject
patient
acut
pancreat
peculiar
process
glucagon
proceed
intestin
quit
differ
ordinari
glucagon
process
either
pancrea
intestin
gener
peculiar
gllp
aim
studi
evalu
acut
pancreat
patient
confirm
cytokin
involv
appear
pulmonari
failur
investig
effect
somatostatin
cytokin
associ
lung
injuri
prospect
clinic
studi
examin
patient
sever
pancreat
acuta
eleven
group
treat
earli
somatostatin
mg
everi
hour
day
second
group
treat
standard
therapi
pulmonari
failur
assess
basi
radiograph
find
computeris
tomographi
scan
bacteriolog
diagnosi
endotrach
aspir
acidbas
abnorm
serum
concentr
determin
time
cours
studi
white
blood
cell
count
amylas
transaminas
urea
creatinin
patient
develop
mod
laboratori
paramet
indic
sir
increas
serum
concentr
elev
patient
high
signific
differ
p
patient
develop
pulmonari
failur
three
group
patient
group
ii
peak
serum
concentr
cytokin
found
patient
group
ii
increas
valu
lung
injuri
treat
mechan
ventil
patient
pulmonari
drainag
six
patient
even
decort
three
patient
correl
increas
serum
valu
chang
chest
radiograph
depend
increas
valu
cytokin
sever
lung
injuri
higher
valu
comparison
patient
group
group
ii
show
signific
differ
valu
cytokin
valu
higher
group
ii
serum
concentr
cytokin
significantli
higher
p
five
patient
die
pulmonari
failur
compar
surviv
high
cytokin
valu
associ
develop
pulmonari
failur
increas
mortal
acut
pancreat
patient
initi
aggress
treatment
somatostatin
decreas
cytokin
releas
may
predict
good
outcom
patient
reduc
appear
sever
pulmonari
failur
method
twentysix
normal
volunt
mean
age
year
femal
male
spontan
breath
submit
abdomin
circumfer
measur
thereaft
obtain
rr
tv
fvc
mip
mep
repeat
measur
compress
abdomen
use
extern
band
achiev
basal
abdomin
circumfer
took
band
measur
respiratori
paramet
result
see
tabl
abdomin
compress
extern
band
decreas
tv
mip
mep
last
one
compress
affect
rr
fvc
leukocyt
count
differenti
paramet
assess
chemokin
myeloperoxidas
mpo
measur
neutrophil
activ
albumin
measur
lung
permeabl
assess
paramet
significantli
higher
abdomin
fluid
two
compart
cell
count
concentr
compar
blood
p
leukocyt
count
neutrophil
countpercentag
concentr
also
significantli
higher
lung
compar
blood
plasma
valu
p
absolut
number
percentag
activ
mpo
concentr
neutrophil
lung
higher
time
point
periton
patient
even
day
compar
short
ventil
control
p
alveolar
membran
permeabl
measur
rel
coeffici
excret
ratio
albumin
excret
excret
ratio
increas
periton
patient
time
point
discuss
neutrophil
accumul
activ
abdomin
caviti
pulmonari
compart
patient
periton
like
compartment
variou
compart
bodi
host
defens
system
vari
extent
natur
impress
pulmonari
respons
develop
earli
secondari
periton
neutrophil
activ
lung
permeabl
increas
normal
valu
valu
iap
mmhg
igp
vs
ibp
app
good
correl
ibp
igp
r
p
bland
altman
analysi
show
good
agreement
igp
almost
ident
ibp
mean
bia
conclus
estim
iap
via
igp
ibp
feasibl
novel
igp
method
less
time
consum
fulli
autom
autocalibr
allow
continu
trend
foleymanomet
offer
costeffect
altern
accur
reproduc
cova
obtain
paramet
sedat
patient
around
hour
period
thu
vari
substanti
variat
may
even
pronounc
nonsed
patient
therefor
iap
app
continu
variabl
like
pressur
monitor
often
possibl
day
adapt
treatment
accordingli
background
goal
studi
air
tonometri
common
method
examin
splanchnic
hypoxia
often
predictor
sever
clinic
complic
sepsi
renal
failur
urodilatin
one
indic
renal
function
retroperspect
casecontrol
studi
conduct
consid
whether
interrel
splanchnic
ischaemia
renal
function
approv
local
ethic
commite
intens
care
patient
studi
age
patient
diverg
year
median
age
year
hemodynam
variabl
includ
continu
cardiac
output
airtonometr
variabl
via
nasogastr
tube
tonocap
datex
helsinki
finland
arteri
lactat
urin
product
heart
rate
central
venou
pressur
cvp
mean
arteri
pressur
measur
everi
hour
furthermor
renal
valu
urodilatin
anf
urin
excret
assess
hour
increas
co
gap
valu
within
first
hour
determin
curv
estim
correl
bivari
correl
indic
renal
function
use
spearman
rho
pearson
correl
cvp
increas
within
first
hour
assess
similar
co
gap
increas
result
discuss
air
tonometri
valu
renal
function
signific
contigu
p
found
bivari
correl
level
p
co
gap
increas
urin
urodilatin
assess
hour
result
spearman
rho
p
co
gap
increas
urodilatin
extract
p
co
gap
increas
urin
excret
hour
strongest
correl
found
co
gap
increas
urodilatinecreatinin
ratio
p
correl
co
gap
increas
serum
creatinin
also
appreci
interrel
cvp
increas
co
gap
increas
pearson
p
spearman
rho
p
furthermor
time
ventil
correl
posit
co
gap
increas
p
studi
suggest
co
gap
increas
predictor
decreas
urodilatin
valu
indic
renal
failur
therefor
air
tonometri
help
tendenti
detect
deterior
renal
function
sign
multiorgan
failur
introduct
eap
may
lead
compromis
chest
wall
mechan
worsen
lung
mechan
ga
exchang
temporari
relief
may
lead
reperfus
injuri
investig
effect
eap
reperfus
injuri
respiratori
system
mechan
ga
exchang
pressur
control
ventil
pcv
without
spontan
breath
method
porcin
model
eap
set
cmh
co
insuffl
twice
hour
pressur
relief
hour
end
anesthetis
pig
kg
receiv
pcv
n
biphas
posit
airway
pressur
bipap
n
posit
end
expiratori
pressur
cmh
allow
spontan
total
ventil
randomli
assign
control
group
n
without
eap
eap
group
n
mode
measur
lung
mechan
ga
exchang
perform
everi
hour
control
group
chang
observ
time
mode
result
eap
group
see
tabl
second
eap
phase
lung
mechan
deterior
return
baselin
valu
pressur
relief
bipap
mode
oxygen
last
pressur
relief
wors
baselin
conclus
eap
appli
twice
hour
worsen
chest
wall
lung
mechan
impair
ga
exchang
regardless
ventil
mode
chang
complet
revers
pressur
relief
spontan
breath
present
bipap
less
impair
lung
complianc
oxygen
deliveri
lead
differ
ga
exchang
background
organ
dysfunct
attribut
intraabdomin
hypertens
known
abdomin
compart
syndrom
ac
recognis
sourc
morbid
mortal
icu
decompress
laparatomi
consid
sole
definit
therapi
ac
howev
randomis
trial
perform
assess
role
surgeri
studi
characterist
outcom
critic
ill
patient
ac
treat
nonop
focus
natur
cours
organ
dysfunct
retrospect
studi
patient
ac
intraabdomin
pressur
iap
mmhg
least
one
organ
failur
admit
medic
surgic
intens
care
unit
two
consecut
year
focus
organ
failur
time
rais
iap
evolut
patient
undergo
decompress
laparatomi
hemodynam
instabl
defin
depend
vasopressor
therapi
respiratori
failur
pf
renal
failur
creatinin
level
mgdl
increas
baselin
found
episod
ac
patient
manag
nonop
mortal
patient
die
higher
apach
ii
score
admiss
vs
surviv
group
p
incid
organ
failur
highest
record
iap
significantli
differ
discharg
organ
function
return
basic
level
survivor
medium
length
stay
conclus
group
critic
ill
patient
ac
treat
nonop
mortal
patient
surviv
discharg
icu
without
organ
dysfunct
conclud
select
patient
ac
may
requir
decompress
laparatomi
respond
nonop
observ
support
therapi
introduct
splanchnic
ischemia
due
sepsi
hemorrhag
believ
involv
pathogenesi
multipl
organ
dysfunct
syndrom
previou
studi
perform
laboratori
studi
microcirculatori
blood
flow
small
intestin
mucosa
porcin
model
septic
shock
demonstr
microcirculatori
blood
flow
mbf
redistribut
jejun
musculari
toward
mucosa
aim
studi
measur
chang
mbf
jejunum
stepwis
occlus
superior
mesenter
arteri
sma
method
data
sepsi
group
extract
previous
publish
studi
swiss
landrac
pig
kg
anesthet
mechan
ventil
cardiac
output
co
measur
use
thermodilut
sma
flow
ultrason
transit
time
flowmetri
mbf
measur
jejun
mucosa
musculari
use
laser
doppler
flowmetri
septic
shock
group
group
n
sepsi
induc
fecal
periton
sma
occlus
group
group
n
sma
flow
reduc
step
use
occlud
result
present
percent
baselin
mean
sd
p
compar
baselin
p
mucosa
vs
musculari
septic
shock
co
sma
flow
mbf
jejun
musculari
decreas
respect
mbf
jejun
musculari
remain
virtual
unchang
nonsept
anim
stepwis
occlus
sma
baselin
produc
decreas
musculari
blood
flow
mucos
blood
flow
decreas
less
conclus
reduc
region
blood
flow
microcirculatori
flow
decreas
less
intestin
mucosa
musculari
suggest
redistribut
flow
away
musculari
toward
mucosa
septic
nonsept
subject
blood
flow
redistribut
appear
pronounc
septic
nonsept
anim
object
vasopressor
recommend
circulatori
support
acut
sepsi
maintain
blood
pressur
differ
effect
cardiac
output
co
renal
blood
flow
rbf
particular
may
impair
rbf
increas
risk
renal
insuffici
aim
studi
compar
effect
rbf
five
vasopressor
noradrenalin
na
adrenalin
adr
dopamin
dop
phenylephrin
pe
vasopressin
vp
acut
sepsi
seven
anaesthet
dog
co
rbf
measur
directli
use
flow
probe
mean
arteri
pressur
map
measur
cannul
femor
arteri
system
vascular
resist
svr
deriv
sepsi
induc
inject
escherichia
coli
vasopressor
randomli
infus
recommend
rate
tabl
min
percentag
chang
map
co
svr
rbf
compar
baselin
calcul
data
express
mean
sd
statist
analysi
perform
use
onegroup
test
five
vasopressor
increas
map
p
effect
co
vari
adr
dop
produc
greatest
increas
p
svr
increas
na
pe
vp
p
decreas
adr
p
wherea
na
dop
increas
rbf
p
rfb
decreas
adr
pe
p
tabl
conclus
despit
similar
effect
map
vasopressor
differ
effect
co
svr
rbf
na
dop
effect
vasopressor
preserv
rbf
sepsi
adr
pe
neg
effect
vasopressor
epinephrin
induc
tissu
perfus
deficit
porcin
endotoxin
shock
evalu
region
co
content
gradient
lp
ratio
background
hypothes
epinephrin
epi
oppos
norepinephrin
ne
select
advers
effect
viscer
perfus
use
treat
hypotens
endotoxin
shock
specif
want
test
hypothesi
perfus
defici
could
detect
region
venou
arteri
co
content
gradient
oppos
pco
gradient
conclus
epi
unlik
ne
induc
overal
rel
reduct
splanchnic
blood
flow
specif
reduc
gastric
wall
perfus
evalu
region
co
content
gradient
lactat
gradient
lp
ratio
gastric
wall
increas
accordingli
find
suggest
epi
use
firstlin
vasopressor
septic
shock
avail
onlin
http
method
small
segment
jejun
mucosa
expos
midlin
laparotomi
antimesenter
incis
anesthet
paralyz
normoventil
pig
po
muc
clarktyp
surfac
oxygen
electrod
hbo
tissu
reflect
spectrophotometri
pu
laserdoppl
velocimetri
measur
system
haemodynam
mesentericven
acidbas
blood
ga
variabl
system
acidbas
blood
ga
variabl
record
measur
perform
stabil
period
baselin
measur
interv
increas
dosag
avp
avp
group
n
ukghour
salin
placebo
ctrl
group
n
result
avp
infus
lead
signific
decreas
cardiac
index
mlkgmin
vs
mlkgmin
system
oxygen
deliveri
mlkgmin
vs
mlkgmin
concomit
increas
system
oxygen
extract
ratio
vs
avp
decreas
significantli
microvascular
blood
flow
pu
vs
pu
mesenter
venou
oxygen
tension
mmhg
vs
mmhg
microvascular
hemoglobin
oxygen
satur
vs
without
statist
increas
mesenter
venou
lactat
concentr
mmoll
vs
mmoll
conclus
intraven
administ
avp
decreas
dosedepend
manner
intestin
oxygen
suppli
mucos
tissu
oxygen
tension
via
reduct
microvascular
blood
flow
healthi
pig
introduct
hyperdynam
circul
septic
shock
character
hyperdynam
phase
increas
cardiac
output
decreas
peripher
vascular
resist
consequ
low
pressur
use
norepinephrin
pure
vasoconstrictor
aim
increas
vascular
resist
blood
pressur
subgroup
patient
septic
shock
respond
usual
high
dose
norepinephrin
usual
patient
differ
therapeut
approach
use
studi
tri
evalu
role
high
dose
norepinephrin
treatment
septic
shock
depart
therapeut
approach
septic
shock
includ
use
aggress
haemodynam
monitor
pulmonari
arteri
catheter
use
norepinephrin
andor
dobutamin
combin
along
fluid
resuscit
retrospect
studi
present
patient
septic
shock
requir
high
dose
norepinephrin
patient
catheter
swanganz
cathet
receiv
adequ
fluid
resuscit
pulmonari
wedg
pressur
mmhg
norepinephrin
use
titrat
maintain
mean
arteri
pressur
mmhg
nine
patient
dobutamin
ad
achiev
cariac
index
lminm
result
two
patient
never
recov
septic
shock
die
anoth
six
patient
expir
later
time
multipl
organ
failur
despit
fact
improv
shock
wean
norepinephrin
cours
final
four
patient
surviv
discharg
intens
care
unit
mean
day
intens
care
unit
stay
apach
ii
score
differ
survivor
nonsurvivor
tabl
use
high
dose
norepinephrin
treatment
septic
shock
guidanc
aggress
haemodynam
monitor
may
improv
surviv
group
patient
high
mortal
may
need
reconsid
label
patient
norepinephrineresist
septic
shock
usual
dose
ineffect
tri
high
dose
switch
anoth
regimen
valu
shown
mean
rang
materi
method
twentysix
intens
care
patient
five
women
men
select
surgeri
show
n
increas
gastricarteri
pco
co
gap
differ
within
least
hour
increas
co
gap
taken
indic
decreas
splanchnic
perfus
furthermor
patient
match
one
postsurgeri
intens
care
patient
without
increas
co
gap
tonometr
variabl
via
nasogastr
tube
tonocap
datex
helsinki
finland
hemodynoam
variabl
temperatur
arteri
lactat
measur
everi
hour
differ
pct
pctdiff
ildiff
lbp
lbpdiff
valu
day
surgeri
day
also
assess
mean
sap
apach
score
system
gener
condit
patient
evalu
afterward
enrol
two
group
group
sap
group
sap
statist
analysi
done
use
covari
analysi
time
patient
breath
oper
room
defin
covari
mean
pctdiff
significantli
higher
adjust
mean
p
group
increas
co
gap
decreas
group
adj
mean
signific
differ
lbp
valu
group
signific
one
due
gener
condit
patient
adj
mean
sap
group
adj
mean
sap
group
p
valu
also
signific
differ
mean
group
suggest
ildiff
valu
even
higher
group
decreas
stabl
co
gap
day
surgeri
adj
mean
stablegroup
adj
mean
increasinggroup
p
signific
differ
lactat
cardiac
index
blood
pressur
mean
arteri
pressur
two
group
furthermor
tendenti
signific
differ
icu
time
patient
increas
co
gap
longer
icu
patient
mean
group
increas
co
gap
min
vs
min
one
p
differ
pct
valu
suggest
increas
co
gap
measur
air
tonometri
accompani
later
increas
pct
valu
tonometri
earlier
method
detect
aspect
inflamm
find
fit
longer
time
icu
patient
increas
co
gap
purpos
evalu
morpholog
vascular
gallbladd
icu
patient
examin
ultrasonographi
us
color
doppler
cd
contrastenhanc
ce
studi
assess
valu
method
diagnosi
aac
prospect
examin
concecut
patient
admit
icu
varieti
diagnos
patient
examin
day
admiss
icu
followup
examin
perform
everi
day
total
examin
obtain
patient
examin
gallbladd
examin
us
cd
ce
studi
galactosebas
microbubbl
shu
levovist
sonograph
paramet
obtain
distent
wall
thicken
containt
pericholecyct
fluid
pericholecyct
edema
vascular
normal
abnorm
flow
signal
estim
find
correl
clinic
laboratori
paramet
histolog
cholecystectomi
perform
four
patient
one
sonograph
abnorm
icu
two
abnorm
three
abnorm
four
abnorm
sonograph
abnorm
hypervascularis
detect
cd
ce
studi
two
patient
surgic
prove
aac
conclus
gb
abnorm
frequent
seen
us
icu
patient
even
patient
suffer
aac
sonograph
critiria
specif
cd
imag
especi
ce
imag
use
detect
hyperemia
acut
stage
gb
inflamm
may
improv
accuraci
method
earli
diagnosi
aac
avail
onlin
http
object
investig
factor
may
predict
outcom
patient
sever
abdomin
sepsi
requir
treatment
intens
care
unit
icu
design
retrospect
record
review
survivor
nonsurvivor
compar
clinic
laboratori
microbiolog
therapeut
data
identifi
specif
poor
prognost
factor
set
tertiari
referr
centr
patient
studi
survivor
nonsurvivor
nonsurvivor
significantli
longer
stay
icu
day
vs
day
p
significantli
laparotomi
per
patient
vs
p
patient
open
abdomen
follow
surgeri
vs
p
significantli
blood
transfus
vs
p
significantli
higher
mean
apach
ii
score
admiss
vs
p
initi
surgeri
perform
emerg
procedur
patient
four
delay
greater
hour
survivor
sourc
erad
initi
laparotomi
patient
patient
die
develop
multiorgan
failur
regard
none
patient
surviv
requir
dialysi
wherea
nonsurvivor
dialys
nonsurvivor
organ
isol
periton
fluid
bacterem
episod
frequent
isol
organ
periton
fluid
nonsurvivor
escherichia
coli
conclus
patient
abdomin
sepsi
risk
die
delay
surgeri
sourc
sepsi
control
first
oper
addit
four
relook
laparotomi
renal
failur
requir
dialysi
longer
icu
stay
cultur
pathogen
periton
caviti
blood
higher
apach
ii
score
requir
blood
transfus
contribut
significantli
background
origin
known
target
molecul
plasmodium
vivax
blood
group
antigen
darc
emerg
promiscu
bind
site
chemokin
besid
red
blood
cell
darc
also
express
endotheli
cell
even
duffyneg
individu
howev
function
darc
system
inflamm
remain
unknown
neutrophil
pmn
depend
model
lpsinduc
arf
sought
assess
whether
darc
play
role
develop
organ
failur
system
inflamm
method
arf
induc
intraperiton
inject
lp
wildtyp
mice
wt
darc
genedefici
mice
darc
hour
inject
blood
sampl
drawn
kidney
remov
plasma
creatinin
crea
well
blood
urea
concentr
serv
indic
renal
function
renal
myeloperoxidas
activ
mpo
indic
total
renal
pmn
content
untreat
wt
darc
constitut
correspond
control
group
data
analysi
includ
anova
subsequ
multipl
comparison
analys
appropri
hour
wt
develop
sever
intraren
arf
threefold
increas
crea
darc
hand
display
signific
protect
arf
exhibit
small
clinic
irrelev
increas
crea
hour
fig
mpo
differ
wt
darc
group
show
significantli
elev
renal
mpo
lp
inject
peak
hour
fig
declin
thereaft
even
lp
inject
rtpcr
fail
detect
darc
mrna
express
kidney
wt
wherea
could
demonstr
cerebr
express
darc
mrna
hour
lp
administr
aim
studi
investig
earli
cellular
event
ir
injuri
use
elect
aortic
surgeri
model
twenti
patient
undergo
elect
abdomin
aortic
aneurysm
surgeri
prospect
recruit
ten
underw
convent
open
repair
endovascular
aneurysm
repair
evar
mucos
biopsi
sigmoid
colon
taken
immedi
preoper
postop
microscop
examin
perform
use
h
e
tunel
stain
apoptosi
situ
hybrdis
techniqu
use
detect
mrna
express
intraop
system
splanchnic
blood
sampl
convent
surgeri
group
evar
group
system
blood
taken
plasma
assay
nitrosothiol
nitric
oxid
donor
histolog
featur
acut
inflamm
preoper
postop
biopsi
either
group
h
e
tunel
stain
show
rise
apoptot
bodi
follow
convent
surgeri
signific
chang
follow
evar
express
occur
colon
epithelium
local
base
crypt
splanchnic
blood
show
fourfold
increas
nitrosothiol
increas
within
min
reperfus
peripher
blood
show
fivefold
increas
student
test
p
signific
increas
releas
colon
system
circul
follow
reperfus
accompani
increas
nitrosothiol
colon
epithelium
sourc
apoptosi
rather
necrosi
shown
princip
mode
cell
death
earli
ir
injuri
introduct
risk
stratif
sever
ill
patient
remain
problemat
result
increas
interest
potenti
circul
marker
cytokin
procalcitonin
brain
natriuret
peptid
recent
report
indic
use
plasma
dna
prognost
marker
variou
diseas
state
trauma
myocardi
infarct
stroke
knowledg
plasma
dna
investig
set
critic
ill
patient
intens
care
set
method
fiftytwo
consecut
patient
studi
gener
intens
care
unit
blood
sampl
taken
admiss
store
analysi
plasma
dna
level
estim
pcr
method
use
primer
human
gene
patient
follow
month
addit
plasma
dna
concentr
found
significantli
differ
patient
develop
sepsi
state
septic
patient
median
ngml
iqr
nonsept
patient
median
ngml
iqr
p
receiv
oper
characterist
roc
curv
calcul
use
plasma
dna
predictor
death
sepsi
see
tabl
result
present
demonstr
plasma
dna
may
use
prognost
marker
mortal
sepsi
critic
ill
patient
research
clearli
need
use
novel
marker
intens
care
set
possibl
mechan
releaseclear
plasma
dna
diseas
state
avail
onlin
http
set
icu
surgic
depart
method
twentysix
multipl
trauma
patient
enrol
studi
nine
develop
infect
hospit
stay
inflamm
paramet
measur
daili
discharg
icu
pmn
migrat
determin
fresh
whole
blood
novel
readyforus
membran
filter
assay
percentag
pmn
migrat
blood
filter
upon
fmetleuph
stimul
relev
paramet
measur
convent
method
commerci
avail
method
statist
paramet
cutoff
group
infect
patient
occurr
infect
noninfect
patient
determin
receiveroper
characterist
curv
patient
assign
one
two
altern
differ
specif
valu
occur
beyond
critic
cutoff
least
day
least
day
sequenc
vice
versa
valu
occur
patient
conting
tabl
set
yesno
decis
specif
infect
noninfect
group
sensitivityspecif
calcul
signific
threshold
p
fisher
exact
test
specif
highest
signific
taken
relev
pmn
migrat
cutoff
least
day
sequenc
occur
infect
eight
nine
infect
patient
three
noninfect
patient
ie
sensit
specif
p
fever
day
sequenc
show
specif
sensit
p
paramet
signific
discrimin
power
conclus
among
varieti
relat
paramet
pmn
migrat
prove
sensit
predict
marker
infect
impair
pmn
migrat
indic
impend
infect
earli
recognit
infect
risk
may
help
initi
aggress
antimicrobi
therapi
clinic
manifest
infect
thu
improv
therapeut
success
prospect
studi
patient
suffer
sir
admiss
gener
icu
patient
divid
two
studi
group
accord
time
onset
sir
group
eight
patient
apach
ii
score
age
year
sir
within
day
admiss
group
patient
apach
ii
score
age
year
sir
first
week
stay
icu
clinic
laboratori
measur
record
three
consecut
day
includ
temperatur
white
blood
count
wbc
erythrocyt
sediment
rate
esr
creactiv
protein
crp
pct
infect
confirm
posit
blood
bronchoalveolar
lavag
urin
bodi
fluid
cultur
evalu
differ
studi
group
test
use
cutoff
valu
pct
determin
use
youden
index
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
pct
also
estim
result
infect
confirm
four
patient
group
patient
group
b
serum
concentr
crp
wbc
esr
similar
group
well
septic
nonsept
patient
within
group
pct
valu
group
differ
significantli
comparison
group
b
ngml
vs
ngml
p
howev
septic
patient
group
significantli
increas
pct
valu
compar
septic
patient
group
b
ngml
vs
ngml
p
best
cutoff
valu
sensit
specif
ppv
npv
pct
group
b
present
tabl
method
sixti
highrisk
patient
mean
age
year
two
risk
factor
sever
initi
condit
proinflammatori
diseas
anamnesi
repeat
oper
expect
cardiopulmonari
bypass
cpb
time
hour
age
year
preced
hospit
antibacteri
therapi
enrol
studi
besid
routin
clinic
investig
perform
daili
blood
plasma
sampl
collect
day
surgeri
pct
valu
determin
use
immunoluminometr
assay
lumitest
pct
brahm
aktiengesellschaft
germani
patient
divid
two
group
group
without
group
b
postop
infecti
complic
data
compar
test
p
consid
statist
signific
result
differ
age
cpb
aorta
crossclamp
time
group
initi
pct
concentr
exceed
normal
valu
ngml
postop
patient
develop
infecti
complic
pneumonia
one
surgic
site
infect
ssi
one
pneumonia
ssi
one
sepsi
one
pneumonia
sepsi
icu
hospit
stay
surgeri
significantli
longer
group
b
compar
group
day
vs
day
respect
p
pct
level
significantli
higher
patient
infect
observ
period
differ
group
apach
ii
score
appear
second
day
postop
data
present
tabl
conclus
pct
level
higher
remain
increas
longer
patient
postop
infect
pct
monitor
use
earli
diagnost
predict
sever
postoperatic
infect
cardiac
surgeri
method
small
molecular
weight
discov
new
type
solubl
elisa
develop
two
type
antibodi
evalu
use
serum
sampl
patient
sepsi
sir
diseas
healthi
control
time
determin
creactiv
protein
endotoxin
solubl
iblhamburg
procalcitonin
pct
brahm
sofa
score
also
carri
new
assay
detect
small
molecular
weight
specif
kda
kda
solubl
serum
concentr
normal
control
specimen
mean
sd
ngml
cutoff
level
establish
ngml
mean
elisa
detect
sepsi
sir
mean
concentr
sepsi
sir
ngml
ngml
respect
sequenti
studi
signific
associ
sofa
score
serum
endotoxin
level
serum
increas
earli
phase
infect
detect
much
faster
easier
blood
cultur
test
new
assay
correl
solubl
iblhamburg
pct
brahm
conclus
elisa
detect
specificallyu
sepsi
earli
phase
infect
use
monitor
sever
sepsi
small
molecular
new
marker
diagnos
sepsi
avail
onlin
http
method
subject
present
studi
patient
sir
admit
emerg
unit
plasma
level
se
determin
elisa
admiss
day
admiss
normal
rang
se
ngml
presenc
variou
organ
failur
diagnos
patient
sofa
score
higher
point
organ
dysfunct
score
system
twosid
fisher
exact
test
use
analyz
differ
incid
organ
failur
mortal
p
indic
statist
signific
result
discuss
sofa
score
first
day
emerg
unit
significantli
higher
patient
elev
se
level
admiss
dae
group
n
normal
se
level
admiss
dan
group
n
incid
respiratori
failur
period
significantli
higher
dae
group
dan
group
p
renal
failur
also
significantli
higher
dae
group
dan
group
p
mortal
day
admiss
dae
group
significantli
higher
th
edan
group
p
observ
suggest
determin
plasma
level
se
might
use
predict
develop
organ
failur
especi
respiratori
renal
failur
outcom
patient
sir
might
potenti
risk
develop
multiorgan
failur
metabol
chang
differ
organ
critic
state
often
subtl
remain
unrecogn
convent
hemodynam
metabol
paramet
sinc
develop
microdialysi
techniqu
mimic
passiv
function
capillari
blood
vessel
possibl
examin
interstiti
space
intact
tissu
precondit
anim
low
dose
endotoxin
shown
induc
endotoxin
hyperrespons
socal
endotoxin
toler
exact
pathophysiolog
mechan
involv
still
fulli
elucid
appear
repres
essenti
mechan
prevent
unreason
expans
inflammatori
indiscrimin
immun
metabol
respons
specif
antibodi
develop
studi
data
avail
effect
endotoxaemia
without
endotoxin
precondit
regard
region
metabol
monitor
microdialysi
techniqu
materi
method
ten
pig
kg
randomli
assign
control
group
n
pretreat
group
n
endotoxaemia
induc
pretreat
consist
inject
increment
dose
endotoxin
sae
day
experi
rang
ngkg
day
ngkg
day
ngkg
day
ngkg
day
control
group
receiv
salin
inject
time
interv
day
prior
experi
neither
group
receiv
inject
main
find
studi
describ
variou
metabol
consequ
endotoxin
precondit
prior
lethal
endotoxin
shock
also
effect
endotoxaemia
per
se
local
metabol
three
tissu
compart
possibl
use
sequenti
microdialysi
techniqu
molecul
tissu
extracellular
fluid
surround
microdialysi
capillari
diffus
semiperm
part
capillari
dialys
pump
capillari
chang
concentr
substrat
surround
milieu
reflect
concentr
dialys
therebi
sampl
dialys
differ
time
interv
subseqeu
analysi
concentr
give
idea
substrat
concentr
extracellular
space
observ
time
role
cellular
metabol
sepsi
highli
controversi
issu
studi
suggest
tissu
blood
flow
reduc
endotoxaemia
lead
cellular
oxygen
debt
consequ
anaerob
metabol
studi
suggest
septic
insult
cellular
dysoxia
data
clearli
confirm
endotoxaemia
accompani
increas
metabol
variou
tissu
system
oxygen
consumpt
object
much
current
known
lipoprotein
role
septic
shockmani
studi
recent
implic
lipoprotein
innat
immun
lipopolysacchardi
mani
question
whether
low
valu
serum
lipoprotein
relat
impair
innat
immun
endotoxin
poor
prognosi
conduct
prospect
studi
analyz
serum
lipid
glucos
triglycerid
creactiv
protein
septic
shock
patient
evalu
possibl
relat
outcom
design
prospect
observ
analysi
serum
patient
meet
criteria
septic
shock
set
medicosurg
icu
univers
hospit
patient
eighteen
patient
analyz
studi
select
consecut
patient
met
criteria
septic
shock
icu
collect
blood
sampl
analysi
day
deathw
analyz
total
cholesterol
cholesterol
fraction
high
densiti
lipoprotein
hdl
low
densiti
lipoprotein
low
densiti
lipoprotein
triglycerid
glycemia
creactiv
protein
marker
inflam
result
present
mean
standard
deviat
analysi
divid
patient
survivor
nonsurvivor
day
perform
pair
student
test
differ
continu
variabl
correl
coeffici
determin
accord
multiplelevel
regress
analysi
p
consid
signific
mortal
rate
patient
nonsurvivor
group
eight
patient
survivor
two
group
similar
apach
ii
score
nonsurvivor
survivor
ns
day
statist
differ
substanc
analyz
day
onward
achiev
signific
statist
differ
survivor
nonsurvivor
total
cholestherol
hdl
fraction
trigycerid
glycemia
creactiv
protein
correl
creactiv
protein
hdl
fraction
total
cholesterol
triglycerid
glycemia
good
independ
variabl
found
glycemia
trigycerid
conclus
patient
hypocholesterolemia
low
level
hdl
fraction
hypertriglyceridemia
hyperglicemia
statist
signific
relat
poor
prognosi
creactiv
protein
show
good
correl
paramet
object
present
studi
investig
pathophysiolog
role
ino
induct
renal
proxim
tubul
experiment
endotoxemia
human
bolu
inject
ngkg
lipopolysaccharid
escheria
coli
administ
eight
healthi
volunt
four
malefour
femal
age
year
volunt
five
malesix
femal
age
year
receiv
vehicl
control
differ
time
point
arteri
blood
urin
collect
analyz
nitratesnitrit
stabl
metabolit
amount
ino
mrna
determin
quantit
realtim
rtpcr
isol
cell
urin
urinari
excret
present
proxim
tubular
cell
confin
distal
tubular
cell
measur
well
administr
endotoxin
result
expect
increas
proinflammatori
cytokin
pgml
p
accompani
fever
maximum
temperatur
p
flulik
symptom
cardiovascular
chang
heart
rate
bpm
baselin
bpm
hour
p
mean
arteri
pressur
mmhg
mmhg
p
chang
significantli
differ
control
group
blood
sampl
show
signific
chang
metabolit
follow
administr
endotoxin
twelv
hour
endotoxin
administr
urinari
level
metabolit
doubl
p
wherea
signific
chang
observ
control
group
effect
associ
increas
ino
mrna
measur
hour
endotoxin
administr
urinari
excret
increas
hour
p
wherea
remain
unchang
control
differ
excret
observ
result
indic
system
inflamm
induc
endotoxin
human
result
upregul
renal
ino
associ
proxim
tubul
injuri
background
aim
moder
hypothermia
cpb
inhibit
intramyocardi
synthesi
sinc
express
inflammatori
mediat
induc
nitric
oxid
synthas
ino
regul
map
kinas
mapk
pathway
studi
intend
analyz
effect
moder
hypothermia
cpb
signal
pathway
myocardium
method
twelv
young
pig
assign
temperatur
regimen
standar
cpb
normothermia
n
moder
hypothermia
n
myocardi
probe
sequenti
sampl
right
ventricl
hour
cpb
myocardi
express
ino
detect
quantifi
competit
rtpcr
andor
western
blot
phosphoryl
map
map
kinas
detect
western
blot
intracellular
localis
ino
ensur
immunohistochem
stain
mrna
protein
level
detect
soon
min
initi
cpb
aortic
clamp
group
lower
pig
hypothermia
other
p
respect
differ
persist
cpb
level
ino
detect
cpb
without
differ
group
phosphoryl
map
map
kinas
detect
cpb
level
map
kinas
map
kinas
tend
lower
anim
hypothermia
other
p
conclus
studi
show
first
time
cardiac
surgeri
induc
express
myocardium
soon
min
institut
cpb
aortic
clamp
associ
activ
map
map
kinas
pathway
inhibit
express
hypothermia
relat
inhibit
map
kinas
corp
tokyo
japan
elastas
inhibitor
extract
human
urin
use
treat
patient
acut
pancreat
acut
circulatori
failur
sinc
year
ago
japan
object
current
studi
perform
order
evalu
efficaci
uti
vascular
endotheli
disord
critic
ill
thirteen
sever
patient
apach
ii
score
transport
emeg
room
elect
randomli
assign
either
treat
group
control
group
number
patient
treat
group
five
eight
patient
untreat
group
maximum
dose
uti
uml
administr
patient
treat
group
emerg
room
admiss
icu
neutrophil
elastas
level
level
thrombomodulin
tm
level
protein
c
level
uti
level
plasma
examin
daili
day
hospit
valu
express
mean
sd
unpair
student
test
use
p
consid
statist
signific
untreat
group
uti
level
plasma
day
hospit
siginificantli
higher
treat
group
vs
uml
p
also
tm
level
also
significantli
differ
untreat
group
treat
group
vs
ful
p
day
examin
valu
show
signific
differ
two
group
clinic
cours
halftim
uti
short
min
plasma
level
linear
decreas
hour
administr
differ
uti
level
day
consid
spontan
uti
vascular
endotheli
disord
recogn
higer
uti
level
group
day
group
untreat
group
studi
propos
import
highdos
administr
uti
acut
phase
critic
ill
inhibit
vascular
endotheli
disord
investig
effect
urinari
trypsin
inhibitor
uti
output
plasma
mean
neutrophil
elastas
pmne
cytokin
particip
studi
trauma
patient
shock
arriv
insutitut
divid
two
group
one
group
administr
u
intraven
uti
control
group
day
hospit
group
measur
serum
level
uti
pmne
thrombomodulin
protein
c
sir
score
sofa
score
index
sever
pmne
level
utiadminist
group
observ
significantli
lower
control
group
day
hospit
data
suggest
uti
suppress
vascular
endotheli
cell
disord
inhibit
product
pmne
direct
inhibit
pmne
background
exosom
small
vesicl
nm
releas
cell
activ
previous
shown
exosom
deriv
platelet
septic
patient
induc
apoptosi
endotheli
vascular
smooth
muscl
cell
redoxdepend
pathway
sinc
reactiv
oxygen
speci
may
involv
myocardi
dysfunct
sepsi
aim
studi
investig
possibl
role
exosom
sepsisinduc
myocardi
dysfunct
method
exosom
separ
filtrat
ultracentrifug
plasma
septic
shock
patient
ssp
healthi
volunt
separ
exosom
infus
plasma
concentr
langendorffperfus
heart
new
zealand
rabbit
experi
isol
rat
papillari
muscl
expos
plasma
concentr
exosom
septic
patient
healthi
control
result
incub
exosom
ssp
min
induc
reduct
posit
neg
timepressur
deriv
respect
n
p
incub
exosom
healthi
volunt
time
induc
nonsignific
decreas
posit
neg
timepressur
deriv
respect
n
p
ns
effect
inhibit
lnmma
exposur
rat
papillari
muscl
exosom
ssp
caus
decreas
develop
tension
gmm
pre
vs
gmm
post
n
p
posit
timetens
deriv
gmm
pre
vs
gmm
post
n
p
incub
exosom
healthi
volunt
induc
signific
differ
develop
tension
gmm
pre
vs
gmm
post
n
p
ns
posit
timetens
deriv
gmm
pre
vs
gmm
post
n
p
ns
conclus
infus
exosom
platelet
septic
patient
induc
myocardi
dysfunct
isol
rabbit
heart
rat
papillari
muscl
prepar
attenu
dysfunct
exposur
nitric
oxid
inhibitor
lnmma
indic
possibl
role
exosomeinduc
myocardi
depress
avail
onlin
http
sepsi
syndrom
consequ
overwhelm
system
respons
infect
rapidli
lead
organ
dysfunct
accompani
system
inflamm
hematolog
abnorm
gramneg
bacteria
lipopolysaccharid
lp
domin
role
activ
variou
cell
secret
sever
proinflammatori
cytokin
includ
cytokin
also
import
induc
procoagul
effect
sepsi
hand
tolllik
receptor
respons
lp
signal
caus
activ
clear
inappropri
tlr
respons
bacteri
infect
could
critic
consequ
therefor
signal
inhibitor
attract
therapeut
medic
sepsi
benzisothiazol
deriv
found
signal
transduct
inhibitor
use
report
gene
assay
system
also
suppress
lpsinduc
upregul
proinflammatori
cytokin
adhes
molecul
procoagul
activ
human
vascular
endotheli
cell
andor
peripher
mononuclear
cell
halfmaxim
inhibitori
concentr
ic
compound
assay
rang
singl
intraven
administr
mgkg
protect
mice
death
murin
dgalactosaminesensit
endotoxin
shock
model
tabl
model
mgkg
complet
improv
elev
inflammatori
cytokin
hematolog
abnorm
furthermor
mgkg
also
prevent
mice
lethal
shock
murin
cecal
ligat
punctur
model
lp
potent
predomin
microbi
mediat
induc
intens
inflamm
procoagul
respons
close
correl
event
inhibit
respons
vitro
prevent
lethal
shock
anim
model
therefor
conclud
becom
novel
therapeut
medic
sepsi
septic
shock
inhibit
signal
transduct
improv
endotheli
cell
leukocyt
cell
function
purpos
present
studi
evalu
effect
continu
infus
nacetyl
cystein
nac
serum
cytokin
level
gastric
intramucos
ph
human
suffer
sever
sepsi
fiftythre
patient
includ
studi
appli
mgkg
nac
n
nac
group
bolu
intraven
min
continu
mgkghour
intraven
hour
infus
control
group
n
control
group
administ
dose
dextros
solut
hemodynam
paramet
heart
rate
mean
arteri
pressur
nasopharyng
bodi
temperatur
arteri
blood
ga
chang
ph
po
pco
plasma
cytokin
level
tumor
necrosi
biochem
paramet
hematocrit
leucocyt
thrombocyt
urea
creatinin
total
billirubin
direct
billirubin
total
protein
albumin
serum
glutam
oxal
transaminas
serum
glutam
piruv
transaminas
sodium
potassium
intramucos
ph
stay
time
intens
care
unit
time
mechan
ventil
support
mortal
control
group
record
measur
obtain
baselin
min
start
studi
repeat
immedi
hour
nac
infus
differ
found
accord
paramet
found
effect
nac
infus
affect
cytokin
level
patient
outcom
gastric
intramucos
ph
sever
sepsi
human
limit
number
patient
studi
short
period
observ
find
need
confirm
larger
clinic
trial
nac
infus
dosetitr
manner
howev
result
support
use
nac
patient
sever
sepsi
mpo
activ
mda
level
lung
homogen
found
increas
oa
group
administr
nac
significantli
reduc
tissu
mpo
mda
level
p
lung
histopatholog
also
protect
nac
oainduc
experiment
lung
injuri
model
conclus
present
studi
demonstr
oleic
acid
induc
myeloperoxydas
activ
consequ
increas
mda
level
lung
tissu
data
suggest
elev
level
lung
tissu
repres
role
excess
format
peroxynitrit
efficaci
nac
treatment
prevent
peroxynitritemedi
oainduc
lung
injuri
due
antioxid
antiinflammatori
properti
nac
seem
promis
agent
treatment
critic
ill
patient
lung
injuri
state
aim
studi
investig
whether
therapeut
administr
novel
antihuman
interferongamma
monoclon
antibodi
mab
could
improv
outcom
lethal
model
gramneg
bacterem
shock
method
gramneg
bacterem
shock
induc
anesthet
cynomolgu
monkey
intraven
inject
approxim
cfu
live
escherichia
coli
treatment
administ
anim
develop
symptom
shock
meet
least
two
predefin
criteria
reduct
blood
pressur
increas
heart
rate
oliguria
urin
output
mlkg
bodi
weighthour
six
anim
receiv
placebo
eight
treat
mgkg
human
mab
invas
hemodynam
monitor
anesthesia
continu
hour
anim
return
cage
follow
daili
clinic
sign
day
five
six
placebotr
cynomolgu
monkey
die
requir
euthanasia
within
hour
e
coli
challeng
one
anim
surviv
day
contrast
six
eight
anim
treat
human
mab
surviv
day
p
vs
placebo
specif
within
treat
group
two
anim
die
earli
sepsi
day
day
respect
two
anim
euthan
day
limb
necrosi
caus
catheterrel
thrombosi
directli
sepsi
symptom
one
anim
euthan
day
due
sepsi
symptom
three
anim
surviv
day
appear
good
health
treatment
mab
decreas
system
respons
e
coli
furthermor
renal
dysfunct
evidenc
increas
creatinin
significantli
decreas
treatment
mab
conclus
studi
demonstr
primat
model
e
coliinduc
septic
shock
neutral
mab
administ
onset
clinic
sign
sepsi
improv
surviv
attenu
patholog
chang
associ
develop
multipl
organ
dysfunct
suggest
blockad
potenti
repres
effect
mode
intervent
lethal
septic
shock
method
simul
intervent
trial
neutral
bodi
tissu
necrosi
factor
antitnf
sepsi
base
mechanist
mathemat
model
includ
bacteri
infect
host
respons
therapeut
intervent
simul
case
differ
bacteri
load
virul
well
individu
propens
mount
modul
inflammatori
respons
submit
case
three
dose
durat
antitnf
present
result
simul
evalu
use
model
improv
patient
select
construct
logist
model
fourvalu
outcom
help
treatment
surviv
irrespect
treatment
die
irrespect
treatment
harm
treatment
independ
predictor
measur
time
diseas
detect
min
later
includ
serum
tnf
activ
protein
c
thrombin
tissu
factor
blood
pressur
cell
count
result
statist
model
report
valid
cohort
control
surviv
week
depend
dose
durat
treatment
surviv
rang
higher
dose
antitnf
although
effect
also
result
consider
harm
fig
conclus
model
point
improv
patient
select
therapi
could
individu
avail
onlin
http
impair
host
defens
mechan
follow
surgic
stress
burn
major
surgeri
polytrauma
consid
import
develop
infecti
complic
sepsi
test
whether
interferon
ifn
gamma
improv
monocyt
lymphocyt
function
reduc
death
relat
sepsi
order
restor
antimicrobi
defens
capac
recombin
human
ifngamma
administ
intraven
daili
six
immunoparalyz
patient
inform
consent
obtain
patient
case
studi
receiv
local
hospit
ethic
committe
approv
intracytoplasm
cytokin
product
isol
peripher
blood
mononuclear
cell
assess
flow
cytometri
follow
vitro
activ
phorbol
myrist
acet
plu
ionomycin
monocyt
human
leukocyt
antigendr
hladr
express
also
measur
immunoparalysi
defin
decreas
level
hladr
express
monocyt
decreas
level
ifngamma
appli
immunoparalyt
patient
low
monocyt
hladr
express
restor
defici
hladr
express
vitro
cytokin
product
complet
within
day
recoveri
immunoparalysi
result
clearanc
sepsi
four
six
patient
ifngamma
administr
septic
patient
accompani
immunoparalysi
new
therapeut
strategi
year
p
higher
sap
ii
score
vs
p
delay
admiss
critic
care
unit
ccu
higher
pneumonia
group
day
vs
day
p
delay
handl
physiotherapist
also
higher
day
vs
day
p
pneumonia
associ
longer
period
mechan
ventil
day
vs
day
p
longer
stay
ccu
vs
p
univari
analysi
qualit
factor
present
tabl
earli
mechan
ventil
upper
cervic
spine
involv
inhospit
mortal
relat
pneumonia
overal
mortal
higher
pneumonia
group
studi
suggest
earli
aggress
handl
patient
cervic
spine
injuri
particularli
complet
motor
deficit
could
benefici
decreas
pneumonia
incid
associ
advers
event
past
year
clinic
pulmonari
infect
score
cpi
purpos
diagnost
tool
ventilatorassoci
pneumonia
vap
cpi
incorpor
five
variabl
temperatur
white
blood
cell
wbc
tracheal
secret
po
fio
rx
rang
cpi
posit
predict
valu
ppv
found
cutoff
point
recent
cpi
purpos
order
monitor
cours
vap
efficaci
therapi
object
evalu
cpi
diagnosi
monitor
cours
ill
children
vap
design
retrospect
observ
studi
set
pediatr
icu
nation
children
hospit
data
collect
cpi
collect
hour
diagnosi
vap
diagnosi
daili
first
week
patient
evalu
mean
paw
posit
end
expiratori
pressur
peep
po
fio
rx
score
pcr
wbc
number
bronchial
suctioningsday
also
evalu
influenc
paramet
cpi
final
score
data
analys
student
test
p
chi
squar
p
univari
analysi
correl
coeffici
r
popul
incid
vap
patient
mortal
four
patient
mean
cpi
valu
time
diagnosi
statist
higher
hour
patient
vs
p
patient
ppv
day
diagnosi
popul
divid
two
group
patient
cpi
group
n
patient
cpi
group
n
time
two
group
report
statist
signific
differ
peep
vs
p
paw
max
vs
p
po
fio
vs
p
pcr
reduct
vs
patient
p
microbiolog
posit
vs
p
po
fio
increas
significantli
group
p
univari
analysi
reveal
po
fio
relat
cpi
score
r
wbc
number
suctioningday
rx
score
relat
patient
cpi
surviv
wherea
patient
persist
high
cpi
hour
diagnosi
vap
die
analysi
msofa
score
reveal
signific
differ
circulatori
p
respiratori
p
score
die
survivor
day
later
diagnosi
vap
conclus
cpi
elev
ppv
diagnosi
vap
earli
predictor
poor
outcom
patient
vap
allow
good
monitor
cours
ill
aim
ventilatorassoci
pneumonia
vap
common
caus
morbid
icu
patient
still
evid
invas
bronchoscop
techniqu
form
part
routin
approach
suspect
vap
studi
compar
specimen
result
term
sensit
specif
taken
bronchoalveolar
lavag
bal
fluid
endotrach
aspir
eta
examin
valu
clinic
pulmonari
infect
score
cpi
diagnosi
vap
studi
includ
adult
patient
icu
receiv
mechan
ventil
hour
receiv
antibiotherapi
vap
clinic
suspect
patient
contraind
bronchoscopi
exclud
vap
defin
clinic
criteria
follow
presenc
new
progress
lung
infiltr
chest
xray
plu
least
two
follow
clinic
criteria
fever
white
blood
cell
count
mm
mm
purul
eta
microbiolog
sampl
procedur
perform
patient
use
distal
tracheal
suction
bal
cpi
calcul
threshold
valu
enabl
identif
vap
patient
determin
bal
colonyform
unit
cfu
ml
patient
eta
cfuml
exact
conform
achiev
determin
bal
cfuml
eta
cfuml
patient
although
eta
result
threshold
level
show
conform
bal
result
patient
accept
bal
cfuml
refer
valu
cpi
determin
sensit
posit
predict
valu
diagnosi
accept
cpi
refer
valu
possibl
inaccur
diagnosi
high
everi
one
two
patient
vap
nearli
one
patient
miss
everi
five
patient
vap
conclus
bal
result
provid
superior
diagnosi
vap
compar
eta
threshold
level
cfuml
may
reduc
eta
evalu
cpi
alon
suitabl
diagnosi
exclus
vap
method
prospect
studi
month
includ
patient
requir
mechan
ventil
hour
admiss
icu
patient
random
ito
two
group
one
group
suction
cess
anoth
group
oess
vap
defin
accord
follow
criteria
chest
radiograph
examin
show
new
progress
infiltr
new
onset
purul
sputum
signific
quantit
cultur
pathogen
respiratori
secret
tracheal
aspir
cfuml
bronchoalveolar
lavag
cfuml
protect
bronchial
brush
cathet
cfuml
statist
analysi
realiz
chisquar
test
student
test
took
p
consid
signific
differ
conclus
conclud
seri
ctss
reduc
ventilatorassoci
pneumonia
incid
exogen
pneumonia
background
cpi
accept
tool
clinic
estim
ventilatorassoci
pneumonia
vap
encompass
five
compon
temperatur
blood
leukocyt
tracheal
secret
oxygen
index
chest
roentgenogram
vap
consid
frequent
complic
mechan
ventil
sever
polytrauma
patient
current
issu
highlight
influenc
vap
develop
patient
mortal
aim
studi
evalu
vap
develop
sever
polytrauma
patient
accord
cpi
criteria
basi
determin
patient
clinic
cours
design
prospect
observ
studi
set
seventeenb
trauma
intens
care
unit
method
thirtyon
sever
polytrauma
patient
iss
admiss
requir
mechan
ventil
day
develop
vap
enrol
record
length
stay
patient
examin
cpi
criteria
daili
period
day
pneumonia
occurr
patient
divid
subpopul
accord
sever
posttraumat
complic
calcul
mean
cpi
valu
patient
consid
cpi
point
indic
vap
period
vap
occur
ventil
day
observ
clinic
cours
vap
depend
sever
posttraumat
complic
patient
posttraumat
complic
mean
cpi
valu
patient
sever
complic
mean
cpi
valu
patient
singl
organ
failur
surviv
rate
patient
pulmonari
contus
surviv
rate
patient
sever
sepsi
surviv
rate
patient
multipl
organ
failur
syndrom
organ
involv
surviv
rate
respect
vap
resolut
shorter
patient
adequ
initi
antibiot
therapi
conclus
data
suggest
length
day
could
precis
estim
sever
vap
dynam
mean
cpi
valu
show
good
correl
degre
posttraumat
complic
cpic
dynam
could
serv
good
clinic
tool
determin
whether
patient
would
recov
might
expect
bad
outcom
curr
opin
crit
care
ow
p
day
mv
er
ow
p
mortal
er
ow
vap
incid
er
group
ow
group
p
vap
incid
accord
day
mv
complet
set
er
group
ow
group
p
vap
diagnosi
done
mean
fiberopt
bronchioalveolar
lavag
bal
nonfiberopt
bal
tracheal
aspir
earli
vap
incid
er
group
ow
group
p
signific
differ
isol
germ
group
multiresist
germ
ow
group
p
late
vap
also
differ
due
candida
spp
isol
cultur
p
initi
mv
set
differ
icu
relat
higher
incid
vap
patient
come
medic
surgic
ward
higher
preval
multiresist
germ
earli
vap
candida
late
vap
reproduc
paramet
predict
durat
ventil
length
stay
rsvinduc
respiratori
failur
previous
healthi
children
tasker
found
alveolararteri
gradient
aado
mean
airway
pressur
map
first
hour
aado
map
subsequ
hour
identifi
rsvposit
case
risk
prolong
stay
anoth
studi
found
aado
first
hour
best
predictor
develop
sever
diseas
need
prolong
stay
method
data
collect
case
respiratori
failur
region
pediatr
icu
four
rsv
season
fortysix
exclud
altern
diagnosi
remain
case
bronchiol
rsvposit
six
ventil
rsvneg
ventil
rsvposit
three
congenit
heart
diseas
four
chronic
lung
diseas
one
treat
differ
unit
prior
admiss
rsvneg
case
three
congenit
heart
andor
chronic
lung
diseas
group
assess
tasker
criteria
multipl
regress
model
use
identifi
predict
marker
length
ventil
depend
variabl
shown
factor
predict
sever
rsvposit
rsvneg
respiratori
failur
similar
unabl
confirm
find
previou
studi
suggest
institut
specif
institut
high
map
within
first
hour
provid
predict
factor
guid
clinician
talk
parent
may
help
resourc
plan
multicentr
studi
uk
unlik
yield
use
inform
year
patient
admit
intens
care
unit
icu
fortyon
patient
least
one
posit
blood
cultur
bc
icu
stay
patient
requir
treatment
day
found
good
correl
length
icu
stay
ratio
patient
posit
bc
fig
catheterrel
bloodstream
infect
cbi
fig
seventyfour
patient
stay
day
icu
requir
treatment
day
onehalf
patient
posit
bc
found
patient
compar
sap
ii
score
admiss
patient
get
posit
bc
doubl
icu
mortal
doubl
icu
length
stay
lo
tabl
introduct
sever
infect
resist
microorgan
broadspectrum
antibiot
constitut
major
concern
icu
physician
purpos
record
microorgan
usual
respons
infect
icu
pattern
resist
antibiot
period
perform
prospect
studi
june
decemb
includ
patient
hospit
hour
infect
present
period
record
well
sensit
microorgan
special
antimicrobi
agent
total
patient
includ
studi
men
women
mean
age
year
mean
icu
stay
day
one
hundr
fiftyon
infect
record
ventilatorassoci
pneumonia
primari
bacteremia
catheterrel
infect
mening
surgic
infect
microorgan
commonli
isol
pseudomona
aeruginosa
acinetobact
baumannii
klebsiella
pneumonia
staphylococcu
epidermidi
pattern
resist
follow
p
aeruginosa
sensit
ceftazidim
case
imipenem
ciprofloxacin
piperacillin
tazobactam
colistin
baumannii
sensit
imipenem
case
ampicillinsulbactam
colistin
k
pneumonia
sensit
imipenem
case
piperacillintazobactam
case
colistin
signific
resist
gramneg
microorgan
broadspectrum
antibiot
notic
pose
import
therapeut
problem
chang
antibiot
polici
strict
hand
hygien
measur
could
possibl
help
us
face
omin
situat
tabl
global
exhaust
patient
stay
hour
icu
falseneg
pneumonia
frequent
document
microbiolog
also
strong
correl
intern
qualiti
data
miss
discord
valu
surveil
databas
extern
valid
conclus
specif
high
although
sensit
quit
low
bac
accur
report
pn
lack
sensit
might
relat
factor
percept
surveil
extern
control
instrument
profession
background
data
collector
poor
knowledg
protocol
eg
case
definit
valid
crucial
credibl
data
provid
opportun
person
technic
assist
implement
continu
basi
surveil
programm
conclus
patient
subject
signific
number
cvc
interrupt
per
day
could
relat
blood
stream
infect
specif
epidermidi
due
hand
manipul
cvc
interrupt
avail
onlin
http
conclus
cdc
guidelin
prevent
catheterrel
infect
notic
subclavian
prefer
femor
jugular
venou
access
data
support
recommend
also
suggest
new
refin
name
peripher
insert
central
cathet
prefer
femor
jugular
access
jugular
prefer
femor
venou
access
one
use
antimicrobialimpregn
cathet
posit
effect
shown
primarili
triplelumen
cathet
object
compar
incid
cvc
colon
two
group
patient
use
doublelumem
central
venou
cathet
impregn
chlorhexidin
silver
sulfadiazin
standard
one
patient
undergo
insert
doublelumen
cvc
icu
random
receiv
either
central
venou
cathet
impregn
chlorhexidin
silver
sulfadiazin
standard
one
cathet
tip
cultur
rollplat
method
remov
one
hundr
nine
patient
enrol
success
insert
cathet
impregn
group
standard
group
statist
signific
differ
group
age
seven
infectionrel
risk
factor
icu
diagnosi
mean
sofa
score
insert
site
durat
catheter
wrong
locat
xray
sign
allergi
cathet
colon
rate
mean
time
durat
catheter
group
group
day
day
respect
p
mean
sofa
score
group
respect
p
colon
rate
cathet
group
cathet
group
p
thirtyon
cathet
present
gramposit
cocci
four
associ
gramneg
bacilli
tyre
fungi
three
cathet
present
gramneg
bacilli
alon
one
cathet
present
fungi
alon
rollplat
compar
studi
doublelumen
central
venou
cathet
impregn
chlorhexidin
silver
sulfadiazin
standard
one
show
statist
signific
differ
colon
rate
two
group
patient
incom
patient
admit
digest
medic
postsurg
icu
present
organ
dysfunct
sever
inflammatori
respons
primari
diseas
creactiv
protein
mgl
routin
schedul
weekli
screen
fungal
colon
colon
index
ci
comput
everi
patient
preemptiv
antifung
therapi
administ
patient
ci
subsequ
interrupt
ci
due
econom
concern
report
increas
resist
antifung
drug
chang
therapeut
strategi
result
antifung
therapi
administ
probabl
patent
infect
evolut
ci
candidemia
total
cost
therapi
report
result
see
tabl
ci
decreas
patient
receiv
preemptiv
therapi
patient
one
fluconazol
drug
use
preemptiv
therapi
despit
limit
studi
conclud
sever
ill
medic
postsurg
patient
digest
diseas
risk
fungal
infect
candidemia
screen
fungal
colon
allow
earli
determin
patient
risk
fungal
infect
preemptiv
treatment
effici
lower
level
colon
small
number
costli
cur
antifung
treatment
may
prove
expens
greater
number
preemptiv
cheaper
treatment
introduct
aim
nosocomi
bloodstream
fungal
infect
candida
speci
icu
risen
dramat
past
two
decad
fact
fungal
infect
critic
ill
patient
difficult
diagnos
associ
high
mortal
rate
high
concentr
proinflammatori
cytokin
regist
serum
bronchoalveolar
lavag
bal
patient
sever
bronchopneumonia
differ
kind
host
respons
fungal
infect
well
defin
aim
correl
serum
bal
level
criticali
ill
patient
confirm
bronchopneumonia
associ
candidiasi
bacteri
sepsi
research
whether
level
consent
prove
fungal
origin
sever
pneumonia
associ
sever
sepsi
involv
patient
admit
hour
icu
enrol
patient
subdivid
two
group
group
patient
sever
sepsi
bacteri
bronchopneumonia
group
b
patient
sepsi
confirm
candidemia
bronchopneumonia
regist
level
standard
blind
nonbronchoscop
bronchoalveolar
lavag
bnbbal
serum
admiss
day
treatment
measur
cytokin
elisa
assay
result
present
regist
patient
age
year
data
mean
sd
present
tabl
valu
confirm
result
obtain
author
mice
human
correl
could
explain
suppress
effect
high
level
mononuclear
phagocyt
activ
candida
methicillinresist
staphylococcu
aureu
candidiasi
sever
bronchopneumonia
precoci
increas
level
bronchial
serum
repres
confirm
fungal
sepsi
neg
predict
valu
order
predict
develop
multiorgan
failur
death
chronic
obstruct
pulmonari
diseas
patient
nine
patient
solid
organ
transplant
recipi
patient
autoimmun
diseas
six
cirrhosi
patient
patient
miscellan
diseas
follow
eortcmsg
criteria
patient
classifi
proven
ia
n
probabl
ia
n
possibl
ia
n
colon
n
mean
sap
ii
score
predict
mortal
overal
mortal
n
mortal
proven
probabl
group
respect
among
patient
surviv
colon
aspergillu
risk
factor
ia
postmortem
examin
done
patient
autopsi
show
hyphael
invas
aspergillu
mainli
lung
target
organ
among
proven
case
n
underw
autopsi
autopsi
rate
one
patient
lupu
posit
bronchial
biopsi
treat
surviv
autopsi
recruit
probabl
group
n
autopsi
rate
group
colon
aspergillu
n
autopsi
rate
five
proven
case
compromis
host
factor
accord
eortcmsg
definit
three
liver
cirrhosi
one
pneumonia
man
one
klebsiella
sepsi
multiorgan
failur
conclus
studi
prove
ia
emerg
infecti
diseas
icu
nonhaematooncolog
patient
broad
group
patient
risk
ia
ia
diagnos
patient
without
characterist
describ
eortcmsg
definit
seem
worthwil
investig
valid
avail
diagnos
tool
group
patient
background
evalu
clinic
util
aerosol
antibiot
patient
ventilatorassoci
pneumonia
hamper
ineffici
avail
nebul
aerogen
pulmonari
drug
deliveri
system
apd
develop
higheffici
lung
deposit
novel
therapi
mechan
ventil
patient
compar
deliveri
amikacin
amik
via
apd
vs
aeroneb
pro
ap
vs
misti
mn
mechan
ventil
patient
want
determin
amik
concentr
sputum
relat
devic
effici
previous
determin
vitro
method
twelv
patient
volumecycl
ventil
variou
primari
diagnos
vent
set
enrol
purul
secret
fever
xray
evid
pneumonia
separ
studi
day
day
washout
patient
receiv
sulfitefre
amik
mgml
mg
via
mn
mg
via
ap
mg
via
apd
anticip
higher
effici
random
order
tracheal
aspir
obtain
min
postdos
amikacin
concentr
determin
data
compar
vitro
measur
lung
dose
use
typic
adult
ventil
set
treatment
well
toler
tabl
present
evalu
sputum
amik
concentr
tracheal
aspir
normal
start
dose
mgmlmg
start
dose
vitro
lung
dose
per
cent
total
dose
mean
sd
sputum
concentr
greater
ap
apd
mn
p
lung
dose
apd
ap
mn
p
conclus
apd
deliv
amik
greater
effici
market
nebul
concentr
amik
sputum
consist
rel
devic
effici
measur
vitro
high
effici
deliveri
via
apd
may
make
aerosol
amik
viabl
part
treatment
regimen
ventilatorassoci
pneumonia
safeti
analysi
n
patient
differ
found
group
twenti
patient
group
l
group
c
present
least
one
advers
event
ae
consid
treatmentrel
p
treatment
withdrawn
follow
occurr
ae
consid
treatmentrel
l
vs
c
patient
p
conclus
levofloxacin
mg
twice
daili
dose
least
efficaci
cefotaxim
g
three
time
daili
ofloxacin
mg
twice
daili
combin
antibiot
therapi
patient
sever
cap
hospit
icu
success
rate
around
method
twenti
patient
receiv
linezolid
mg
intravensouli
everi
hour
cvvh
perform
use
highli
permeabl
polysulfon
membran
pshf
baxter
germani
av
freseniu
germani
mean
blood
flow
rate
ultrafiltr
rate
mlmin
mlmin
respect
postdilut
perform
linezolid
concentr
serum
ultrafiltr
determin
highperform
liquid
chromatographi
mean
linezolid
serum
concentr
peak
cmax
mean
trough
level
cmin
elimin
halflif
hour
total
clearanc
cltot
hemofiltr
clearanc
clhf
volum
distribut
vd
lhour
mlmin
l
respect
result
indic
patient
sever
gramposit
infect
undergo
cvvh
treat
effect
dose
mg
linezolid
everi
hour
object
ceftazidim
use
treatment
ventilatorassoci
pneumonia
vap
due
recogn
antipseudomon
activ
standard
ceftazidim
treatment
intermitt
perfus
ip
howev
continu
perfus
cp
may
advantag
sinc
antibacteri
activ
depend
exposur
time
concentr
minimum
inhibitori
concentr
howev
evid
clinic
efficaci
treatment
vap
compar
ip
limit
controversi
thu
aim
present
studi
determin
whether
ceftazidim
cp
repres
optim
vap
standard
treatment
method
compar
prospect
cohort
patient
n
receiv
gday
intraven
iv
ceftzadim
cp
histor
control
group
n
receiv
hour
iv
ceftazidim
ip
vap
treat
day
two
antibiot
ceftazidim
plu
anoth
aminoglycosid
quinolon
vap
defin
accord
follow
criteria
chest
radiograph
examin
show
new
progress
infiltr
new
onset
purul
sputum
signific
quantit
cultur
pathogen
respiratori
secret
tracheal
aspir
cfuml
bronchoalveolar
lavag
cfuml
protect
bronchial
brush
cathet
cfuml
differ
group
test
mean
student
test
exact
chisquar
test
permut
use
statxact
softwar
signific
difer
defin
p
signific
differ
age
sex
diagnosi
apach
ii
score
etiolog
agent
bacteremia
organ
dysfunct
antimicrobi
therapi
group
cp
group
show
significantli
lower
clinic
failur
cp
vs
ip
p
significantli
lower
mortal
attribut
vap
cp
vs
ip
p
addit
cp
patient
receiv
onethird
less
daili
dose
treat
intermitt
conclud
ceftazidim
administ
continu
perfus
treatment
ventilatorassoci
pneumonia
may
significantli
improv
clinic
efficaci
compar
intermitt
administr
reduc
antibiot
dosag
background
goal
studi
recent
administr
modu
antibiot
becom
matter
debat
continu
infus
suggest
studi
whether
plasma
concentr
imipenem
suffici
maintain
use
load
dose
continu
infus
regimen
regimen
would
superior
higher
amount
drug
given
standard
intermitt
bolu
regimen
random
critic
ill
patient
icuacquir
pneumonia
receiv
imipenem
either
hour
continu
infus
con
n
bolu
dose
g
everi
hour
bol
n
group
load
dose
g
imipenem
administ
follow
continu
infus
bolu
treatment
hour
load
plasma
imipenem
concentr
measur
baselin
hour
arteri
blood
sampl
taken
immedi
prior
begin
continu
regimen
respect
bolu
administr
patient
age
vs
year
sap
ii
score
vs
renal
function
creatinin
clearanc
vs
mlmin
compar
group
result
discuss
hour
plasma
imipenem
concentr
similar
group
howev
mean
imipenem
plasma
trough
concentr
follow
time
point
hour
significantli
higher
con
bol
comparison
hour
patient
con
concentr
minimum
inhibitori
concentr
pseudomona
aeruginosa
achiev
three
patient
bol
data
suggest
continu
infus
advantag
benefit
therefor
investig
clinic
outcom
studi
conclus
continu
imipenem
infus
administ
g
hour
guarante
suffici
plasma
concentr
compar
standard
regimen
g
everi
hour
associ
insuffici
trough
concentr
introduct
delirium
occur
mani
mechan
ventil
mv
medic
intens
care
unit
icu
patient
associ
poor
outcom
mv
patient
spend
icu
day
delirium
patient
becom
deliri
spend
icu
day
delirium
sccm
sedat
analgesia
guidelin
call
routin
delirium
screen
treatment
haloperidol
sought
understand
whether
guidelin
repres
chang
current
practic
examin
haloperidol
use
icu
larg
tertiari
care
academ
medic
center
hypothesi
hypothes
haloperidol
commonli
use
antipsychot
medic
icu
use
haloperidol
patient
receiv
mv
hour
significantli
less
rate
delirium
mv
patient
report
literatur
method
juli
june
prospect
collect
data
patient
admit
icu
univers
pittsburgh
medic
center
tertiari
care
academ
medic
center
icu
bed
serv
medic
surgic
trauma
neuro
solidorgan
transplant
patient
calcul
overal
rate
treatment
antipsychot
gener
mean
total
daili
dose
receiv
haloperidol
icu
patient
incur
hospit
icu
admiss
studi
period
hospit
requir
mechan
ventil
receiv
antipsychot
icu
haloperidol
frequent
use
antipsychot
administ
dose
risperidon
olanzapin
next
common
haloperidol
given
mv
hour
patient
icu
day
mv
hour
patient
receiv
mean
sd
daili
haloperidol
dose
mg
day
icu
day
one
four
mv
hour
icu
patient
receiv
haloperidol
use
howev
haloperidol
dose
durat
seem
appropri
either
appropri
treat
major
deliri
patient
sccm
guidelin
repres
signific
departur
exist
clinic
practic
icu
delirium
common
literatur
suggest
studi
need
defin
incid
icu
delirium
icu
patient
popul
evalu
impact
treatment
haloperidol
outcom
critic
care
introduct
remifentanil
hydrochlorid
remi
increasingli
use
critic
ill
remibas
analgesia
sedat
supplement
propofol
p
midazolam
mid
compar
hypnoticbas
techniqu
use
fentanyl
fent
morphin
morph
combin
p
mid
day
mechan
ventil
neurotrauma
patient
openlabel
treatment
remi
fent
morph
randomis
remi
infus
start
titrat
effect
supplement
p
day
mid
day
introduc
infus
rate
provid
optim
sedat
sa
analgesia
nonemild
pain
fent
morph
administ
p
mid
accord
routin
practic
mean
arteri
pressur
map
heart
rate
hr
intracrani
pressur
icp
cerebr
perfus
pressur
cpp
measur
time
min
follow
dose
titrat
tabl
remi
predict
pharmacokinet
organindepend
elimin
allow
remifentanil
hydrochlorid
remi
easili
titrat
provid
optim
analgesia
rapid
dissip
effect
even
prolong
infus
critic
ill
patient
remibas
analgesia
sedat
supplement
propofol
p
midazolam
mid
compar
hypnoticbas
techniqu
use
fentanyl
fent
morphin
morph
combin
p
mid
day
mechan
ventil
neurotrauma
patient
openlabel
treatment
remi
fent
morph
randomis
remi
infus
start
titrat
effect
supplement
p
day
mid
day
introduc
remi
infus
rate
provid
optim
sedat
sa
analgesia
nonemild
pain
fent
morph
administ
p
mid
accord
routin
practic
studi
drug
reducedstop
daili
schedul
assess
neurolog
function
observ
case
analysi
logtransform
data
overal
mean
neurolog
assess
time
unpair
test
betweensubject
variabl
f
test
around
assess
time
significantli
reduc
remi
group
compar
fent
morph
tabl
present
median
rang
time
reduc
analgesiased
neurolog
assess
hour
time
assess
neurolog
function
achiev
significantli
faster
predict
use
remifentanilbas
analgesia
sedat
tabl
overal
introduct
remifentanil
titrat
rapid
organindepend
metabol
make
ideal
suit
use
critic
ill
patient
establish
safeti
popul
import
studi
remifentanil
greater
day
limit
studi
compar
safeti
efficaci
remifentanilbas
analgesia
sedat
rba
hypnoticbas
sedat
hb
icu
patient
medic
condit
requir
longterm
day
mechan
ventil
one
hundr
five
patient
randomis
receiv
either
rba
hb
remifentanil
infus
start
titrat
effect
provid
optim
analgesia
sedat
supplement
midazolam
mid
bolu
introduc
remifentanil
rate
hb
mid
fentanyl
morphin
investig
choic
administ
accord
routin
clinic
practic
advers
event
ae
record
throughout
treatment
posttreat
period
clinic
differ
observ
incid
advers
event
seventeen
patient
receiv
rba
patient
receiv
hb
least
day
tabl
present
ae
remifentanil
well
toler
use
period
day
intens
care
patient
mechan
ventil
advers
event
relat
prolong
recoveri
muopioid
effect
report
remifentanil
infus
start
titrat
effect
optim
analgesia
sedat
supplement
mid
bolu
introduc
remifentanil
rate
hb
administ
accord
routin
clinic
practic
time
start
treatment
start
wean
process
extub
record
sedat
agit
score
pain
index
record
throughout
studi
result
twentynin
rba
patient
hb
patient
start
wean
treatment
period
extub
median
percentag
time
appropri
analgesiased
greater
regimen
tabl
present
time
start
studi
drug
start
wean
period
extub
conclus
remifentanilbas
analgesia
sedat
significantli
decreas
time
mechan
ventil
remifentanil
may
use
agent
costeffect
care
icu
patient
thorac
surgeri
usual
requir
anaesthesia
exclud
onelung
ventil
olv
olv
caus
increas
shunt
qsqt
clinic
expon
lower
oxygen
pressur
blood
lower
spo
defenc
mechan
prevent
lower
oxygen
pressur
hypox
pulmonari
vasoconstrict
hpv
lung
exclud
ventil
anaesthet
use
anaesthesia
especi
inhalatori
one
inhibit
hpv
purpos
purpos
studi
evalu
effect
anaesthesia
total
intraven
anaesthesia
tiva
oxygen
air
propofol
shunt
haemodynam
paramet
patient
undergo
oper
connect
neoplast
lung
diseas
requir
olv
shunt
haemodynam
paramet
evalu
use
data
collect
cathet
introduc
pulmonari
arteri
swanganz
cathet
studi
carri
patient
american
societi
anesthesiologist
asa
asaii
undergo
plan
oper
patient
premed
oral
midazolam
cathet
introduc
pulmonari
arteri
anaesthet
induct
accord
pressur
curv
patient
receiv
balanc
anaesthesia
combin
epidur
anaesthesia
thorac
segment
thorac
epidur
anaesthesia
fentanyl
salin
tiva
propofol
accord
robert
schema
heart
rate
blood
pressur
spo
temperatur
pulmonari
arteri
pulmonari
arteri
pressur
pulmonari
capillari
wedg
pressur
cardiac
output
cardiac
index
ci
qsqt
mark
nine
interv
induct
anaesthesia
min
ii
immedi
induct
anaesthesia
check
tube
posit
horizont
posit
iii
determin
respiratori
mixtur
twolung
ventil
later
posit
iv
min
start
olv
later
posit
v
min
start
olv
later
posit
vi
min
start
twolung
ventil
immedi
pulmonari
arteri
ligat
oper
lung
vii
min
start
twolung
ventil
immedi
pulmonari
arteri
ligat
oper
lung
viii
min
extub
ix
min
extub
obtain
result
analys
statist
spo
decreas
substanti
iv
v
mean
arteri
pressur
map
v
co
iv
relat
output
valu
statist
increas
notic
pressur
pulmonari
arteri
iiv
viii
qsqt
iiviii
highest
interv
iv
v
conclus
olv
caus
increas
qsqt
consequ
lower
spo
min
min
exclud
oper
lung
ventil
olv
connect
lower
spo
increas
pressur
pulmonari
arteri
propofol
use
tiva
caus
increas
shuntapproxim
four
time
increas
qsqt
caus
critic
lower
oxygen
pressur
arteri
blood
tiva
transit
decreas
ci
map
notic
avail
onlin
http
object
object
studi
analyz
incid
accident
withdraw
nonintravascular
cathet
critic
care
unfortun
ketamin
exert
side
effect
mani
research
use
benzodiazepin
cover
undesir
effect
studi
design
prospect
control
studi
set
gener
icu
object
prove
efficaci
ketamin
midazolam
altern
analgesiased
asthma
patient
polytrauma
method
use
model
jahangir
colleagu
patient
multipl
injuri
histori
asthma
includ
icu
stay
nine
spontan
breath
five
mechan
ventil
patient
randomis
two
group
group
patient
receiv
infus
ketamin
midazolam
two
drug
mix
one
syring
mg
ketamin
mg
midazolam
mean
rate
infus
ketamin
ngkghour
midazolam
ngkghour
midazolam
ad
elimin
side
effect
ketamin
sedat
group
patient
receiv
infus
ketamin
mgkghour
follow
paramet
haemodynam
ventil
monitor
heart
rate
mean
arteri
pressur
respiratori
rate
arteri
endexpiratori
po
arteri
po
transcutan
oxygen
satur
spo
pulmonari
complianc
resist
ventil
patient
subject
percept
pain
use
visual
analogu
scale
va
point
ramsey
sedat
scale
wake
sleep
level
rate
appear
side
effect
ketamin
mixtur
midazolam
led
insignific
chang
hemodynam
group
patient
signific
chang
note
tachycardia
mild
hypertens
respiratori
function
remain
well
maintain
except
group
patient
mild
hyperventil
note
document
increas
respiratori
complianc
reduct
pulmonari
resist
midazolam
help
prevent
side
effect
ketamin
administr
prolong
infus
midazolam
sign
accumul
increas
dose
necessari
va
score
almost
similar
group
ramsey
scale
score
also
similar
consciou
level
case
agit
group
patient
ketamin
midazolam
mixtur
good
altern
analgesiased
patient
asthma
multipl
injuri
consid
higher
dose
need
better
patient
comfort
aim
studi
evalu
three
differ
method
order
carri
magnet
reson
brain
scan
children
studi
analyz
asa
iii
nonpremed
children
divid
three
group
patient
b
c
use
laryng
mask
inhalatori
induct
three
group
three
differ
kind
mainten
inhalatori
mainten
intraven
mainten
mainten
balanc
anesthesia
children
age
year
underw
inhalatori
anesthesia
sevofluran
mac
spontan
breath
induct
maintenanceth
b
children
age
year
underw
inhalatori
anesthesia
sevofluran
mac
induct
endoven
anesthesia
propofol
mainten
c
children
age
year
use
inhalatori
anesthesia
sevofluran
mac
induct
balanc
anesthesia
mainten
demonstr
discharg
time
use
inhalatori
mainten
spontan
breath
shorter
use
mainten
intraven
propofol
anesthesia
one
halogen
side
effect
increas
cerebr
blood
flow
patient
reduc
intracran
complianc
eg
brain
tumor
mainten
balanc
gener
anesthesia
sevofluran
propofol
could
appropri
group
c
three
group
find
signific
side
effect
conclus
posit
confirm
synergi
inhalatori
intraven
techniqu
join
advantag
gener
balanc
anesthesia
patient
reduc
intracrani
complianc
introduct
critic
ill
patient
absorb
enter
medic
note
intraven
iv
prodafalgan
prdfg
recent
introduc
parenter
bioprecursor
paracetamol
caus
hypotens
prospect
studi
conduct
popul
icu
patient
requir
iv
prdfg
rectal
temperatur
enter
rout
prdfg
g
infus
min
temperatur
heart
rate
systolicdiastol
blood
pressur
mean
blood
pressur
map
record
min
follow
infus
intervent
correct
hypotens
record
result
seventytwo
event
patient
prdfg
administr
record
map
drop
significantli
min
follow
prdfg
infus
initi
increas
noradrenalin
occur
event
fluid
bolu
given
conclus
prdfg
caus
signific
hypotens
requir
activ
intervent
event
data
substanti
anecdot
knowledg
relationship
paracetamol
acetaminophen
hypotens
critic
ill
associ
iv
prepar
prospect
random
control
studi
aim
compar
efficaci
two
method
analgesia
patient
chest
trauma
rib
fractur
continu
epidur
cathet
analgesia
region
intrapleur
analgesia
ripa
seventythre
patient
unilater
chest
trauma
random
two
group
group
patient
place
epidur
cathet
level
th
group
patient
place
intrapleur
cathet
level
fifth
intercost
space
use
lidocain
analgesia
group
control
group
receiv
intraven
analgesia
opioid
appli
ml
lidocain
bolu
intrapleur
cathet
four
six
time
per
hour
clamp
cathet
min
epidur
analgesia
appli
mg
lidocain
start
continu
infus
rate
mgkghour
exceed
dose
mg
lidocain
per
hour
monitor
level
thermohipanesthesia
level
analgesia
visual
aanalogu
scale
point
paramet
respiratori
cardiovascular
function
respiratori
rate
arteri
oxygen
satur
sao
heart
rate
arteri
blood
pressur
central
venou
pressur
abil
expector
thermohipanesthesia
unilater
significantli
shorter
group
patient
wherea
group
patient
bilater
longer
durat
level
analgesia
similar
group
point
group
patient
achiev
frequent
applic
lidocain
potenti
danger
toxic
respiratori
rate
decreas
sao
increas
abil
expector
improv
group
patient
heart
rate
arteri
blood
pressur
remain
stabl
group
patient
episod
tachycardia
hypotens
undesir
trauma
patient
techniqu
place
intrapleur
cathet
easier
conclus
ripa
accept
altern
epidur
analgesia
patient
thorac
trauma
materi
fortyf
patient
patient
divid
two
group
group
patient
ca
men
five
women
age
year
ca
caus
ventricular
fibril
case
asystolia
eight
patient
ca
appear
acut
coronari
syndrom
fifti
percent
patient
die
hospit
treatment
group
ii
patient
age
year
men
three
women
stabl
coronari
arteri
diseas
group
vein
blood
sampl
taken
ca
two
consecut
day
patient
assess
concentr
hormon
adrenocortycotrop
hormon
acth
cortisol
cort
renin
aldosteron
aldo
vasopressin
avp
ntermin
natriuret
propeptyd
type
b
ntpbnp
patient
group
ii
concentr
aforement
hormon
assess
blood
sampl
taken
result
analyz
statist
method
result
data
mean
sd
present
tabl
patient
ca
die
hospit
compar
patient
ca
surviv
markabl
higher
concentr
cort
renin
lower
acth
avp
found
strong
activ
hormon
mechan
regul
waterelectrolyt
balanc
control
blood
pressur
patient
ca
high
concentr
cortisol
concomit
improp
increas
acth
suggest
bad
resolut
patient
ca
clarifi
endocrin
derang
patient
recov
traumat
nontraumat
brain
injuri
bi
patient
men
mean
age
year
investig
bi
due
spontan
intracerebr
hemorrhag
n
trauma
n
ischem
stroke
n
ruptur
brain
aneurysm
n
median
glasgow
coma
score
admiss
icu
durat
mechan
ventil
rang
day
patient
enrol
studi
transfer
rehabilit
unit
hormon
assess
includ
measur
thyroxin
triiodothyronin
thyrotropin
tsh
cortisol
corticotropin
acth
prolactin
testosteron
estradiol
insulinlik
growth
factor
dehydroepiadrosteron
sulphat
dhea
function
outcom
assess
glasgow
outcom
scale
go
entir
patient
popul
sever
endocrin
abnorm
observ
includ
low
n
low
n
high
tsh
n
low
tsh
n
high
cortisol
n
low
acth
n
high
acth
n
high
prolactin
n
low
testosteron
n
low
n
low
dhea
n
none
patient
cortisol
level
local
refer
rang
unstress
individu
go
rang
distribut
follow
go
n
go
n
go
n
go
n
go
n
signific
correl
go
r
p
r
p
acth
r
p
dhea
r
p
contrast
go
correl
tsh
cortisol
prolactin
testosteron
estradiol
level
conclud
endocrin
abnorm
common
patient
recov
acut
traumat
nontraumat
bi
relat
patient
function
outcom
remain
defin
whether
hormon
chang
adapt
reflect
patholog
recent
reduct
morbid
mortal
patient
surgic
icu
maintain
normoglycemia
insulin
demonstr
studi
mitochondria
sepsi
critic
ill
hyperglycemia
diabet
suggest
effect
therapi
mitochondri
integr
oxid
stress
state
may
contribut
posit
result
treatment
twenti
liver
biopsi
obtain
postmortem
patient
random
intens
insulin
therapi
iit
convent
insulin
therapi
cit
randomli
select
mitochondri
investig
studi
patient
cit
iit
group
compar
age
type
sever
durat
critic
ill
mean
blood
glucos
level
mmoll
p
median
daili
insulin
dose
iu
p
respect
hypertroph
mitochondria
increas
number
abnorm
irregular
crista
reduc
electrondens
matrix
observ
electron
microscopi
seven
nine
patient
cit
group
contrast
one
iit
patient
p
addit
significantli
higher
activ
complex
iii
complex
iv
respiratori
chain
trend
higher
activ
complex
complex
ii
complex
v
dehydrogenas
enzym
inhibit
superoxid
link
hyperglycem
complic
diabet
found
iit
compar
cit
group
conclus
mainten
normoglycemia
iit
appear
prevent
ultrastructur
function
abnorm
hepatocyt
mitochondria
associ
critic
illnessinduc
hyperglycemia
alter
may
contribut
benefit
intervent
analys
need
link
posit
effect
iit
mitochondri
integr
effect
oxid
stress
state
critic
ill
nonintens
care
set
recognit
patient
elev
troponin
ctnt
instig
appropri
treatment
includ
antiplatelet
agent
glycaem
control
reduc
risk
death
myocardi
infarct
surgic
intens
care
unit
icu
cardiothorac
intens
insulin
therapi
reduc
morbid
mortal
among
critic
ill
patient
aimsmethod
retrospect
audit
perform
consecut
admiss
gener
noncardiothorac
icu
establish
incid
rais
ctnt
ctnt
ngml
treatment
prescrib
outcom
measur
antiplatelet
use
glycaem
control
allcaus
mortal
icu
admiss
unit
protocol
state
insulin
infus
commenc
blood
glucos
bm
mmoll
incid
cardiac
myocyt
damag
diagnos
elev
ctnt
associ
allcaus
mortal
rate
patient
vs
patient
ctnt
normal
patient
p
median
length
admiss
day
patient
rais
ctnt
day
patient
normal
ctnt
p
case
rais
ctnt
occur
within
first
hour
admiss
icu
patient
elev
ctnt
patient
alreadi
aspirin
two
clopidogrel
clear
contraind
antiplatelet
therapi
four
patient
prescrib
aspirin
elig
patient
receiv
antiplatelet
therapi
patient
elev
ctnt
set
note
assess
glycaem
control
patient
bm
mmoll
bm
mmoll
past
histori
impair
glucos
tolerancediabet
mellitu
present
patient
elev
bm
mmoll
insulin
therapi
commenc
patient
bm
mmoll
patient
prescrib
insulin
delay
infus
commenc
median
hour
rang
hour
hypoglycaemia
bm
mmoll
document
patient
receiv
insulin
mortal
rate
high
patient
rais
bm
bm
mmoll
mortal
vs
bm
mmoll
ns
one
patient
without
elev
bm
surviv
conclus
elev
marker
cardiac
myocyt
damag
common
critic
ill
patient
associ
increas
mortal
rate
use
antiplatelet
agent
optimis
glycaem
control
group
might
reduc
morbid
mortal
aetiolog
rais
ctnt
critic
ill
specif
treatment
outcom
requir
investig
insulin
requir
mainli
cardiothorac
surgic
patient
suggest
strongli
associ
itu
mortal
poor
glycaem
control
prospect
record
insulin
administr
solubl
human
insulin
infus
actrapid
novo
nordisk
consecut
gener
itu
patient
admit
period
unit
guidelin
set
attempt
achiev
arteri
blood
glucos
concentr
mmoll
patient
subsequ
divid
two
group
accord
whether
requir
insulin
first
hour
blood
glucos
measur
use
radiomet
abl
system
blood
ga
analys
sampl
taken
least
everi
hour
ninetyeight
patient
includ
studi
receiv
insulin
receiv
insulin
time
first
hour
admiss
patient
group
accordingli
patient
histori
diabet
insulin
group
insulin
group
mean
sd
number
hour
patient
receiv
insulin
record
blood
glucos
patient
receiv
insulin
mean
sd
total
insulin
dose
first
hour
insulin
group
iu
mortal
insulin
group
insulin
group
chisquar
p
death
among
previous
diagnos
diabet
patient
patient
exclud
analysi
mortal
respect
chisquar
p
p
mean
sd
length
stay
itu
day
insulin
group
day
insulin
group
onetail
test
unequ
varianc
p
conclus
increas
length
stay
itu
predict
insulin
requir
maintain
blood
glucos
mmoll
first
hour
itu
admiss
increas
mortal
may
predict
insulin
requir
maintain
blood
glucos
mmoll
first
hour
itu
admiss
nondiabet
patient
introduct
elev
blood
glucos
concentr
import
factor
mortal
morbid
critic
ill
patient
previous
random
control
trial
show
blood
glucos
level
mmoll
associ
less
multiorgan
failur
significantli
higher
surviv
rate
compar
level
mmoll
platelet
play
crucial
role
hemostasi
inflamm
howev
effect
shortterm
elev
blood
glucos
level
platelet
activ
yet
evalu
systemat
object
evalu
influenc
blood
glucos
level
platelet
vitro
method
citrat
blood
sampl
drawn
healthi
blood
donor
male
age
year
mean
sd
exclus
criteria
smoke
use
drug
interf
platelet
function
blood
sampl
adjust
glucos
sigma
taufkirchen
germani
final
concentr
mmoll
control
group
mmoll
group
mmoll
group
respect
sampl
incub
min
fluorescencelabel
monoclon
antibodi
beckmancoult
krefeld
germani
evalu
platelet
reactiv
bachem
heidelberg
germani
adenosinediphosph
adp
sigma
taufkirchen
germani
ad
analys
perform
flowcytomet
epic
xl
beckmancoult
mean
fluoresc
intens
calcul
determin
platelet
aggreg
perform
turbidimetr
procedur
bct
dade
behr
marburg
germani
aggreg
induc
adp
collagen
mgl
epinephrin
dade
behr
statist
intergroup
differ
perform
oneway
anova
initi
blood
glucos
concentr
mmoll
blood
glucos
level
signific
influenc
express
without
stimul
contrast
observ
signific
decreas
express
group
compar
control
group
unstimul
p
p
adp
p
similar
observ
made
express
unstimul
p
p
adp
p
also
group
signific
decreas
express
observ
adp
stimul
signific
differ
seen
aggregometri
either
agonist
vitro
studi
demonstr
elev
blood
glucos
level
reduc
express
platelet
receptor
contrast
platelet
function
measur
aggregometri
show
impair
conclud
acut
hyperglycemia
lead
lower
platelet
function
thirtyfour
patient
blood
glucos
bg
level
control
mean
artifici
pancrea
aim
bg
control
mgdl
investig
first
measur
gc
perform
acut
condit
patient
second
measur
done
week
first
measur
patient
gc
perform
clamp
bg
level
mgdl
insulin
infus
rate
iir
mukgmin
indic
valu
mgkgmin
blood
insulin
level
iir
respect
normal
valu
calcul
indic
insulin
sensit
patient
classifi
four
group
b
c
accord
ie
ratio
mukcal
ie
ratio
b
ie
ratio
c
ie
ratio
ie
ratio
follow
paramet
studi
administ
energi
glucos
e
administ
insulin
sofa
score
valu
daili
mean
bg
level
bgm
blood
cpeptid
reactiv
cpr
insulin
clearanc
ic
mlkgmin
neg
correl
ie
ratio
r
comparison
ie
ratio
n
b
ie
ratio
n
signific
differ
p
bgm
vs
p
ic
vs
p
signific
differ
e
cpr
sofa
score
comparison
c
ie
ratio
n
ie
ratio
n
signific
differ
p
bgm
vs
p
signific
differ
e
cpr
ic
sofa
score
interpret
ie
ratio
daili
measur
indic
glucos
toler
howev
discrep
valu
ie
ratio
patient
group
b
mechan
discrep
unclear
influenc
ic
andor
increas
glucos
metabol
bg
ex
mass
action
effect
activ
glucos
etc
group
b
decreas
group
specul
valu
measur
bg
level
mgdl
ie
ratio
bg
control
aim
mgdl
measur
valu
ie
ratio
consid
use
evalu
glucos
toler
also
understand
mechan
glucos
intoler
acut
ill
sever
patient
tight
glycaem
control
periop
critic
ill
patient
may
carri
risk
hypoglycaemia
howev
blood
glucos
target
mmoll
shown
benefit
critic
ill
mainli
postcardiothorac
surgeri
patient
unusu
patient
given
glucos
infus
admiss
hour
tight
group
inconsequenti
hypoglycaem
episod
blood
glucos
mmoll
perceiv
risk
hypoglycaemia
starv
patient
receiv
insulin
achiev
tight
glycaem
control
widespread
concern
report
safeti
monitor
ongo
prospect
doubleblind
randomis
control
studi
addit
glucos
make
differ
trial
investig
whether
initi
addit
glucos
infus
improv
outcom
critic
care
patient
receiv
tight
glycaem
control
patient
receiv
glucos
nacl
mlhour
full
nutrit
taken
monitor
excess
hypoglycaem
episod
nacl
group
set
accept
incid
blood
glucos
mmoll
advers
consequ
hourli
arteri
line
sampl
test
regularli
calibr
accucheck
roch
diagnost
bedsid
monitor
insulin
actrapid
novo
nordisk
u
ml
nacl
administ
continu
infus
bolus
accord
algorithm
studi
period
time
studi
infus
given
investig
remain
blind
complet
data
obtain
patient
group
gave
inform
consent
accord
local
medic
ethic
guidelin
advers
incid
death
record
patient
incomplet
data
differ
group
group
mean
sd
group
mean
sd
age
bodi
mass
index
apach
ii
score
sopra
admiss
reason
cardiac
surgeri
death
itu
total
hypoglycaem
mmoll
hyperglycaem
mmoll
episod
total
hour
studi
period
mean
sd
hour
outsid
prescrib
rang
mmoll
patient
studi
period
present
tabl
tight
glycaem
control
appear
safe
patient
receiv
either
glucos
nacl
mlhour
sever
injuri
activ
system
inflammatori
respons
syndrom
stimul
releas
cortisol
adren
cortex
rel
cortisol
insuffici
well
describ
critic
ill
patient
especi
sever
sepsi
associ
increas
mortal
conflict
data
regard
effect
major
trauma
haemorrhag
shock
endogen
cortisol
level
effect
earli
rel
cortisol
defici
measur
random
cortisol
level
patient
sever
trauma
haemorrhag
shock
admit
icu
initi
resuscit
emerg
surgeri
injuri
sever
score
iss
fluid
blood
product
requir
inotrop
requir
fluid
resuscit
mortal
day
also
measur
rel
cortisol
defici
defin
random
cortisol
level
nmoll
six
patient
cortisol
level
nmoll
group
patient
mean
sd
iss
mean
cortisol
level
nmoll
none
requir
inotrop
support
mortal
fourteen
patient
cortisol
level
nmoll
group
patient
mean
iss
mean
cortisol
level
six
requir
inotrop
support
mortal
patient
also
significantli
higher
fluid
blood
product
requir
conclus
cortisol
defici
common
patient
major
trauma
associ
higher
iss
increas
fluid
blood
product
requir
increas
inotrop
requir
increas
mortal
patient
may
benefit
earli
steroid
replac
therapi
object
studi
investig
function
integr
hypothalamicpituitaryadren
axi
critic
ill
stimul
lowdos
acth
stimul
test
ldst
hcrh
studi
includ
male
mechan
ventil
patient
mean
age
year
underli
diagnos
includ
major
oper
n
multipl
trauma
n
stroke
n
pancreat
n
patient
enrol
studi
day
initi
mechan
ventil
median
apach
ii
sofa
score
studi
day
rang
rang
respect
patient
underw
stimul
first
ldst
follow
day
hcrh
acth
cortisol
concentr
determin
min
hcrh
normal
cortisol
respons
ldst
hcrh
defin
peak
plasma
concentr
respect
appropri
acth
respons
hcrh
consid
twofold
increas
acth
observ
entir
patient
popul
baselin
cortisol
mean
sd
stimul
cortisol
median
follow
ldst
four
patient
subnorm
stimul
cortisol
level
ldst
four
patient
also
subnorm
peak
cortisol
concentr
follow
hcrh
analysi
individu
acth
respons
four
patient
reveal
two
pattern
three
patient
twofold
eightfold
increas
acth
note
wherea
one
patient
fail
augment
appropri
acth
level
peak
acth
time
baselin
valu
conclus
signific
subset
critic
ill
patient
evid
diminish
cortisol
product
follow
dynam
stimul
ldst
disord
mostli
due
primari
adren
dysfunct
also
hypothalamicpituitari
failur
aim
studi
determin
statu
hypothalamicpituitaryadren
axi
critic
ill
patient
earli
sepsi
andor
septic
shock
investig
whether
adren
respons
relat
mortal
fortytwo
patient
male
median
age
year
rang
year
cortisol
corticotropin
acth
dehydroepiandrosteron
sulphat
dhea
level
measur
onset
sepsi
andor
septic
shock
adren
respons
assess
ldst
peak
cortisol
ldst
consid
repres
inadequ
respons
entir
patient
popul
hormon
concentr
follow
median
mean
sd
valu
baselin
cortisol
stimul
cortisol
increment
cortisol
acth
pgml
dhea
ngml
eight
patient
inadequ
cortisol
respons
follow
ldst
overal
patient
die
patient
surviv
differ
survivor
nonsurvivor
regard
baselin
cortisol
vs
p
stimul
cortisol
vs
p
acth
vs
pgml
p
dhea
vs
ngml
p
level
contrast
nonsurvivor
lower
increment
cortisol
follow
ldst
compar
survivor
vs
p
conclus
substanti
proport
patient
evid
adren
hyporespons
onset
sepsi
andor
septic
shock
attenu
adren
respons
associ
higher
mortal
rate
patient
introduct
patient
septic
shock
recent
found
rel
adren
insuffici
etomid
known
inhibit
hydroxylas
could
interfer
cortisol
respons
corticotropin
hypothesi
patient
receiv
etomid
corticotropin
stimul
test
higher
incid
rel
adren
insuffici
retrospect
studi
electron
record
patient
serum
cortisol
level
drawn
march
august
review
patient
short
corticotropin
stimul
test
done
icu
admiss
septic
shock
identifi
cohort
divid
receiv
etomid
corticotropin
stimul
test
incid
rel
adren
insuffici
compar
two
group
data
collect
includ
demograph
presenc
rel
adren
insuffici
presenc
coagulopathi
use
steroid
medic
known
interfer
cortisol
synthesi
use
etomid
time
interv
administr
cosyntropin
test
histori
adrenalpituitari
diseas
mortal
rel
adren
insuffici
defin
respons
less
corticotropin
stimul
septic
shock
defin
accpsccm
criteria
comparison
group
made
use
chisquar
test
patient
mean
age
year
white
male
coagulopathi
found
patient
ten
patient
dexamethason
test
none
patient
medic
known
interfer
test
patient
previou
histori
adrenalpituitari
diseas
patient
receiv
etomid
diagnos
rel
adren
insuffici
compar
patient
p
rel
adren
insuffici
note
patient
receiv
etomid
within
hour
compar
patient
receiv
etomid
later
hour
test
p
mortal
rate
patient
rel
adren
insuffici
compar
patient
without
rel
adren
insuffici
p
increas
incid
rel
adren
insuffici
etomid
administr
septic
shock
follow
etomid
administr
increas
incid
unrel
time
interv
etomid
administr
corticotropin
test
background
goal
chronic
obstruct
pulmonari
diseas
copd
increasingli
recogn
system
diseas
hormon
metabol
musculoskelet
implic
gener
process
involv
oxid
stress
inflammatori
mediat
cytokin
endocrin
hormon
begun
understood
aim
studi
assess
chang
oxid
stress
treatment
exacerb
copd
measur
erythrocyt
e
plasma
p
glutathion
peroxidas
gpx
malondialdehyd
mda
superoxid
dismutas
sod
pretreat
period
posttreat
period
patient
acut
exacerb
copd
twenti
healthi
smoker
nonsmok
histori
lung
diseas
serv
control
subject
result
data
present
tabl
result
consist
earli
report
topic
thought
treatment
increas
antioxid
level
everi
time
although
clinic
improv
achiev
therefor
result
suggest
consid
increas
antioxid
capac
show
tissu
improv
gpx
sod
mda
level
use
marker
prognosi
success
treatment
exacerb
copd
object
assess
antioxid
enzym
activ
critic
ill
patient
sepsi
compar
control
patient
without
sepsi
evalu
chang
antioxid
enzym
activ
convalesc
period
success
treatment
sepsi
prospect
casecontrol
studi
medic
adult
intens
care
unit
bed
routin
venou
blood
sampl
obtain
septic
patient
n
age
year
apach
ii
score
without
antioxid
treatment
agematch
sexmatch
hospitalis
control
patient
without
clinic
laboratori
sign
sepsi
pair
convalesc
sampl
taken
week
recoveri
avail
five
patient
measur
activ
superoxid
dismutas
copper
zinc
ec
cuznsod
erytrocyt
base
superoxid
gener
xanthin
oxidas
tetrazolium
reduct
activ
paraoxonas
ec
serum
paraoxon
phenylacet
serum
concentr
total
highdens
lipoprotein
hdl
cholesterol
creactiv
protein
also
measur
consid
p
statist
signific
higher
cuznsod
activ
mean
sem
ug
hb
septic
patient
comparison
healthi
control
ug
hb
p
hand
activ
measur
paraoxon
uml
resp
phenylacet
uml
lower
sepsi
compar
control
uml
resp
uml
p
resp
p
recoveri
differ
activ
cuznsod
patient
control
moreov
found
posit
correl
activ
level
total
hdl
cholesterol
sepsi
recoveri
observ
age
sex
depend
activ
enzym
septic
patient
control
conclus
patient
admit
intens
care
unit
sever
sepsi
exhibit
abnorm
anitoxid
enzym
activ
purpos
assess
efficaci
scaveng
lung
injuri
intraabdomin
sepsi
rat
spraguedawley
rat
male
g
underw
cecal
ligat
punctur
clp
cecum
punctur
needl
obtain
two
hole
gentl
pressur
appli
ligat
cecum
exterior
small
amount
fece
follow
closur
abdomin
incis
five
hour
later
anim
inject
intraperiton
polyethylen
glycol
absorb
catalas
scaveng
hydrogen
peroxid
group
dimethyl
sulfoxid
scaveng
hydroxyl
radic
b
group
polyethylen
glycol
absorb
superoxid
dismutas
scaveng
superoxid
ion
salin
control
group
surviv
evalu
hour
clp
surviv
anim
sacrif
carbon
dioxid
inhal
outcom
lung
protein
synthesi
evalu
nitrotyrosinetyrosin
ratio
oxid
damag
dna
evalu
deoxyguanosin
ratio
homogen
lung
tissu
measur
hplc
neutrophil
accumul
lung
evalu
myeloperoxidas
activ
mpo
intracellular
adhes
express
cell
lung
evalu
patholog
examin
result
mpo
express
nitrotyrosinetyrosin
ratio
ratio
significantli
lower
scavengertr
group
b
c
salinetr
group
howev
differ
surviv
rate
group
b
c
control
conclus
scaveng
attenu
neutrophil
accumul
lung
injuri
improv
surviv
result
suggest
factor
lung
injuri
may
respons
mortal
rat
model
sepsi
howev
addit
studi
superoxid
earli
phase
late
assess
outcom
indic
conclus
sh
cardiac
surgeri
appear
common
associ
major
morbid
level
routin
monitor
avail
onlin
http
everyday
practic
observ
differ
potassium
level
measur
routin
biochemistri
ga
analysi
machin
expect
sinc
former
measur
serum
potassium
later
measur
plasma
potassium
serumplasma
potassium
concentr
differ
relat
patient
platelet
count
increas
statist
signific
level
thrombocytaemiaw
measur
serumplasma
potassium
differ
icu
patient
within
first
hour
admiss
compar
differ
measur
chronic
sever
ill
urem
patient
well
group
healthi
volunt
measur
serum
potassium
ska
plasma
potassium
pka
serumplasma
potassium
differ
spdifa
ska
pka
age
platelet
plt
count
icu
patient
group
previous
healthi
suffer
major
catastroph
road
traffic
accid
gastrointestin
bleed
major
trauma
less
hour
measurementsw
also
measur
serum
potassium
skb
plasma
potassium
pkb
serumplasma
potassium
differ
spdifb
skb
pkb
age
plt
count
chronic
urem
patient
renal
replac
therapi
group
b
patient
come
treatment
schedul
evid
acut
diseas
variabl
skc
pkc
spdifc
measur
healthi
volunt
group
c
blood
sampl
obtain
radial
arteri
serum
potassium
collect
vacutain
tube
plasma
potassium
syring
treat
heparin
platelet
count
measur
edtatr
plasma
sampl
potassium
level
measur
use
equip
conclus
suggest
plasma
potassium
reliabl
serum
potassium
critic
ill
sinc
latter
depend
platelet
count
evalu
patient
act
accord
plasma
level
sinc
pseudohyperkalemia
like
even
normal
platelet
countsth
higher
spdif
observ
critic
ill
impli
number
platelet
count
convent
method
probabl
activ
aggreg
initi
acut
phase
reaction
myelinolysi
ml
may
relat
excess
rapid
correct
hyponatremia
studi
clearli
demonstr
assumpt
prospect
analyz
determin
ml
follow
correct
sever
hyponatremia
patient
admit
univers
medic
icu
juli
march
hyponatremia
mmoll
includ
cerebr
computeris
tomographi
ct
scan
perform
within
day
cerebr
magnet
reson
imag
mri
scan
systemat
plan
month
ml
diagnosi
ascertain
hyperintens
lesion
present
sequenc
area
consid
normal
initi
imag
clinic
biolog
data
assess
everi
hour
correct
natremia
therapeut
option
left
discret
intensivist
object
test
hypothes
chlorid
account
increas
proport
base
deficit
treatment
diabet
ketoacidosi
dka
perceiv
discrep
chang
anion
gap
bicarbon
base
deficit
treatment
primarili
due
chlorid
effect
method
retrospect
cohort
studi
children
year
n
admit
acut
manag
dka
two
paediatr
icu
stewart
physicochem
theori
use
calcul
independ
effect
chlorid
bicarbon
base
deficit
via
linear
regress
model
model
use
quantifi
effect
chlorid
base
deficit
evalu
relationship
chang
anion
gap
bicarbon
base
deficit
correct
chlorid
result
eighteen
children
median
age
year
weight
kg
follow
hour
initi
therapi
insulin
fluid
resuscit
steadi
improv
ph
time
mean
ph
howev
hour
signific
base
deficit
persist
mean
mmoll
despit
anion
gap
normalis
mean
mmoll
base
deficit
time
almost
exclus
due
hyperchloraemia
relationship
chang
anion
gap
bicarbon
base
deficit
improv
dramat
approach
oneforon
correct
chlorid
slope
r
slope
r
respect
chlorid
confound
effect
interpret
base
deficit
bicarbon
treatment
dka
occur
anion
gap
may
better
marker
track
resolut
ketoacidosi
therefor
incorpor
treatment
guidelin
set
special
icu
belorussian
center
paediatr
oncolog
object
estim
influenc
nutrit
statu
sever
septic
complic
mortal
children
neutropenia
follow
prospect
case
sepsi
case
sepsi
case
sever
sepsi
case
septic
shock
accord
accpsccm
criteria
among
neutropen
children
age
year
myeloprolif
diseas
solid
tumor
mean
prism
ii
score
time
icu
admiss
patient
sepsi
sever
sepsi
patient
septic
shock
compar
percent
weight
loss
period
chemotherapi
sepsi
onset
among
survivor
nonsurvivor
control
group
includ
children
leukemia
lymphoma
match
age
gender
durat
treatment
without
septic
complic
statist
analysi
test
use
result
decreas
bodi
mass
mean
weight
loss
previou
month
found
patient
sepsi
sever
sepsi
septic
shock
differ
nutrit
condit
among
survivor
nonsurvivor
weight
loss
sepsi
summar
tabl
control
group
weight
loss
found
patient
mean
level
weight
loss
significantli
p
lower
patient
sepsi
mortal
control
group
mortal
rate
patient
sepsi
sever
sepsi
septic
shock
signific
differ
p
weight
loss
survivor
nonsurvivor
found
group
patient
weight
loss
chemotherapi
cancer
risk
factor
associ
increas
morbid
mortal
object
determin
chang
rest
energi
expenditur
ree
bodi
temperatur
jugular
bulb
oxygen
satur
sjvo
patient
brain
injuri
brain
death
method
fiftytwo
patient
glasgow
coma
scale
score
admit
intens
care
unit
octob
novemb
includ
studi
among
patient
group
n
includ
patient
brain
death
group
divid
two
subgroup
later
group
n
consist
patient
brain
death
includ
studi
group
n
consist
patient
progress
brain
death
intens
care
unit
stay
although
initi
brain
dead
group
n
consist
patient
brain
injuri
brain
death
ree
use
indirect
calorimetri
sjvo
bodi
temperatur
record
daili
simultan
first
day
studi
ree
valu
express
percentag
basal
metabol
rate
bmr
calcul
use
harrisbenedict
equat
differ
term
age
apach
ii
score
admiss
reason
coma
bmr
group
group
p
mean
bodi
temperatur
p
mean
sjvo
valu
p
mean
ree
valu
kcal
mean
bmr
kcal
mean
bmr
p
group
group
respect
group
mean
bodi
temperatur
lower
mean
sjvo
higher
valu
brain
death
p
group
although
mean
ree
lower
valu
brain
death
differ
statist
signific
p
studi
found
mean
valu
ree
higher
bmr
patient
brain
injuri
mean
ree
bodi
temperatur
lower
mean
sjvo
higher
braindead
patient
patient
brain
death
reduc
transloc
potenti
pathogen
bacteria
gut
chang
immun
system
may
respons
appear
aim
randomis
doubleblind
trial
investig
chang
concentr
cytokin
patient
receiv
either
een
enrich
lab
placebo
patient
method
thirtythre
patient
undergo
either
pyloruspreserv
pancreaticoduodenectomi
whippl
oper
enrol
een
enrich
either
lab
synbiot
n
placebo
n
suppli
doubleblind
randomis
period
day
begin
day
oper
sampl
taken
surgeri
well
postop
day
plasma
sampl
centrifug
quickli
frozen
concentr
cytokin
measur
specif
elisa
techniqu
opteia
human
set
pharmingen
usa
standard
procedur
result
increas
group
day
significantli
progress
decreas
could
seen
contrast
decreas
oper
increas
day
nearli
level
onset
investig
placebo
group
pgml
verum
group
pgml
simultan
amount
interferon
gamma
decreas
postop
verum
group
increas
placebo
group
differ
seen
tendenc
signific
could
shown
concentr
increas
oper
howev
higher
increas
day
surgeri
day
verum
group
placebo
group
summari
conclus
enrich
een
lab
seem
signific
influenc
known
postop
increas
decreas
concentr
contrast
lab
suppli
seem
impair
amount
investig
necessari
elucid
underli
mechan
modern
intens
care
medicin
strive
enter
nutrit
en
sinc
shown
protect
gut
mucos
function
reduc
infect
morbid
hasten
recoveri
ill
contribut
lower
mortal
rate
en
requir
function
intact
gastrointestin
tract
may
caus
diarrhoea
attend
risk
pulmonari
aspir
data
indic
discrep
prescript
deliveri
en
carri
risk
undernutrit
therefor
design
studi
aim
identifi
discrep
prescrib
deliv
nutrit
evalu
benefit
problem
associ
en
parenter
nutrit
pn
also
compar
actual
amount
fat
glucos
nitrogen
deliv
calcul
requir
method
data
nutrit
suppli
energi
intak
amount
glucos
fat
nitrogen
gut
function
diarrhoea
gastric
retent
vomit
regist
daili
patient
admit
icu
week
patient
treat
less
day
exclud
energi
requir
calcul
accord
harrisbenedict
equat
nitrogen
n
demand
set
gnkg
data
base
treatment
day
present
mean
sem
result
twentysix
patient
stay
icu
day
thu
includ
studi
averag
patient
receiv
adequ
amount
energi
around
kcalday
third
day
throughout
studi
period
energi
deliv
fat
account
daili
n
suppli
approxim
g
good
correl
prescrib
administ
amount
enter
nutrit
r
total
amount
energi
deliv
administ
enter
bowel
function
consid
normal
day
daili
registr
gut
function
demonstr
diarrhoea
gastric
retent
vomit
conclus
en
gradual
increas
accord
nutrit
guidelin
predomin
first
day
energi
input
usual
adequ
within
day
admiss
en
gener
well
toler
complic
diarrhoea
frequent
enter
fed
patient
gastric
retent
common
among
patient
given
pn
correl
prescrib
receiv
amount
enter
feed
high
background
aim
studi
develop
standard
procedur
assess
patient
nutrit
need
provid
individu
enter
nutrit
en
regimen
use
softwar
tool
accomplish
task
fast
safe
yet
simpl
way
studi
took
place
surgic
intens
care
unit
univers
surgic
depart
hippocr
hospit
procedur
involv
input
patient
data
age
weight
sex
along
data
relev
clinic
statu
patient
well
treatment
detail
special
softwar
analyz
data
determin
nutrit
paramet
implement
evidencebas
equat
calcul
accur
individu
patient
daili
nutrit
need
total
energi
protein
hydrocarbon
fat
vitamin
miner
well
concentr
nutrient
total
en
volum
administ
basi
softwar
design
monitor
administ
regimen
alarm
case
mismatch
calcul
accord
underli
diseas
clinic
statu
nutrit
paramet
patient
inform
user
metabol
complic
like
occur
accord
laboratori
test
patient
purpos
studi
computercalcul
en
regimen
administ
randomli
select
patient
unit
compar
regimen
would
administ
without
help
comput
larg
differ
en
calcul
comput
number
time
comput
design
use
differ
prepar
order
better
suit
patient
nutrit
need
reduct
time
consum
calcul
decreas
fals
calcul
wherea
earli
recognit
metabol
complic
increas
util
special
softwar
seem
abl
help
health
profession
select
optim
en
regimen
estim
appropri
fluid
volum
accord
patient
need
conclus
implement
softwar
enabl
health
profession
overcom
burden
calcul
also
accomplish
label
statist
analysi
record
manag
thu
allow
provis
individu
en
becom
effici
standard
routin
procedur
promot
simpl
fast
safe
way
provid
individu
nutrit
support
qualiti
nutrit
servic
would
certainli
benefit
routin
clinic
applic
difficult
achiev
transpylor
placement
enter
feed
tube
infant
case
found
new
method
place
enter
diet
tube
postpylor
feed
infant
patient
intub
mm
id
nasoenter
feed
tube
drawn
scale
surfac
inner
wire
stylet
insert
advanc
esophagu
gastric
lumen
special
made
mm
id
intratrach
tube
cuff
connect
bodai
connector
use
fiberscop
whose
proxim
end
seal
except
small
hole
insuffl
oxygen
place
compos
tube
esophagu
transor
mm
od
fiberscop
insert
compos
tube
distal
end
lead
stomach
cuff
inflat
order
fix
posit
prevent
leakag
air
insuffl
gastric
lumen
inflat
gastric
caviti
air
distal
orific
enter
feed
tube
advanc
distal
duodenum
direct
view
fiberscop
distanc
antrum
determin
scale
tube
method
tri
four
patient
trial
succeed
without
complic
continu
postpylor
enter
feed
safe
begun
immedi
aim
method
present
studi
design
investig
role
enter
nutrit
postop
sepsisinduc
product
index
oxid
stress
five
group
male
wistar
rat
subject
midlin
laparotomi
feed
gastrostomi
ten
rat
allow
recov
oper
stress
day
serv
control
remain
rat
alloc
receiv
gastrostomi
either
enter
feed
fresubinhp
energi
freseniuskabi
mlhour
kcalday
water
hour
subdivid
two
group
intraperiton
inject
mgkg
escherichia
coli
lipopolysacchardi
lp
difco
sigma
chemic
placebo
two
hour
later
rat
sacrif
first
subject
blood
liver
tissu
sampl
product
quantifi
measur
total
nitrit
plu
nitrat
concentr
serum
sampl
liver
tissu
homogen
mean
spectrophotometr
method
use
modif
griess
reaction
synthas
mrna
express
examin
homogen
liver
tissu
rnazol
rtpcr
result
basal
product
found
serum
control
rat
oper
found
induc
signific
increas
p
level
serum
inject
lp
induc
level
p
enter
feed
found
significantli
decreas
p
level
group
contrast
liver
homogen
found
significantli
increas
p
enter
nutrit
plu
lpstreat
rat
compar
placebo
feed
plu
lp
interestingli
lp
found
induc
induc
synthas
ino
mrna
express
liver
tissu
regardless
enter
feed
liver
placebo
lp
treat
anim
express
ino
mrna
find
indic
earli
enter
feed
lead
reduct
circul
level
induc
oper
sepsi
increas
hepat
level
probabl
via
effect
lpsinduc
ino
increas
larginin
uptak
reduc
suscept
peroxid
reaction
compar
lctcontain
fat
emuls
possess
strong
proinflammatori
oxid
damag
potenti
aim
studi
compar
pulmonari
metabol
effect
two
fat
emuls
prospect
measur
intrapulmonari
oxygen
consumpt
vo
ipulm
lung
lactat
product
llp
glucos
flux
trough
lung
gf
energi
expenditur
ee
respiratori
quotient
rq
adult
posttraumat
ard
patient
receiv
convent
fat
emuls
studi
entri
patient
randomli
switch
lct
mctlct
lipid
emuls
patient
lct
group
n
continu
receiv
convent
lctcontain
fat
emuls
mctlct
group
n
mctcontain
fat
emuls
start
group
fat
emuls
infus
dose
gkgday
vo
ipulm
estim
subtract
calcul
vo
use
revers
fick
method
whole
bodi
vo
use
indirect
calorimetri
datex
ohmeda
mcovx
metabol
monitor
measur
calcul
perform
simultan
achiev
steadyst
condit
period
hour
overal
mortal
set
found
substanti
increas
vo
ipulm
compon
whole
bodi
vo
group
median
interquartil
rang
mctlct
group
abrupt
mean
valu
min
sustain
signific
increas
ee
mean
kcalkg
maxim
correspond
increas
whole
bodi
vo
hour
vo
ipulm
show
constant
declin
reach
minimum
median
valu
interquartil
rang
whole
bodi
vo
hour
absolut
valu
vo
ipulm
also
decreas
mlkgmin
mlkgmin
chang
accompani
signific
variat
llp
gf
rq
conclud
observ
decreas
vo
ipulm
mctlct
group
concomit
increas
whole
bodi
vo
ee
without
signific
chang
rq
llp
gf
indic
increas
oxygen
consumpt
metabol
purpos
outsid
lung
data
suggest
infus
mctcontain
fat
emuls
could
lead
signific
decreas
oxygen
use
lung
nonmetabol
purpos
ie
free
radic
format
lipid
peroxid
observ
posit
shortterm
metabol
effect
mctlctcontain
fat
emuls
could
potenti
clinic
applic
reduc
oxid
damag
caus
larg
inflammatori
mass
lung
ard
patient
recogn
ischem
effect
sympathomimet
toxin
variou
vascular
bed
hypothes
renal
insuffici
set
cocain
amphetaminerel
rhabdomolysi
associ
direct
ischem
injuri
renal
tubul
independ
extent
muscl
damag
volum
deplet
method
retrospect
studi
consecut
patient
diagnosi
rhabdomyolysi
seen
emerg
depart
month
data
includ
blood
urea
nitrogen
bun
white
blood
cell
count
urin
toxicolog
screen
hematocrit
chang
second
posthydr
hematocrit
use
approxim
degre
initi
volum
deplet
creatin
kinas
ck
creatinin
level
follow
serial
patient
obviou
renal
failur
present
defin
first
creatinin
equal
mgdl
exclud
statist
analysi
util
twotail
student
test
continu
variabl
fisher
exact
test
categor
variabl
result
see
tabl
two
group
identifi
patient
test
posit
cocain
amphetamin
test
neg
nine
patient
tox
group
patient
tox
group
obviou
renal
failur
exclud
p
conclus
despit
lower
ck
valu
suggest
smaller
amount
myoglobin
deliveri
kidney
despit
demonstr
differ
marker
volum
deplet
bun
percentag
dehydr
patient
tox
group
still
higher
admiss
creatinin
level
find
suggest
vasoact
sympathomimet
drug
abus
ischem
effect
kidney
independ
effect
myoglobin
deposit
volum
deplet
poison
appropri
diagnost
approach
crucial
assess
carbon
monoxid
co
cardiac
damag
qt
dispers
qtd
measur
inhomogen
repolar
use
indic
arrhythmogen
object
aim
present
prospect
studi
evalu
relationship
patient
age
qt
dispers
surfac
ecg
carbon
monoxid
poison
method
carbon
monoxid
intox
confirm
patient
arteri
blood
ga
analysi
patient
subdivid
two
group
accord
age
year
group
age
year
group
ii
qt
dispers
measur
surfac
electrocardiogram
bazzet
formula
use
correct
qtd
heart
rate
qtcd
measur
qt
interv
calcul
admiss
ecg
admiss
signific
differ
group
group
ii
regard
gender
carboxyhemoglobin
level
admiss
qtd
qtc
qtcd
interv
group
significantli
increas
compar
group
ii
qt
interv
signific
differ
qt
interv
measur
group
group
ii
hour
admiss
conclus
although
qt
dispers
increas
patient
co
poison
agerel
increas
qtd
absenc
qt
interv
prolong
may
address
group
high
risk
complic
aaod
vomit
two
time
per
day
patient
diarrhoea
three
time
per
day
three
patient
aspir
pneumonia
renal
failur
seen
one
patient
admit
hospit
day
prevent
dehydr
result
abstin
employ
train
educ
crimin
behaviour
shown
tabl
conclus
although
major
patient
group
made
use
methadon
programm
still
often
suffer
health
problem
common
intraven
drug
user
underweight
respiratori
problem
hepat
b
hepat
c
hivposit
patient
found
complic
aaod
infrequ
sever
aaod
naltrexon
combin
cbt
provid
clinic
lead
opiat
abstin
patient
year
significantli
higher
particip
employ
train
educ
signific
decreas
crimin
activ
ingest
caustic
substanc
produc
sever
injuri
esophagu
also
gastrointestin
tract
even
result
death
degre
extent
damag
depend
sever
factor
like
type
substanc
quantiti
intent
quantiti
prognost
valu
ml
sever
ml
sever
acut
phase
perfor
necrosi
may
occur
often
devast
consequ
esophagu
stomach
injuri
associ
high
mortal
morbid
rate
mediastin
gastrobronchi
fistula
chemic
periton
perfor
gastrointestin
tract
occur
perfor
may
occur
late
phase
especi
ingest
alkalin
solut
inflamm
invad
deepli
continu
releas
ohaft
come
contact
proteinlongterm
complic
includ
strictur
format
esophagu
antral
stenosi
develop
esophag
carcinoma
aim
studi
evalu
whether
earli
diagnosi
surgic
treatment
essenti
improv
prognosi
method
novemb
novemb
six
patientswer
admit
depart
mean
age
year
male
femal
ratio
averag
time
caustic
ingest
admiss
emerg
ward
hour
ingest
substanc
alkali
acid
casesth
blood
ga
examin
endoscopi
comput
tomographi
chestabdomin
xray
perform
request
orotrach
intub
ventilatori
support
antibiot
therapi
earli
initi
metronidazol
tazobactanpiperacillin
optim
hemodynam
stabil
achiev
combin
surgic
procedur
perform
acut
phase
laparoscop
esophagealtot
gastrectomi
open
cervicotomi
cervicostomi
percutan
enterostomi
enter
nutrit
gastricesophag
reconstruct
perform
subsequ
blood
ga
examin
show
mean
ph
mean
base
excess
endoscopi
reveal
multipl
deep
brownishblack
ulcer
four
patient
perfor
two
patient
chest
xray
reveal
air
bubbl
close
inferior
iiird
part
oesophagu
abdomin
xray
reveal
perfor
icu
stay
day
complic
includ
four
case
postop
complic
includ
first
surgic
procedur
breakup
enterostomi
n
reconstruct
phase
anastomosi
pseudodiverticula
n
anastomosi
leakag
n
die
surgic
mortal
patient
toler
oral
intak
well
surgeri
highprotein
hypercalor
diet
seem
benefici
patient
earli
laparoscop
surgic
treatment
improv
prognosi
sever
case
method
studi
evalu
predefin
subgroup
patient
histori
pulmonari
diseas
includ
prospect
random
control
trial
bnp
test
emerg
diagnosi
acut
dyspnea
patient
randomli
assign
diagnost
strategi
n
bnp
group
without
n
clinic
group
use
bnp
level
provid
rapid
bedsid
assay
time
discharg
total
cost
treatment
record
primari
endpoint
result
baselin
demograph
clinic
characterist
well
match
group
comorbid
extens
includ
coronari
arteri
diseas
hypertens
onehalf
patient
primari
discharg
diagnosi
chf
exacerb
obstruct
pulmonari
diseas
respect
use
bnp
level
significantli
reduc
need
hospit
admiss
vs
p
median
time
discharg
day
bnp
group
compar
day
p
clinic
group
total
cost
treatment
confid
interv
bnp
group
compar
confid
interv
p
clinic
group
fig
inhospit
mortal
group
conclus
use
conjunct
clinic
inform
rapid
measur
bnp
reduc
time
discharg
total
treatment
cost
patient
histori
pulmonari
diseas
present
acut
dyspnea
introduct
prehospit
rapid
sequenc
intub
rsi
intervent
util
airway
manag
noncardiac
arrest
patient
report
patient
outcom
follow
prehospit
rsi
util
medic
emerg
hypothesi
airway
manag
prehospit
rsi
medic
emerg
improv
patient
outcom
method
incid
relat
childhood
age
year
drown
event
examin
prospect
metropolitan
us
sunbelt
citi
popul
million
use
comprehens
utsteinstyl
databas
atrisk
popul
age
year
averag
studi
finit
popul
studi
twothird
adult
child
submers
incid
involv
children
total
case
mean
childrenyear
annual
incid
per
n
occur
age
year
younger
per
certain
year
younger
cohort
compris
mani
case
case
occur
summer
pm
none
site
pool
case
n
apart
involv
tubsspa
annual
rang
bucket
toilet
bayou
lake
creek
total
case
one
child
found
dead
onscen
clearli
requir
resuscit
effort
use
strict
criteria
bystand
perform
cpr
resuscit
case
n
children
surviv
longterm
neurolog
intact
howev
child
remain
apneicpulseless
time
emerg
servic
arriv
averag
respons
min
less
reviv
none
neurolog
intact
total
death
twothird
occur
pool
certain
venu
submers
incid
account
larg
number
percapita
childhood
death
immedi
basic
bystand
cpr
advanc
life
support
definit
resuscit
action
children
drowningrel
incid
consid
drown
incid
studi
occur
residenti
pool
age
year
younger
supervis
safeti
barrier
knowledgeperform
bystand
cpr
appear
major
factor
prevent
childhood
drown
death
aim
compar
incid
prearrest
sign
patient
suffer
unexpect
cardiac
arrest
differ
type
hospit
review
record
patient
suffer
unexpect
cardiac
arrest
period
tertiari
teach
hospit
tertiari
trauma
hospit
two
secondari
hospit
data
patient
characterist
observ
intervent
hour
preced
cardiac
arrest
collect
find
evalu
call
criteria
medic
emerg
team
met
four
hospit
patient
record
review
fiftysix
cardiac
arrest
occur
ward
patient
fulfil
met
call
criteria
mean
time
first
document
abnorm
vital
sign
arrest
hour
rang
hour
proport
patient
meet
met
criteria
differ
significantli
tertiari
teach
hospit
two
secondari
hospit
trauma
hospit
respect
chisquar
p
frequent
criteria
respiratori
distress
spo
oxygen
systol
blood
pressur
mmhg
patient
suffer
cardiac
arrest
elsewher
ward
ie
coronari
care
unit
fulfil
met
criteria
patient
receiv
immedi
intens
treatment
incid
prearrest
sign
thu
potenti
benefit
met
call
certain
criteria
fulfil
appear
vari
consider
hospit
differ
type
cardiopulmonari
resuscit
secur
airway
paramount
import
even
intub
trachea
still
seen
gold
standard
still
reserv
expert
healthcar
professsion
howev
insert
laryng
airway
devic
offer
compar
bagvalv
face
ventilationth
opportun
ventil
patient
effect
moreov
also
place
easili
lay
respond
put
forth
hypothesi
laryng
airway
devic
place
intuit
without
background
knowledg
devic
simpl
welldirect
train
programm
even
improv
perform
aim
studi
investig
intuit
use
differ
airway
devic
firstyear
medic
student
method
devic
test
lmaclass
lmafasttrach
subject
embodi
medic
student
evalu
airway
trainer
regard
mainli
time
correct
placement
devic
number
attempt
initi
tidal
volum
trachea
mannequin
therefor
connect
volumet
initi
tidal
volum
ml
consid
insuffici
exclud
data
analysi
second
evalu
done
specif
train
programm
twenti
subject
lmaclass
group
subject
lmafasttrach
group
initi
tidal
volum
ml
measur
tidal
volum
ml
lmaclass
ml
lmafasttrach
mean
time
correct
placement
lmaclass
lmafasttrach
second
evalu
initi
tidal
volum
ml
record
subject
lmaclass
six
subject
lmafasttrach
time
correct
placement
decreas
significantli
lmaclass
lmafasttrach
measur
tidal
volum
ml
lmaclass
versu
ml
lmafasttrach
class
iii
antiarrhythm
agent
synthes
japan
pure
k
channel
blocker
without
neg
inotrop
effect
nif
effect
antiarrhythm
drug
recommend
patient
ventricular
fibril
vf
resist
antiarrhythm
drug
japan
howev
whether
nif
improv
rate
success
resuscit
outofhospit
cardiac
arrest
shockresist
vf
determin
preliminari
studi
found
signific
improv
proport
patient
surviv
emerg
depart
follow
outofhospit
cardiac
arrest
niftreat
patient
protocol
follow
outofhospit
cardiac
arrest
patient
shockresist
vf
pulseless
vt
three
precordi
shock
epinephrin
mg
bolu
nif
mgkg
bolu
follow
mgkghour
infus
administ
show
outofhospit
cardiac
arrest
patient
shockresist
vf
could
surviv
treatment
protocol
show
detail
clinic
cours
success
recov
patient
treat
protocol
result
a
use
patient
administr
shock
advis
nine
patient
electrocardiograph
document
ventricular
fibril
shock
advis
remain
patient
sensit
specif
defibril
identifi
ventricular
fibril
rhythm
pulseless
electr
activ
probabl
silent
dead
first
shock
success
defibril
heart
nine
patient
expans
knowledg
a
correct
implant
chain
surviv
board
increas
extens
recoveri
cardiopulmonari
arrest
victim
aircraft
intervent
random
telephon
survey
gather
demograph
inform
respond
rate
level
agreement
question
concern
wit
cpr
use
fivepoint
scale
respond
rank
level
agreement
manner
present
tabl
age
level
educ
incom
level
perceiv
health
statu
endoflif
plan
correl
respons
marri
widow
respond
contradistinct
other
believ
wit
cpr
would
benefit
patient
p
respond
desir
cpr
prone
believ
signific
other
allow
cpr
oppos
desir
cpr
p
apt
want
other
present
undergo
cpr
declin
cpr
p
also
felt
strongli
presenc
signific
other
cpr
would
benefit
patient
p
famili
friend
tabl
believ
famili
member
friend
right
n
strongli
agre
n
agre
n
neither
agre
present
room
love
one
disagre
n
disagre
n
strongli
disagre
undergo
cpr
statement
five
respond
answer
nt
know
would
want
room
love
one
n
strongli
agre
n
agre
n
neither
agre
cpr
disagre
n
disagre
n
strongli
disagre
statement
n
nt
know
would
want
familyfriend
n
strongli
agre
n
agre
n
neither
agre
undergo
cpr
disagre
n
disagre
n
strongli
disagre
statement
nt
know
presenc
familyfriend
cpr
n
strongli
agre
n
agre
n
neither
agre
would
benefit
patient
disagre
n
disagre
n
strongli
disagre
statement
n
nt
know
presenc
familyfriend
cpr
n
strongli
agre
n
agre
n
neither
agre
would
benefit
familyfriend
disagre
n
disagre
n
strongli
disagre
statement
n
nt
know
p
desir
present
room
love
cpr
reach
statist
signific
p
two
group
conclus
larg
segment
public
desir
wit
cpr
believ
benefici
age
level
educ
incom
level
endoflif
plan
appear
influenc
belief
marri
widow
respond
apt
consid
wit
resuscit
benefit
patient
peopl
desir
cpr
like
posit
feel
wit
cpr
poor
health
desir
cpr
pessimist
wit
resuscit
although
healthcar
provid
mix
sentiment
would
wise
develop
protocol
accommod
wish
remain
togeth
cpr
healthier
individu
marri
peopl
famili
widow
demand
matter
infirm
desir
cpr
less
demand
less
inclin
avail
formal
program
studi
took
place
highfidel
patient
simul
scenario
wit
cardiac
arrest
due
ventricular
fibril
use
occur
unev
period
min
twentyfour
team
consist
three
physician
randomli
assign
one
two
version
scenario
version
r
realiti
mimic
realiti
arrest
occur
presenc
one
physician
remain
two
physician
summon
help
version
present
three
physician
present
moment
arrest
perform
team
rate
use
videotap
record
simul
first
meaning
measur
fmm
defin
either
precordi
thump
ventil
cardiac
massag
defibril
complet
initi
phase
cip
defin
three
countershock
initi
mask
ventil
cardiac
massag
inject
epinephrin
group
differ
significantli
time
import
measur
tabl
present
studi
design
unmask
addit
burden
teambuild
earli
phase
emerg
situat
team
abl
form
prior
cardiac
arrest
perform
significantli
better
team
form
cardiac
arrest
thu
process
teambuild
associ
signific
delay
crucial
measur
cardiopulmonari
resuscit
research
necessari
improv
teambuild
set
medic
emerg
method
doctor
nurs
resuscit
instructor
conduct
surpris
drill
use
computer
simul
mannequin
sim
instruct
team
arriv
depart
unannounc
present
clinic
scenario
observ
way
depart
function
resuscit
process
document
find
end
exercis
discuss
held
depart
staff
concern
qualiti
resuscit
implement
protocol
treatment
potenti
fatal
arrhythmia
also
review
session
exercis
depart
head
receiv
written
report
qualiti
cpr
exercis
recommend
improv
cpr
manag
implement
surpris
drill
supplement
cpr
train
unifi
languag
introduc
hospit
background
goal
mild
induc
hypothermia
mih
becom
standard
neuroprotect
treatment
anox
brain
injuri
cardiac
arrest
differ
surfac
cool
protocol
success
use
implement
mih
use
icewatersoak
towel
torso
leg
combin
sedationmuscl
paralysi
avoid
shiver
prehospit
cardiac
arrest
patient
age
year
persist
coma
lack
cardiogen
shock
target
temperatur
maintain
hour
evalu
feasibl
protocol
fig
mean
time
reach
target
temperatur
hour
hour
mih
maintain
median
hour
hour
rewarm
period
took
median
hour
hour
mih
treatment
follow
fever
patient
conclus
mih
use
extern
cool
protocol
feasibl
simpl
inexpens
howev
surfac
cool
tardi
imprecis
patient
unsuccess
background
goal
mild
induc
hypothermia
mih
improv
neurolog
recoveri
surviv
cardiac
arrest
patient
initi
rhythm
ventricular
fibril
vf
initi
rhythm
cardiac
arrest
due
noncoronari
caus
may
also
benefit
treatment
evalu
patient
receiv
mih
nonvf
asystol
pulsless
electr
activ
outofhospit
cardiac
arrest
nvfohca
compar
histor
control
n
nvfohca
treat
mih
icu
hospit
length
stay
well
incid
bad
outcom
compar
bad
outcom
defin
cerebr
perform
categori
cpc
death
result
data
present
tabl
tendenc
toward
prolong
length
stay
even
poor
outcom
suggest
liber
mih
inclus
polici
may
result
dissatisfactori
costbenefit
ratio
research
larger
patient
number
need
verifi
result
result
neurolog
complic
seen
patient
complic
follow
new
onset
recurr
headach
three
patient
gener
seizur
two
patient
persist
tremor
one
patient
central
pontin
myelinolysi
one
patient
dysartria
one
patient
myopathi
one
patient
mutism
one
patient
seizur
encount
two
patient
thought
associ
toxic
effect
tacrolimu
immunesuppress
drug
seizur
ceas
cessat
drug
myopathi
present
quadriplegia
seen
one
patient
earli
postop
period
diagnos
emg
muscl
biopsi
lead
prolong
mechan
ventil
icu
stay
hospit
patient
central
pontin
myelinolysi
live
persist
veget
state
year
conclus
neurolog
complic
observ
patient
underw
liver
transplant
complic
associ
use
immunesuppress
drug
conclus
neurolog
complic
frequent
encount
liver
transplant
caus
sever
morbid
prolong
icu
hospit
stay
object
show
cours
concentr
serum
acut
phase
head
injuri
use
patient
method
serum
level
determin
patient
eight
men
two
women
mean
sd
year
two
case
sever
head
injuri
glasgow
coma
scale
gc
blood
sampl
taken
admiss
hour
trauma
serum
protein
concentr
pgml
measur
elisa
yanaihara
industri
tokyo
japan
result
initi
serum
concentr
elev
minimum
pgml
maximum
pgml
mean
pgml
patient
whose
serum
concentr
compar
firsttim
valu
decreas
second
point
hour
injuri
minimum
pgml
maximum
pgml
mean
pgml
hour
two
patient
show
increas
serum
concentr
one
show
highest
level
serum
die
day
fig
mani
studi
done
shown
relat
initi
data
poor
prognosi
also
shown
patient
slight
head
injuri
consciou
gc
whose
elev
serum
concentr
decreas
next
hour
suspect
cerebr
cell
damag
caus
initi
increas
serum
concentr
head
injuri
secondari
brain
damag
serum
concentr
immedi
decreas
human
elisa
kit
measur
serum
concentr
hour
use
detect
slight
variat
earlyphas
secondari
brain
damag
accur
predict
chang
take
place
patient
efficaci
spread
even
background
cerebrospin
fluid
concentr
protein
acid
calciumbind
protein
found
astrocyt
schwann
cell
increas
central
nervou
system
damag
serum
protein
thu
potenti
biomed
marker
brain
cell
damag
sever
report
show
relat
sever
head
injuri
serum
protein
level
trauma
patient
data
endogen
cerebr
diseas
object
aim
studi
evalu
marker
endogen
encephalopathi
method
serum
protein
concentr
pgml
measur
daili
elisa
icu
discharg
icu
patient
men
seven
women
age
year
mean
year
endogen
encephalopathi
apach
ii
score
glasgow
coma
scale
gc
use
assess
sever
electroencephalographi
eeg
computeris
tomographi
ct
also
examin
valu
express
mean
sd
unpair
student
test
test
mannwhitney
u
wilcoxon
signedrank
kruskalw
pearson
correl
coeffici
use
p
consid
statist
signific
result
survivor
nine
nonsurvivor
signific
differ
age
apach
ii
score
gc
signific
differ
level
admiss
survivor
nonsurvivor
level
significantli
lower
survivor
nonsurvivor
day
vs
p
icu
discharg
vs
p
survivor
level
decreas
day
discharg
compar
admiss
level
p
nonsurvivor
signific
chang
compar
admiss
level
correl
level
apach
ii
score
r
p
gc
r
p
eeg
ct
abnorm
correl
level
conclus
serum
concentr
follow
differ
cours
survivor
nonsurvivor
endogen
encephalopathi
although
similar
admiss
differ
serum
protein
survivor
nonsurvivor
appear
first
day
admiss
survivor
nonsurvivor
level
decreas
discharg
also
signific
relationship
sever
eeg
ct
abnorm
level
serum
protein
could
use
biomed
marker
assess
brain
damag
may
predict
prognosi
endogen
encephalopathi
sever
brain
injuri
epidemiolog
western
macedonia
experi
gener
hospit
basi
plan
brain
injuri
manag
tabl
need
strong
prevent
measur
control
high
incid
sbi
region
mortal
rate
accept
compar
report
suggest
adequ
qualiti
initi
stabil
transport
compet
speed
detect
candid
surgic
decompress
nevertheless
system
may
lead
avoid
death
especi
acut
intracrani
hemorrhag
optim
situat
would
presenc
neurosurgeon
medic
team
admit
patient
sever
head
trauma
concentr
injuri
servic
sinc
hospit
receiv
suffici
patient
develop
maintain
expertis
avail
onlin
http
sever
brain
trauma
lead
mark
impair
patient
autonomi
public
health
measur
necessari
organ
earli
multidisciplinari
approach
could
improv
patient
rehabilit
reintegr
social
network
fiftynin
patient
sever
head
injuri
glasgow
coma
scale
includ
studi
patient
male
femal
mean
age
year
rang
year
patient
perform
compar
concomit
intracrani
pressur
icp
measur
intracrani
cathet
tcd
examin
tcd
examin
measur
maximum
mean
end
diastol
veloc
vmax
vmean
vmin
respect
calcul
pulsatil
index
pi
mean
cerebr
arteri
tempor
acoust
window
use
tcd
examin
total
tcd
examin
icp
measur
record
perform
correl
vmax
vmean
vmin
pi
icp
cerebr
perfus
pressur
cpp
statist
signific
linear
correl
tcd
veloc
icp
pi
index
icp
signific
correl
vmax
cpp
vmean
cpp
best
correl
found
vmin
cpp
pi
index
cpp
linear
correl
regress
tcd
find
icp
cpp
present
tabl
conclus
tcd
examin
use
reliabl
noninvas
method
determin
concret
number
icp
pi
index
reliabl
tcd
blood
flow
veloc
target
therapeut
strategi
patient
sever
head
injuri
must
keep
mind
pi
estim
chang
cpp
time
absolut
valu
cpp
introduct
cerebr
blood
flow
cbf
reduc
around
area
contus
brain
head
injuri
howev
sinc
cerebr
metabol
also
reduc
may
repres
appropri
flowmetabol
coupl
rather
ischaemia
match
cbf
metabol
quantifi
oxygen
extract
fraction
oef
perform
magnet
reson
imag
mri
oxygen
positron
emiss
tomographi
opet
quantifi
cbf
oef
region
pericontusion
oedema
head
injuri
method
local
ethic
approv
five
patient
sever
head
injuri
underw
structur
mri
opet
first
week
injuri
two
studi
perform
immedi
success
everi
effort
made
maintain
stabl
physiolog
fluid
attenu
invers
recoveri
flair
mri
sequenc
provid
cerebrospin
fluidnul
weight
mri
imag
oedema
hyperintens
flair
imag
coregist
voxel
resiz
opetderiv
map
cbf
oef
use
publish
methodolog
patient
coregist
flair
imag
inspect
largest
appar
region
pericontusion
oedema
region
manual
outlin
appli
pet
map
cbf
oef
region
oedema
calcul
result
compar
unit
refer
data
obtain
healthi
volunt
result
normal
valu
cbf
oef
obtain
volunt
dataset
mix
greywhit
region
gmin
respect
pericontusion
region
show
significantli
lower
cbf
gmin
observ
wide
rang
valu
across
subject
within
individu
lesion
gmin
respect
howev
mean
oef
valu
low
much
smaller
rang
valu
across
patient
individu
imag
voxel
confid
interv
popul
mean
pericontusion
cbf
oef
gmin
respect
wide
rang
cbf
valu
make
clinician
wari
predict
viabil
tissu
region
pericontusion
oedema
valu
threshold
gmin
irrevers
ischemia
stroke
literatur
threshold
irrevers
ischemia
head
injuri
unknown
upper
confid
interv
oef
maximum
oef
voxel
suggest
reduct
cbf
may
appropri
metabol
demand
tissu
determin
whether
relationship
cerebr
perfus
pressur
cpp
intracrani
pressur
icp
surviv
children
sever
traumat
brain
injuri
stbi
first
hour
icp
monitor
retrospect
review
case
note
children
age
year
admit
paediatr
intens
care
unit
southampton
gener
hospit
follow
head
injuri
intracrani
pressur
monitor
undertaken
period
icp
cpp
mean
arteri
pressur
evalu
hourli
mean
calcul
first
hour
icp
monitor
primari
outcom
measur
surviv
children
categoris
three
group
group
overal
function
within
normal
rang
group
surviv
neurolog
impair
group
die
result
injuri
children
admit
unit
period
studi
follow
head
injuri
intracrani
monitor
place
within
first
hour
nearli
twothird
male
suffer
stbi
mean
sd
admit
glasgow
coma
score
crude
mortal
rate
compar
mean
icp
first
hour
found
signific
differ
three
group
mean
icp
sd
hour
follow
group
mmhg
group
mmhg
group
mmhg
mean
confid
interv
ci
icp
mmhg
ci
lower
group
group
p
mmhg
ci
lower
group
group
p
differ
group
maintain
hour
mean
icp
sd
hour
group
mmhg
group
mmhg
group
mmhg
mean
ci
icp
mmhg
ci
lower
group
group
p
mmhg
ci
lower
group
group
p
time
also
signific
differ
cpp
group
group
hour
although
signific
differ
detect
group
studi
suggest
children
low
icp
first
hour
stbi
crucial
intact
surviv
help
differenti
poor
outcom
neurolog
impair
death
cpp
help
stratifi
patient
surviv
group
group
question
remain
whether
improv
outcom
aggress
measur
reduc
icp
increas
cpp
wessex
head
injuri
matrix
whim
one
rare
behaviour
scale
design
follow
recoveri
headinjur
patient
throughout
whole
spectrum
alter
state
conscious
exit
coma
complet
recoveri
studi
explor
valid
whim
relat
behaviour
assess
tool
coma
scale
gl
comanear
coma
scale
cnc
western
neuro
sensori
stimul
profil
wnssp
well
relat
bispectr
index
bi
deriv
electroencephalograph
measur
twentynin
braininjur
comatos
patient
age
year
follow
longitudin
behaviour
electrophysiolog
measur
overal
evolut
score
whim
correl
significantli
evolut
score
obtain
gl
r
p
cnc
r
p
wnssp
r
p
well
bi
measur
r
p
rel
gl
cnc
wnssp
whim
show
particularli
good
sensit
document
subtl
chang
recoveri
patient
minim
consciou
state
bi
index
global
evolv
parallel
behaviour
scale
howev
show
bad
sensit
mani
patient
coma
veget
state
present
bi
score
high
observ
patient
regain
normal
conscious
result
confirm
use
whim
especi
assess
minim
consciou
patient
howev
even
global
relat
observ
behaviour
scale
valid
electrophysiolog
measur
bi
index
unsatisfactori
assess
alter
state
conscious
neuropsycholog
test
lockedin
syndrom
preliminari
result
feasabl
studi
lockedin
syndrom
li
characteris
complet
loss
voluntari
motor
output
preserv
sensori
input
conscious
result
ventral
pontin
lesion
commun
possibl
via
spare
vertic
eye
movement
andor
eyelid
blink
aim
studi
adapt
standard
neuropsycholog
test
eyerespons
mode
use
li
patient
assess
five
patient
li
year
age
year
control
modifi
version
direct
backward
digit
span
work
memori
door
peopl
test
episod
memori
wisconsin
card
sort
test
execut
function
lexi
phonolog
lexicosemant
process
evip
vocabulari
knowledg
two
new
test
design
measur
sustain
select
attent
auditori
stimuli
like
li
patient
control
subject
respond
via
eye
movement
result
show
patient
perform
normal
rang
measur
howev
differ
perform
subject
found
studi
demonstr
feasibl
complet
neuropsycholog
test
chronic
li
survivor
reemphasis
fact
li
patient
recov
global
intact
cognit
potenti
nevertheless
interindividu
differ
observ
suggest
interest
batteri
detect
deficit
maxim
commun
famili
medic
staff
patient
li
thirtyf
nicu
patient
age
year
male
median
glasgow
coma
scale
motor
traumat
brain
injuri
aneurism
subarachnoid
hemorrhag
postop
studi
infect
clinic
suspect
patient
confirm
microbiolog
data
analys
total
sc
dose
mean
hour
icu
admiss
median
five
administr
per
patient
mean
dose
mg
mgkg
decreas
significantli
dcf
sc
p
icp
mmhg
p
paco
sjvo
differ
pre
post
dcf
cpp
stabl
dcf
pre
mmhg
post
mmhg
ns
hr
significantli
drop
beatsmin
p
blood
ga
analysi
renal
hepat
paramet
differ
dcf
sc
diuresi
maintain
decreas
much
mlhour
p
effect
dcf
icp
shown
fig
effect
dcf
map
cpp
hourli
urin
output
shown
fig
conclud
dcf
sc
low
dosag
advantag
effect
enabl
good
reduct
bodi
ith
associ
reduct
icp
side
effect
cpp
map
minim
renal
hepat
function
affect
avail
onlin
http
background
wide
varieti
drug
current
test
manag
acut
ischem
stroke
glycoprotein
iibiiia
inhibitor
low
molecular
weight
heparin
show
great
therapeut
potenti
manag
acut
ischem
stroke
trial
test
effect
enoxaparin
tirofiban
combin
infarct
volum
shortterm
clinic
outcom
risk
intracerebr
hemorrhag
ich
anim
experiment
model
autolog
fibrinrich
clot
introduc
common
carotid
arteri
two
hour
embol
placebo
enoxaparin
tirofiban
enoxaparintirofiban
infus
intraven
min
neurolog
deficit
evalu
use
neuroscor
hour
stroke
incid
ich
infarct
volum
evalu
histolog
analysi
infarct
volum
larger
placebo
group
enoxaparin
tirofiban
enoxaparintirofiban
group
neuroscor
hour
higher
group
receiv
drug
simultan
ich
present
group
tabl
conclus
probabl
besid
anticoagul
antiaggreg
effect
enoxaparin
tirofiban
intrins
effect
drug
impact
infarct
volum
combin
drug
result
synerg
effect
probabl
due
prevent
reperfus
damag
slight
improv
shortterm
clinic
outcom
could
seen
drug
mean
less
tissu
damag
better
longterm
clinic
improv
expect
trial
none
drug
increas
risk
ich
investig
must
done
defin
right
therapeut
window
opportun
agent
introduct
intract
statu
epilepticu
respond
convent
pharmacotherapi
medic
emerg
deeper
suppress
cortic
activ
document
electrocerebr
silenc
titrabl
length
time
electrocerebr
silenc
maintain
make
thiopenton
ideal
drug
initi
manag
statu
epilepticu
longlast
antiepilept
drug
regimen
establish
thiopentoneinduc
burst
suppress
taper
discontinu
minim
chanc
recurr
method
twentyon
pediatr
patient
suffer
idiopath
gener
tonic
clonic
disord
age
onset
year
includ
studi
patient
admit
pediatr
icu
initi
manag
emerg
room
rapid
sequenc
intub
cricoid
pressur
done
induct
dose
mgkg
thiopenton
intraven
iv
mgkg
succinylcholin
iv
addit
bolus
mgkg
thiopenton
administ
min
interv
complet
areflexia
achiev
continu
intraven
thiopenton
infus
mgkghour
maintain
titrat
obtain
electroencephalogram
eeg
burst
suppress
continu
singl
channel
process
eeg
use
cerebr
function
analyz
monitor
intermitt
multichannel
electroencephalogram
eeg
done
control
clinic
electroencephalograph
seizur
activ
patient
start
phenytoin
phenobarbiton
thiopenton
infus
progress
taper
hour
final
discontinu
therapeut
serum
level
achiev
antiepilept
medic
statist
valu
obtain
tabl
outcom
versu
eeg
suppress
employ
fisher
exact
test
signific
quantifi
p
patient
show
burst
suppress
five
show
flat
record
two
patient
burst
suppress
categori
show
recurr
seizur
activ
control
initi
none
flat
one
two
patient
eeg
seizur
recur
earlier
clinic
seizur
rapidli
control
increas
rate
thiopenton
infus
sustain
control
seizur
activ
achiev
ad
valproic
acid
antiepilept
regimen
two
patient
conclud
tightli
control
serum
level
care
monitor
eeg
therapeut
effici
initi
taper
thiopenton
infus
icu
set
mechan
ventil
hemodynam
monitor
allow
physician
establish
therapeut
serum
level
convent
antiepilept
agent
reduc
relaps
rate
avoid
introduct
variou
model
use
predict
mortal
patient
admit
intens
care
unit
icu
base
first
icu
day
find
model
develop
daili
score
system
subsequ
icu
day
consensu
regard
definit
futil
reliabl
way
identifi
patient
icu
care
futil
purpos
retrospect
studi
determin
whether
identifi
factor
associ
futil
sickest
patient
admit
icu
hypothes
increas
acut
physiolog
score
ap
first
icu
day
third
icu
day
would
identifi
sick
patient
futil
care
defin
sickest
critic
ill
patient
first
day
apach
iii
predict
mortal
rate
higher
among
icu
admiss
enter
apach
iii
databas
stay
icu
day
first
day
predict
mortal
rate
higher
patient
surviv
day
icu
exclud
six
patient
author
medic
record
review
research
admiss
includ
studi
demograph
first
third
day
apss
probabl
hospit
death
date
death
obtain
patient
predominantli
caucasian
male
first
third
icu
day
mean
apss
respect
predict
mortal
rate
respect
observ
hospit
mortal
rate
increas
ap
third
icu
day
compar
first
icu
day
patient
two
patient
increas
ap
surviv
hospit
discharg
compar
without
increas
p
two
patient
surviv
hospit
discharg
one
die
within
hour
discharg
second
one
admit
icu
multipl
trauma
die
year
hospit
discharg
conclus
increas
ap
third
icu
day
sickest
patient
identifi
group
patient
whose
shortterm
longterm
prognos
dismal
introduct
base
excess
lactat
lac
use
monitor
icu
patient
result
differ
pathophysiolog
derang
perfus
inflamm
renal
function
individu
signific
lac
predict
outcom
critic
ill
patient
still
uncertain
focu
retrospect
studi
retriev
patient
prospect
collect
databas
januari
decemb
age
diagnosi
apach
ii
score
lac
entranc
hour
admiss
record
univari
multivari
analys
perform
former
base
matrix
collinear
pearson
coeffici
denot
collinear
result
univari
analysi
receiveroper
characterist
roc
curv
built
identifi
best
predict
valu
mortal
age
year
apach
ii
lac
admiss
mmoll
mmoll
respect
lac
hour
mmoll
mmoll
respect
variat
lac
calcul
hour
valu
minu
admiss
valu
result
mmoll
respect
conclus
lower
valu
higher
valu
lac
associ
poor
prognosi
icu
patient
compar
analysi
two
variabl
measur
hour
admiss
best
discriminatori
power
predict
outcom
aim
assess
tempor
chang
perform
score
specif
hypothesis
period
commenc
data
collect
public
revis
pim
score
may
allow
signific
decalibr
method
prospect
data
collect
singl
tertiari
picu
year
standardis
mortal
ratio
smr
calcul
use
standard
formula
discrimin
assess
via
area
receiveroper
characterist
curv
roc
calibr
use
hosmerlemeshow
good
fit
test
score
calcul
patient
episod
averag
admissionsyear
signific
tempor
variat
either
case
mix
cardiac
surgeri
diseas
sever
data
shown
score
discrimin
well
consist
yield
area
roc
curv
fig
top
surprisingli
pim
demonstr
loss
calibr
hosmerlemeshow
p
onward
pim
also
show
tempor
trend
toward
decalibr
becam
appar
trend
mirror
progress
reduct
smr
fig
bottom
upper
confid
limit
pim
smr
less
interestingli
smr
deriv
either
score
decreas
similar
rate
per
year
conclus
score
continu
discrimin
well
surviv
nonsurviv
expect
pim
better
calibr
pim
although
appear
decalibr
similar
rate
pim
reflect
standard
care
mani
picu
current
exhibit
fewer
death
expect
smr
frequent
calibr
appear
necessari
prolong
icu
length
stay
lo
associ
mani
medic
diagnos
condit
difficult
predict
admiss
icu
prolong
icu
lo
advers
affect
patient
outcom
increas
risk
complic
possibl
mortal
identif
indic
may
help
improv
icu
resourc
util
eg
bed
triag
icu
staf
object
systemat
review
literatur
determin
common
earli
predictor
icu
lo
adult
patient
result
five
studi
identifi
publish
full
combin
total
patient
definit
prolong
lo
vari
popul
evalu
eg
day
gener
icu
day
cvicu
thu
prevent
metaanalys
approxim
patient
prolong
lo
defin
studi
univers
posit
earli
indic
emerg
surgeri
admiss
trauma
need
mechan
ventil
hour
abbrevi
lo
associ
coma
dnr
order
nontrauma
surgic
reason
admiss
apach
creat
predict
model
mortal
consist
predict
lo
conclus
patient
prolong
stay
form
small
percentag
icu
patient
earli
predictor
univers
signific
import
determin
prolong
icu
lo
mani
factor
appear
specif
subgroup
thu
may
limit
broad
applic
gener
icu
score
system
special
popul
result
total
mechan
ventil
patient
includ
mean
age
year
male
cardiovascular
pulmonari
neurolog
reason
mv
intub
itn
mv
perform
emerg
first
day
patient
ventil
bilevel
posit
airway
pressur
modu
continu
posit
pressur
ventil
modu
durat
mv
day
length
cicu
stay
day
overal
patient
die
figur
show
distribut
hm
cicu
includ
patient
registri
rang
hm
emerg
itn
cardiopulmonari
resuscit
itn
hospit
shock
sepsi
pneumonia
ventricular
tachycardia
fibril
sudden
cardiac
death
associ
hm
univari
analysi
limit
admiss
sever
ill
assess
well
organ
dysfunct
cicu
stay
caus
death
conclus
mortal
high
mechan
ventil
patient
cardiovascular
pulmonari
disord
beat
registri
provid
import
data
benchmark
first
step
toward
qualiti
improv
subset
critic
ill
patient
high
mortal
morbid
introduct
intens
care
physician
face
grow
number
immunocompromis
patient
evid
immunosuppress
impact
icu
outcom
poor
conduct
retrospect
cohort
studi
compar
immunocompromis
patient
immunocompet
patient
regard
icu
outcom
furthermor
identifi
prognost
factor
method
period
month
patient
refer
medic
eightb
icu
univers
hospit
categor
immunocompromis
immunosuppress
defin
absolut
neutrophil
count
n
admiss
administr
immunosuppress
drug
prior
admiss
n
use
usual
corticosteroid
cyclosporin
rare
fk
cyclophosphamid
methotrex
record
demograph
data
reason
admiss
apach
iii
score
occurr
septic
shock
need
durat
mechan
ventil
mv
primari
endpoint
studi
icu
surviv
group
compar
fisher
exact
test
categor
variabl
mannwhitney
u
test
continu
variabl
univari
analysi
use
multivari
logist
regress
model
control
sever
risk
factor
overal
mortal
immunocompromis
patient
significantli
higher
mortal
immunocompet
patient
vs
p
differ
even
pronounc
patient
requir
mv
vs
p
patient
neutropenia
tend
higher
mortal
patient
therapi
differ
fail
show
statist
signific
presenc
septic
shock
time
icu
treatment
associ
mortal
septic
shock
significantli
differ
immunocompromis
immunocompet
patient
multivari
analysi
lower
apach
iii
score
admiss
admiss
postop
care
independ
associ
reduc
icu
mortal
wherea
immunosuppress
mv
independ
associ
unfavour
outcom
immunosuppress
remain
associ
higher
icu
mortal
statist
model
adjust
apach
iii
score
postop
care
mechan
ventil
conclus
immunosuppress
independ
risk
factor
death
icu
order
develop
prevent
strategi
control
studi
need
identifi
risk
factor
patient
studi
aim
compar
abil
admiss
lactat
lactat
hour
apach
ii
risk
death
rod
score
discrimin
intens
care
survivor
nonsurvivor
also
combin
lactat
hour
apach
rod
score
obtain
best
discrimin
valu
two
hundr
forti
consecut
admiss
nineb
gener
intens
care
unit
itu
prospect
investig
lactat
valu
admiss
lactat
hour
record
patient
apach
ii
rod
score
calcul
data
submit
intens
care
nation
audit
research
centr
itu
hospit
mortal
analys
area
receiveroper
characterist
roc
curv
calcul
measur
combin
measur
test
discrimin
survivor
nonsurvivor
overal
intens
care
hospit
mortal
respect
lactat
admiss
lactat
hour
significantli
strongli
associ
intens
care
mortal
p
area
roc
curv
show
lactat
measur
discrimin
survivor
nonsurvivor
tabl
best
discrimin
obtain
combin
lactat
hour
apach
probabl
obtain
logist
regress
hour
lactat
valu
give
mortal
respect
lactat
admiss
hour
significantli
strongli
associ
intens
care
mortal
seventyf
per
cent
patient
lactat
valu
hour
surviv
hour
lactat
discrimin
well
apach
ii
rod
score
intens
care
survivor
nonsurvivor
quicker
easier
obtain
combin
lactat
apach
ii
rod
score
appear
improv
discriminatori
power
outcom
predict
model
data
may
help
discuss
regard
patient
prognos
intens
care
view
strong
associ
discrimin
intens
care
survivor
nonsurvivor
widespread
clinic
use
lactat
measur
inclus
hour
lactat
valu
includ
futur
score
system
differ
measur
calcul
osmot
pressur
osmolar
gap
record
patient
admit
two
medicalsurg
intens
care
unit
icu
measur
took
place
immedi
admiss
icu
independ
caus
admiss
sap
ii
apach
ii
score
record
well
icu
outcom
patient
separ
retrospect
two
group
outcom
basi
aliv
b
dead
result
present
tabl
osmolar
gap
calcul
admiss
well
measur
osmolar
may
good
indic
icu
mortal
although
calcul
osmolar
seem
reliabl
prognost
indic
critic
ill
patient
use
calcul
osmolar
gap
seem
better
prognost
indic
icu
mortal
comparison
calcul
osmolar
patient
osmolar
gap
admiss
icu
probabl
death
patient
osmolar
gap
probabl
death
osmolar
gap
mosml
admiss
relat
increas
probabl
death
time
odd
ratio
accord
preliminari
result
introduct
prior
studi
suggest
uninsur
patient
present
emerg
depart
acut
asthma
receiv
poor
qualiti
care
howev
know
whether
insur
statu
affect
resourc
use
outcom
hospit
admiss
patient
statu
asthmaticu
sa
examin
nonfeder
hospit
discharg
six
us
state
select
patient
hospit
sa
defin
sever
sa
sa
icu
admiss
exclud
medicar
patient
focus
workingag
adult
year
classifi
insur
commerci
medicaid
uninsur
assign
comorbid
use
charlsondeyo
index
examin
associ
insur
statu
mechan
ventil
mv
hospit
cost
hospit
mortal
million
hospit
discharg
sa
sever
sa
workingag
adult
popul
incid
compar
commerci
insur
patient
n
medicaid
n
uninsur
n
patient
higher
mv
rate
vs
p
hospit
length
stay
lo
icu
lo
mortal
mean
cost
day
day
respect
commerci
medicaid
uninsur
patient
adjust
age
comorbid
gender
race
medicaid
uninsur
patient
like
receiv
mv
commerci
insur
patient
odd
p
mortal
also
higher
observ
signific
odd
ratio
p
odd
ratio
p
uninsur
patient
also
incur
lower
adjust
hospit
cost
p
hospit
lo
p
comparison
patient
manag
commerci
insur
patient
admit
hospit
insur
statesubsid
insur
appear
sicker
evidenc
higher
mv
rate
wors
mortal
possibl
reason
includ
wors
spectrum
diseas
popul
delay
present
hospit
acut
attack
restrict
admiss
polici
mortal
emerg
depart
sepsi
med
score
previous
deriv
valid
publish
clinic
decis
rule
predict
inhospit
mortal
base
follow
score
system
underli
diseas
expect
fatal
day
metastat
cancer
six
point
tachypnea
hypoxia
three
point
septic
shock
three
point
platelet
three
point
band
two
point
age
year
two
point
lower
respiratori
infect
two
point
nurs
home
resid
two
point
anion
gap
alter
mental
statu
two
point
point
ad
risk
group
assign
object
object
studi
assess
abil
med
score
predict
mortal
method
prospect
observ
cohort
studi
consecut
emerg
depart
ed
patient
seen
urban
univers
hospit
annual
ed
visit
studi
period
februari
februari
patient
age
year
older
risk
infect
indic
ed
physician
order
blood
cultur
includ
med
score
divid
patient
low
risk
point
low
risk
point
moder
risk
point
high
risk
point
high
risk
point
raw
surviv
figur
report
confid
interv
ci
compar
use
tukey
test
pairwis
comparison
patient
visit
elig
studi
includ
overal
mortal
ci
mortal
group
low
risk
low
moder
high
high
group
statist
differ
tukey
test
pairwis
comparison
med
score
good
predictor
mortal
patient
present
ed
sepsi
independ
multicent
valid
need
prior
widespread
applic
rule
test
perform
patient
popul
avail
onlin
http
iatrogen
occurr
intens
care
unit
impact
patient
sever
nurs
workload
descript
exploratori
studi
object
character
iatrogen
occurr
evalu
impact
clinic
condit
patient
nurs
workload
intens
care
unit
icu
data
prospect
collect
period
two
gener
icu
hospit
citi
paulo
use
file
card
record
occurr
patient
sever
nurs
workload
evalu
respect
mean
simplifi
acut
physiolog
score
sap
ii
therapeut
intervent
score
popul
studi
consist
patient
victim
iatrogen
occurr
stay
icu
among
victim
patient
suffer
one
occurr
two
occurr
three
four
occurr
regard
type
event
relat
pressur
ulcer
follow
respect
regard
handl
orotrach
cannula
two
blood
cathet
other
occur
administr
medica
care
probe
drain
handl
equip
occurr
relat
substructur
found
regard
impact
occurr
patient
sever
nurs
workload
statist
signific
differ
found
mean
sap
ii
score
victim
nonvictim
patient
occurr
admiss
icu
compar
sever
nurs
workload
victim
patient
event
differ
observ
mean
score
p
regard
analysi
differ
type
occurr
statist
signific
differ
found
sap
ii
p
p
score
occurr
regard
handl
orotrach
cannula
result
investig
reinforc
need
invest
help
qualifi
profession
work
critic
patient
major
measur
safeti
nurs
assist
qualiti
icu
common
stage
medic
error
report
one
studi
prescrib
stage
account
error
detect
electron
prescrib
ep
decis
support
shown
reduc
medic
error
rate
studi
could
found
critic
care
studi
compar
impact
chang
medic
error
rate
implement
ge
system
qs
clinic
inform
system
ci
decis
support
studi
period
medic
error
identifi
icu
pharmacist
record
error
identifi
use
publish
definit
except
abbrevi
drug
name
regard
error
icu
staff
unawar
studi
take
place
locat
gener
icuhdu
teach
hospit
data
collect
two
period
day
total
introduct
four
period
day
total
week
ci
introduct
total
number
drug
prescrib
record
statist
signific
reduct
medic
error
rate
follow
introduct
ci
error
rate
ci
error
prescript
ci
introduct
error
prescript
one
degre
freedom
df
p
variat
error
rate
ep
time
three
df
p
staff
got
use
new
system
prescrib
system
improv
also
strong
evid
linear
trend
one
df
p
thu
error
rate
appear
reduc
time
ep
conclus
introduct
ci
coincid
reduct
overal
medic
error
rate
suggest
learn
curv
signal
merg
signal
fusion
enhanc
robust
reduc
fals
alarm
multichannel
patient
monitor
recognis
fals
alarm
lead
habitu
among
clinic
staff
distress
patient
goal
work
reduc
number
fals
alarm
produc
standard
patient
monitor
provid
earli
warn
patient
deterior
base
multipl
vital
sign
two
approach
use
first
signal
merg
multipl
signal
merg
order
produc
robust
deriv
measur
exampl
cardiac
respiratori
inform
extract
electrocardiogram
photoplethysmogram
combin
produc
robust
estim
heart
respir
rate
second
signal
fusion
use
combin
advanc
signal
process
method
integr
multipl
vital
sign
develop
global
represent
patient
statu
hypothesi
monitor
system
identifi
period
physiolog
instabl
preced
clinic
appar
advers
event
earli
warn
may
result
reduc
monitor
alarm
prompt
treatment
improv
outcom
period
john
radcliff
hospit
oxford
uk
collect
noninvas
physiolog
data
hour
highrisk
patient
includ
continu
heart
rate
respiratori
rate
oxygen
satur
temperatur
intermitt
noninvas
blood
pressur
system
train
distinguish
period
physiolog
stabil
instabl
two
evalu
studi
taken
place
first
assess
signal
merg
technolog
simul
patient
transport
result
show
signal
merg
give
precis
estim
respir
rate
standard
transport
monitor
suggest
signal
merg
may
reduc
number
fals
alarm
caus
extern
movement
second
studi
assess
alarm
standard
patient
monitor
versu
signal
fusion
technolog
numer
standard
monitor
alarm
record
correspond
physiolog
event
often
due
signal
artefact
nonclin
event
patient
movement
typic
trigger
alert
signal
fusion
technolog
signal
fusion
identifi
physiolog
event
includ
atrial
fibril
elev
blood
pressur
extrem
distress
oxygen
desatur
conclus
signal
merg
fusion
techniqu
may
improv
robust
reduc
falseposit
alarm
potenti
provid
earli
warn
advers
physiolog
event
introduct
frequent
exposur
stress
event
icu
may
associ
increas
preval
depress
burnout
studi
plan
assess
burnout
syndrom
relat
depress
nurs
staff
icu
turkey
mix
surgic
intern
medicin
intens
care
unit
icu
nurs
nonicu
nurs
n
work
metropolitan
univers
uh
state
hospit
sh
least
year
enrol
studi
uh
mix
icu
n
uh
surgic
icu
n
uh
intern
medicin
icu
n
sh
mix
icu
n
sh
surgic
icu
n
sh
intern
medicin
icu
n
uh
anaesthesia
nurs
n
uh
oper
room
nurs
n
anaesthesia
oper
room
nurs
nonicu
nurs
consid
control
group
take
part
followup
patient
beck
depress
maslach
burnout
inventori
adapt
turkish
popul
use
assess
depress
burnout
respect
latter
three
subscal
emot
exhaust
depersonalis
person
accomplish
oneway
anova
bonferroni
post
hoc
test
chisquar
test
use
p
consid
signific
pearson
correl
analysi
done
investig
ingroup
correl
beck
depress
subscal
maslach
burnout
inventori
valu
express
mean
sd
demograph
data
similar
among
group
beck
depress
score
nurs
univers
hospit
higher
state
hospit
p
beck
depress
score
mix
icu
nurs
univers
hospit
higher
nonicu
nurs
p
depersonalis
score
surgic
icu
nurs
univers
hospit
higher
nonicu
nurs
p
although
signific
differ
found
among
nurs
work
differ
icu
term
beck
depress
inventori
mix
icu
nurs
consider
depress
mix
icu
surgic
icu
intern
medicin
icu
nonicu
group
consid
icu
nurs
togeth
posit
correl
found
group
beck
depress
score
emot
exhaust
except
control
group
p
r
conclus
nurs
oper
icu
especi
mix
icu
may
tendenc
depress
icu
staff
patient
method
june
decemb
admiss
year
medic
intens
care
unit
icu
treat
least
hour
elig
admiss
preicu
function
statu
subject
wellb
assess
interview
six
month
admiss
survivor
memori
icu
stay
assess
none
posit
neg
followup
standard
interview
patient
home
perform
use
question
inventori
revis
symptom
checklist
hamilton
anxieti
scale
hamilton
depress
scale
giessen
subject
complaint
list
qualiti
life
qol
scale
total
patient
enrol
cumul
mortal
rate
icu
hospit
followup
followup
survivor
lost
followup
unabl
interview
due
physic
cognit
reason
declin
interview
remain
studi
patient
mean
age
sd
year
male
mean
icu
length
stay
day
mean
apach
ii
score
hour
mean
sofa
total
maximum
score
accord
criteria
patient
diagnosi
ptsd
ptsd
frequent
diagnos
patient
report
poor
preicu
subject
wellb
compar
patient
good
subject
wellb
vs
patient
vs
p
patient
multipl
organ
dysfunct
mod
compar
patient
without
mod
vs
patient
vs
p
patient
neg
memori
icu
stay
compar
patient
posit
memori
vs
patient
vs
p
patient
ptsd
significantli
p
wors
score
global
index
psychopatholog
show
significantli
p
higher
degre
somat
psychic
anxieti
major
depress
bodili
complaint
mental
exhaust
report
poorer
selfperceiv
qol
conclus
small
subgroup
medic
icu
survivor
develop
ptsd
subject
wellb
icu
admiss
mod
icu
memori
associ
ptsd
relat
psychopatholog
symptomatolog
criteria
could
use
identifi
survivor
risk
develop
ptsd
background
cost
consider
may
influenc
therapeut
reason
decis
intens
care
unit
icu
date
data
illumin
associ
cost
consequ
ie
outcom
critic
care
servic
avail
studi
longterm
outcom
healthrel
qualiti
life
hrql
icu
hospit
cost
medic
icu
patient
assess
per
life
year
save
respect
mean
cost
per
quali
increas
sever
ill
sap
ii
quartil
associ
higher
ecp
cost
per
quali
tabl
conclus
larg
proport
patient
surviv
year
report
good
hrql
consid
sever
ill
patient
outcom
ecp
cost
per
qali
low
compar
therapeut
approach
eg
betablock
postmyocardi
infarct
per
ad
life
year
healthrel
qualiti
life
hrqol
relev
measur
intens
care
unit
icu
outcom
studi
aim
evalu
hrqol
survivor
sever
sepsi
septic
shock
sepsi
group
compar
survivor
without
sepsi
control
group
use
specif
questionnair
qolsp
develop
fernandez
method
six
month
icu
discharg
survivor
went
followup
consult
qolsp
appli
qolsp
compris
item
group
three
subscal
evalu
basic
physiolog
activ
bpa
normal
daili
activ
nda
emot
state
es
enabl
calcul
global
index
qolsp
index
patient
sepsi
group
compar
control
group
concern
background
variabl
age
sex
gender
previou
health
state
icu
variabl
reason
admiss
apach
ii
score
length
icu
stay
qolsp
variabl
patient
younger
year
old
icu
stay
day
exclud
patient
exhibit
nonsever
sepsi
icu
admiss
sever
sepsissept
shock
icu
admiss
also
exclud
march
march
total
patient
admit
icu
includ
studi
admit
sever
sepsissept
shock
mortal
sepsi
group
control
group
one
hundr
four
patient
sepsi
group
patient
control
group
complet
qolsp
questionnair
differ
age
previou
health
state
group
patient
sepsi
group
exhibit
significantli
higher
apach
ii
score
significantli
higher
icu
stay
sepsi
survivor
report
significantli
less
problem
bpa
nda
subscal
furthermor
although
statist
signific
exhibit
better
qolsp
index
control
group
tabl
conclus
month
icu
discharg
evalu
specif
critic
care
questionnair
survivor
sever
sepsissept
shock
exhibit
similar
better
hrqol
icu
survivor
without
sepsi
